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This thesis contains ten chapters covering my dissertational studies on diverse 
biosynthetic P450 enzymes including PikC, MycCI, MycG, and TamI, an FAD-
dependent oxidase TamL, two O-methyltransferases MycE anf MycF, and a type III 
polyketide synthase RppA (see next page for details). Chapter 1 is an overall introduction 
of the cytochrome P450 enzymes, which represent my major research targets. Chapter 2-
5 are focused on the biochemical, structural, and bioengineering investigations on the 
cytochrome P450 PikC, which are adapted from four papers including Journal of 
Biological Chemistry, 2006, 281, 26289-26297; 2009, 284, 5723-5730; Journal of the 
American Chemical Society, 2007, 129, 12940-12941; Proceedings of National Academy 
of Sciences, In Press, respectively. Chapter 6 and 7 demonstrate the results from the 
collaboration with Dr. Yojiro Anzai in the project of mycinamicin post-PKS biosynthesis 
that is focused on two P450 enzymes and two O-methyltransferases, which are adapted 
from two papers including Chemistry & Biology, 2008, 15, 950-959 and ChemBioChem, 
2009, 10, 1297-1301. Chapter 8 describes the studies of the tirandamycin biosynthetic 
pathways in collaboration with Mr. Jacob Carlson. Chapter 9 about the type III PKS 
RppA is adapted from the publication of Journal of Biological Chemistry, 2007, 282, 
12765-12772. In chapter 10, I summarize some future directions on the basis of the 
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Chair: David H. Sherman 
 
 
The superfamily of cytochrome P450 monooxygenases is involved in diverse 
oxidative processes including xenobiotic catabolism, steroid synthesis, and biosynthetic 
tailoring of diverse natural products.  During the past decade, the synthetic potential of 
biosynthetic P450 enzymes from microorganisms has gained special attention due to their 
non-membrane bound nature, considerable catalytic efficiency, and high regio- and 
stereoselectivity.  However, current barriers to their application in synthetic chemistry 
include their instability, inherent dependence on separate redox partners, and narrow 
substrate spectra. As these hurdles have been gradually overcome, it is likely that these 
biosynthetic P450s will find expanded use in the production of chemicals, fragrances, 
pharmaceutical compounds, biofuels, and application in bioremediation. 
   My dissertation research has focused on the bacterial cytochrome P450 PikC from 
the pikromycin macrolide antibiotic biosynthetic pathway in Streptomyces venezuelae.  
The inherent substrate flexibility and hydroxylation pattern of PikC suggests its unique 
oxidative mechanism and synthetic potential.  Starting from the crystal structures of 
PikC, we not only elucidated the structural basis for its substrate flexibility, but also 
discovered a unique desosamine sugar anchoring functionality of this enzyme. These 
observations directly inspired a substrate engineering strategy that utilizes the desosamine 
 xvi 
anchor to deliver diverse structures into the PikC active site for selective oxidation.  
Using this approach, the substrate spectrum of PikC has been significantly broadened. 
Specifically, by using an engineered PikCD50N-RhFRED with self-sufficiency and 
significantly higher catalytic efficiency, a series of carbocyclic rings linked to the 
desosamine glycoside were effectively hydroxylated in a regioselective manner.  
Associated analysis of co-crystal structures of PikC with selected unnatural desosaminyl 
substrates provided significant insights into the mechanism of its oxidative selectivity 
control.  Taken together, these results offer an applicable enzymatic solution of a central 
challenge in synthetic chemistry - the selective oxidation of an unactivated sp3 C-H bond. 
   Moreover, a number of other biosynthetic P450 enzymes, two O-
methyltransferases, an FAD-dependent oxidase, and a type III polyketide synthase were 
also studied during the course of my dissertation research. Together, these studies provide 
new insights into biosynthesis of secondary metabolites and how these enzymes can be 












Introduction of Cytochrome P450 Enzymes 
 
1.1 Background 
Cytochrome P450 (CYP) hemoenzymes (EC 1.14.x.x) are entitled as “the most 
versatile biological catalyst in nature” (1) since this superfamily of enzymes catalyze a 
vast variety of reactions including hydroxylation, epoxidation, dealkylation, phenolic 
coupling, ring formation and expansion,  dehydration, isomerization, etc. and their 
substrate spectra are extraordinarily broad  (2).  Not surprisingly, the amazing catalytic 
power of P450 enzymes has been extensively utilized by almost all types of organisms to 
serve diverse essential oxidative processes including xenobiotic catabolism, steroid 
synthesis, and biosynthetic tailoring of diverse secondary metabolites (1, 3), and starts to 
be intensively exploited regarding their great potential in synthetic application due to 
their high regio- and stereoselectivity, cost-effectiveness, and environmental-friendliness 
(4).  
The total number of family members of CYP was growing stably since its 
discovery (5, 6) and began exploding in the modern genome era. For example, the 
complete human genome contains 57 P450 genes (7); 58 P450 genes have been identified 
from the genome sequence of Glycine max (soybean) so far (8); the model actinomycete 
Streptomyces coelicolor A3(2) that produces actinorhodin and undecylprodigiosin 
revealed the presence of 18 different P450 genes (9); the CYP complement (CYPome) of 
wood decaying fungus Phanerochaete chrysosporium has demonstrated more than 100 
CYP genes (10). To date, there have been totally 11,292 P450 genes reported (11).  
Despite the highly divergent evolution of P450 enzymes leading to tremendous 
diversity and low amino acid sequence identity (< 20%) among different family members 
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(12), some key features that enable the common dioxygen activation for catalysis, 
including the obligate heme cofactor with the iron protoporphyrin IX center coordinated 
to the thiolate provided by an absolutely conserved cystein residue; the similarity of 
three-dimensional structures arisen from the similar arrangement of common structural 
elements comprising the well-conserved helices denoted A-L; and a portion of helix I 
near the heme-iron that is involved in the proton delivery for the O-O bond cleavage to 
generate the highly reactive species (see below), are well conserved (2, 13). 
 
1.1.1 A Brief History for Study of P450 Enzymes 
Cytochrome P450 protein was first reported in 1958 as a pigment from rat liver 
microsomes (5). In 1964, Sato and Omura revisited this system and named the “p”igment 
as P450 because it displayed a signature absorption peak at 450 nm upon carbon-
monoxide (CO) binding and reduction. The early studies of P450 enzymes were focused 
on metabolism of carcinogens (14), drugs (15), pesticides (16), vitamins (17), and 
steroids (18) using tissues or microsomes containing CYPs.   In the late 1970s, the 
purified microsomal P450s started to be used for functional analysis (19, 20). Along with 
the development of recombinant DNA technology (21) and heterologous protein 
expression system (22, 23) in 1980s, a much broader range of eukaryotic and prokaryotic 
cytochome P450s became accessible to the growing number of P450 researchers. 
Notably, in 1987, Nebert developed the P450 nomenclature system based on the sequence 
identity that enables individual P450 enzymes to be discussed unambiguously (24).  
Another milestone in the P450 field, the first P450 crystal structure of P450cam from 
Pseudomonas putida was also achieved in the same year (25), after which a fast growing 
number of high-resolution crystal structures of were reported, including the first self-
sufficient P450BM3 structure (26) and the structures of the human P450 2D6 (27) and 3A4 
(28). In the past two decades, much of the interest in P450 research was focused on the 
roles of the major human hepatic P450s such as 3A4 since it is of the significant concern 
for pharmaceutical industry to predict the bioavailability, drug-drug interaction, and 
toxicity (29). Currently, discussion on detailed mechanisms of reactive species generation 
and electron/proton transfer for dioxygen activation (30), structural elucidation of more 
unique P450 enzymes with biomedical significance and/or application potential (13), 
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research on P450 inhibitors (31), and functional characterization of novel P450s through 
genome mining (32) remain the major topics in P450 research. Of particular significance, 
along with the major limitations for application of cytochrome P450s in synthetic 
chemistry including instability, inherent dependence on separate redox partners, and 
narrow substrate spectrum (4) overcome by directed evolution to enhance the thermal and 
process stability (33), use of native (34) or engineered (35) self-sufficient fusion P450 
enzymes, and extension of reaction and substrate spectrum via protein (36, 37) and/or 
substrate engineering (38), respectively, it is promising to take advantage of the synthetic 
capacity of these efficient and selective monooxygenases for production of fine 
chemicals, fragrances, pharmaceutical compounds, biofuels and application in 
bioremediation (4, 39). 
  
1.1.2 Mechanism of Cytochrome P450s 
 
 
Figure 1-1. Reaction catalyzed by cytochrome P450 monooxygenases and consensus 
catalytic cycle. The grey arrows indicate the uncoupling reactions when electron transport 
and/or protonation is not timely, or substrate is absent or improperly positioned for oxidative 
attack. 
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Cytochrome P450 enzymes are highly divergently evolved. In contrast, various 
P450 enzymes share a common mechanism to activate dioxygen, thereby generating the 
highly reactive species for catalysis of diverse reactions. Through the observation of 
intermediates in the catalytic cycle by spectroscopic techniques, the use of diagnostic 
substrates with mechanistically revealing rearrangements during oxidation, the parallel 
study of the chemistry of synthetic metalloporphyrins, and the theoretical computational 
investigations, the consensus catalytic mechanism of cytochrome P450s (13) has been 
established (Fig. 1-1) despite of ongoing debates about the exact nature of the active 
species responsible for the oxygen insertion (30, 40). 
At the resting state, a water molecule acts as the sixth axial ligand to the ferric 
heme-iron (Fe3+), resulting in a low spin state of the heme-iron with the representative 
absorbance at 420 nm. Upon substrate binding, the displacement of the water molecule 
from the active site induces the change of the spin state of the heme iron from the low-
spin to the high-spin, giving rise to a spectral change of the enzyme with an increase in 
absorbance at 390 nm and a decrease at 420 nm. This difference spectrum referred to as 
“Type I” difference spectrum (41) (Fig. 1-2) can be conveniently measured by 
spectrometry and used to deduce the substrate binding affinity to P450 enzymes. In 
contrast, inhibitors and few certain substrates that coordinate directly to the heme iron 
generate the “Type II” difference spectrum (41) (Fig. 1-2), with a maximal absorbance at 
430 nm and a minimum at 390 nm. The loss of the ligand water results in subtle change 
of the iron position relative to the plane of the porphyrin ring, making the heme a better 
 
Figure 1-2. Type I and Type II difference spectrta. 
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electron sink to trigger the first electron transferred from NAD(P)H via redox partners. 
Upon the one electron reduction, the ferrous heme iron (Fe2+) forms a relatively stable 
dioxygen adduct. Subsequently, the second electron reduction (often the rate-limiting 
step) followed by a quick protonation generates the first reactive species – the ferric 
hydroperoxy (Fe3+−OOH) referred to as the “Compound 0”. Following second 
protonation and heterolytic cleavage of the O−O bond with concurrent production of a 
water molecule gives rise to the formation of the most applauded oxidative species − the 
ferryl-oxo species (Fe4+=O) referred to as the “Compound I”. This highly reactive cation 
radical is responsible for insertion of the oxygen atom into the substrate. Based on a 
number of experimental evidences and theoretical researches (30, 40), both “Compound 
0” and “Compound I” are possible to behave as the real catalyst. The choice is believed 
to be dependent on the substrate and the rate of the proton transfer steps relevant to the 
nature of certain P450 enzymes.  Finally, the oxidized product release completes the 
catalytic cycle. Since cytochrome P450s always only use a single oxygen atom from 
dioxygen molecule for oxidation, they represent a class of monooxygenases.    
 
1.1.3 Structure of Cytochrome P450 Enzymes 
Structurally, the overall three-dimensional structures of diverse P450s are 
conservative although their sequence identity could be as low as 20% (12, 13).  In 
general, P450 structures have helices A-L (A, B, B’, and C-L) in common and often five 
additional β sheets (β1-β5) (Fig. 1-3A) (42). The closer to the heme, the peptide 
sequences and structures are more conserved. Thus, the helices I and L that directly 
contact the heme are the most conserved regions. Another highly conserved region is the 
“Cys-Pocket” located at the β-bulge segment immediately prior to the helix L, which 
houses the absolutely conserved cystein that coordinate to the iron protoporphyrin center. 
The helix I (except for the substrate recognition site 4, see below) is conserved because it 
contains several residues directly involved in the dioxygen activation (13). Of particular 
significance, a threonine residue involved in a local helical distortion participates in a 
hydrogen bond network together with several peptide carbonyl groups and several water 
molecules. The arrangement of this H-bond network is believed to be important for the 
proper delivery of protons to the reactive center for the O−O bond cleavage to generate 
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the reactive oxidative species. Interestingly, this threonine is not strictly conserved. In 
P450eryF (43), it substitute an alanine residue for the threonine. To maintain a similar 
pattern of this essential hydrogen bond network, a water molecule takes the place of the 
threonine side chain OH and a hydroxy group from the substrate is specially involved. 
In contrast, the regions controlling substrate specificity in P450 enzymes are very 
different from one another. These regions defined as “substrate recognition sites” (SRSs, 
Fig. 1-3B) include: SRS-1, helix B’ and flanking regions (or a part of open B/C loop 
region); SRS-2, the C-terminal end of helix F; SRS-3, the N-terminal end of helix G; 
SRS-4, the N-terminal half of helix I; SRS-5, the β strand (in β3 area) immediately 
following the helix K; and SRS-6, a central region of β5 (44, 45). So far, most of the 
residues that take part in the substrate binding process in different P450 enzymes have 
been found to be within these six SRSs. Therefore, SRSs analysis would provide useful 
information for molecular design to guide P450 engineering, thereby gaining new 
substrate specificities.  
 
1.1.4 Classification of Cytochrome P450s 
 
 
Figure 1-3. The tertiary structure of P450 monooxygenase as exemplified by the crystal 
structure of ligand-free PikC (PDB ID: 2BVJ) (A) Structure with the conserved secondary 
structure components labeled. Helices E, J, and β2 sheet are not visible from this viewing 
angle. (B) Structure with six substrate recognition sites highlighted in orange (SRS1); yellow 
(SRS2); blue (SRS3); green (SRS4); cyan (SRS5); and magenta (SRS6), respectively. 
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There have been a number of classification systems for cytochrome P450 
monooxygenases based on different classification criteria. For example, diverse P450 
enzymes are classified into hydroxylase, epoxidase, dealkylase, desaturase, dehydrotase, 
isomerase, and so on (2) in terms of the catalyzed reaction types.  They can also be called 
human, plant, bacterial, or fungal P450 enzymes according to their resources. 
Alternatively, on the basis of sequence identity, P450s with more than 40% protein 
sequence identity are grouped into families (1, 2, 3…), subfamilies (A, B, C…, more than 
55% identity), and individual P450s (1, 2, 3…) and thus named accordingly, such as 
CYP1B1, CYP3A4, CYP107L, and etc. Another important classification system of P450 
enzymes is based on the redox partners required for the electron transfer to support their 
catalytic activities. Due to its close relatedness to this dissertational study, herein, this 
classification system is summarized.  
Classically, there are two major redox partner systems (46,47), including an FAD 
containing reductase with a small iron-sulfur redoxin for most bacterial and 
mitochondrial P450s (Class I, Fig. 1-4), and a single FAD/FMN containing flavoprotein 
− cytochrome P450 reductase (CPR) for eukaryotic microsomal P450s (Class II, Fig. 1-
4). P450BM3 (48), which is naturally fused to a eukaryotic-like CPR, is representative of 
the Class III P450 monooxygenase (Fig. 1-4). Recently, a new class (Class IV, Fig. 1-4) 
of self-sufficient cytochrome P450s exemplified by P450RhF from Rhodococcus sp. 
NCIMB 9784 was discovered to be naturally fused to a novel FMN/Fe2S2 containing 
 
 
Figure 1-4. Classification of P450 monooxygenases on the basis of redox partners. 
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reductase domain that is similar to the phthalate family of dioxygenase reductases (49, 
50). Notably, the discovery of diverse self-sufficient P450 enzymes could greatly benefit 
the application of these monooxygenases in biotechnology due to their independence on 
separate redox partner(s) and the significantly higher activity of native or artificial fusion 
enzymes derived from a more efficient electron transport system upon covalent linkage 
(51). Finally, not all cytochrome P450s require redox partners. These exceptional 
enzymes including the soluble P450nor from Fusarium oxysporum (52),  the membrane 
bound P450TxA from fall into the small Class V (Fig. 1-4) (53). 
 
1.1.5 Microbial Secondary Metabolites Biosynthetic P450 Enzymes 
Cytochrome P450 enzymes from microorganisms are enormously diverse. A 
significant majority of microbial P450s have been found to be involved in the 
biosynthesis of secondary metabolites (54). However, the roles of the vast majority of 
them have yet to be elucidated. Functional analysis of these many soluble enzymes is 
likely to result in new biochemistry, more insights into biosynthesis of natural products 
and biodegradation, more candidates for application in biotechnology, and more facile 
models for understanding CYP structures and catalytic mechanisms. 
To date, actinomycetes (especially streptomycetes) represent the richest resource 
of secondary metabolites, accounting for more than two-thirds of microbially derived 
compounds. These compounds are important signal or chemical-defense molecules for 
the life cycles of the host microbes. A lot of them have shown significant biomedical 
Table 1-1. Bioactive secondary metabolites produced by Streptomyces. 
 
Streptomyces sp. Secondary metabolite Bioactivity 
Biosynthetic 
CYP(s) involved Reference 
S. erythraea Erythromycin Antibacterial EryF, EryK (56, 57) 
S. venezuelae Pikromycin Antibacterial PikC (59) 
S. tirandis Tirandamycin Antibacterial TamI Chapter 8 
S. antibioticus Oleandomycin Antibacterial OleP (61) 
S. nodosus Amphotericin Antifungal AmphL, AmphN (62) 
S. noursei Nystatin Antifungal NysL, NysN (63) 
S. avermitilis Avermectin Antiparasitic AveE (64) 
S. sp. MA6548 FK506 Immunosuppressor FkbD (65) 
S. hygroscopius Rampamycin Immunosuppressor RapJ, RapN (66) 
S. peucetius Doxorubicin Anticancer DoxA (67) 
S. larvendulae Mitomycin Anticancer MmcN (68) 
S. fradiae Tylosin Growth promotor TylHI, TylI (69) 
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activities such as antibacterial erythromycin (55-57), pikromycin (58, 59), tirandamycin 
(60), and oleandomycin (61); antifungal amphotericin (62) and nystatin (63); antiparasitic 
avermectin (64); immunosuppressors FK506 (65) and rapamycin (66); anticancer 
doxorubicin (67) and mitomycin (68); and livestock growth promoter tylosin (69). It is 
worth noting that CYPs participate in biosynthesis of all the mentioned bioactive 
secondary metabolites (Table 1-1). The known structures of the products and 
intermediates of certain biosynthetic pathway greatly facilitate the functional analysis of 
these P450 enzymes. These demonstrate that identification of natural product 
biosynthetic gene cluster is an important method to discover new microbial P450s.  
In current genomic era, the whole genome sequencing represents another highly 
efficient process to identify new P450 genes. Recent efforts have uncovered an 
unexpected large number of genes encoding P450 enzymes. For example, the model 
actinomycete Streptomyces coelicolor A3(2) that produces actinorhodin and 
undecylprodigiosin revealed the presence of 18 different P450 genes (9), whereas 
Streptomyces avermitilis MA-4680, the avermectin producer, contains 33 P450s (64), and 
Saccharopolyspora erythraea NRRL 23338, the erythromycin-producing bacterium, 
encodes 36 P450s (70). However, it is of a significant difficulty to determine the 
physiological functions of the large number of these P450 gene products.  
 
1.2 Prior Work 
Pikromycin was isolated in 1951 (71), representing the first discovered macrolide 
antibiotic.  Interestingly, the two structurally related 12-membered macrolides 
methymycin and neomethymycin were also found to be produced by the 14-membered 
pikromycin producer strain – Streptomyces venezuelae (Fig. 1-5) (72, 73). In the past 
more than a decade, the Sherman laboratory has been focused on elucidation of the 
pikromycin biosynthetic pathway and understanding the detailed enzymological 
mechanisms of the unique modular type I polyketide synthase (PKS) and a group of 
intriguing tailoring enzymes. The knowledge accumulated during these investigations has 
greatly advanced the understanding of macrolide biosynthesis, making the pikromycin 
biosynthetic pathway, together with the erythromycin biosynthetic pathway (74), become 
a model system in the field of natural product biosynthesis (75, 76). 
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The first milestone of pikromycin biosynthesis studies was sequencing and 
assembly of the pikromycin biosynthetic gene cluster (58), which identified a cluster of 
genes encoding a five-modular type I polyketide synthase (pikAI-V), a group of enzymes 
responsible for synthesis of 6-deoxysugar desosamine (desI-VIII and desR), a cytochrome 
P450 (pikC), and a number of regulatory (pikD) and self-resistant (pikR1 and pikR2) 
genes (Fig. 1-5). Shortly afterwards, genetic disruption studies unambiguously 
demonstrated that the pikromycin PKS is unique from other known PKS systems since it 
is solely capable of generating two distinct macrolactone products, 10-deoxymethonolide 
and narbonolide (Fig. 1-5) (77, 78). 
The subsequent researches on the desosamine biosynthesis not only functionally 
characterized all enzymes (DesI-DesVI) required for transformation of the primary 
metabolite D-glucose-1-phosphate to thymidine diphosphate D-desosamine (TDP-
desosamine) (75, 79-82), but also identified a glycosyltransferase DesVII (paired with the 
auxiliary protein DesVIII) (83), displaying amazing substrate tolerance toward both 
aglycone and the sugar moiety (84, 85). This unique substrate flexibility has been shown 
 
Figure 1-5. The pikromycin biosynthetic pathway. The pikA locus (blue) encodes a type I 
PKS that directs the biosynthesis of the 12- and 14-membered ring macrolides, 10-
deoxymethonolide and narbonolide (shown in blue), respectively. The des locus (green) 
encodes all proteins responsible for the generation of the desosamine sugar moity (shown in 
green) and attachment to macrolactone, giving rise to macrolides narbomycin and YC-17. The 
pikC (red) encodes a cytochrome P450 monooxygenase responsible for installation of all 
hydroxy groups shown in red.  The figure is adapted from Kittendorf J. D. and Sherman, D. H. 
(74) 
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to be very useful for generating novel unnatural products potentially with improved 
biological activity (82, 85, 86).  
The cytochrome P450 PikC represents the third component (another two are the 
thioesterase in module V (77) and the glycosyltransferase DesVII) with enzymatic 
versatility in pikromycin pathway. Physiologically, PikC catalyzes hydroxylation at C10 
of the 12-membered ring macrolide YC-17 to yield methymycin, or almost equally at the 
C12 position to generate neomethymycin. It is also able to further hydroxylate 
methymycin at C12, giving rise to double hydroxylated product novamethymycin 
(59,87). With respect to 14-membered ring substrate narbomycin, the PikC catalyzed 
hydroxylation predominantly occurs at the C12 position, leading to pikromycin (59). 
Recently, identification of two additional 14-membered ring macrolide antibiotics, 
neopikromycin and novapikromycin in much smaller amounts compared to pikromycin, 
from extracts of S. venezuelae fermentation broth clearly suggested more functionalities 
of PikC (88). Further in vitro reactions confirmed that the minor activity of PikC to 
convert narbomycin into neopikromycin and hydroxylate pikromycin to form 
novapikromycin (88). 
This dissertational study started from the collaboration with Dr. Larissa M. 
Podust, attempting to understand the structural basis for the amazing substrate flexibility 
and hydroxylation versatility of PikC. The observation of a unique desosamine anchoring 
feature initiate the following biochemical studies regarding catalytic mechanism and 
substrate specificity, and the bioengineering work to develop PikC into an efficient and 
cost-effective synthetic enzyme by harnessing its unique desosamine anchoring 
functionality. To date, the results have demonstrated that 1) PikC is a good model to help 
answer some fundamental questions of P450 catalysis; 2) PikC possesses great potential 
to be developed into an applicable catalyst in synthetic chemistry. Moreover, knowledge 
and experience gained during the PikC investigation has been applied to the study of 
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The Structural Basis for Substrate Anchoring, Active Site 




Macrolide antibiotics comprise a large group of medicinal agents characterized by 
a macrocyclic lactone ring, to which one or more sugar residues are covalently linked. 
Despite considerable structural variation, macrolides represent a homogeneous group of 
therapeutic drugs with similar activity spectra and mode of action as anti-infective agents. 
The success of macrolide antibiotics is attributed to their propensity to bind to the large 
subunit of prokaryotic ribosomes and inhibit protein synthesis, thereby preventing 
bacterial growth (1, 2). The first generation macrolide introduced into clinical practice 
over 50 years ago was erythromycin. Since then, macrolide antibiotics have been further 
optimized, resulting in improved 14-, 15-, and 16-membered ring macrolides (the second 
generation), acylides, and ketolides (the third generation) (3). 
Most of the natural product macrolide antibiotics are produced by Streptomyces 
sp. and related bacteria, in which assembly of polyketides from simple carboxylic acid 
precursors is catalyzed by modular polyketide synthases. Over the past 15 years, 
advances in understanding the modular architecture of polyketide biosynthetic machinery 
has enabled development of metabolic engineering approaches for production of new 
antibiotics (4-7). However, significant additional structural variability of polyketide-
derived natural products is due to postpolyketide synthase biosynthetic modifications that 
typically include hydroxylation/epoxidation and/or glycosylation. In most antibiotic 
biosynthetic pathways, hydroxylation(s) occur(s) at the late stages of assembly after 
formation of the natural product scaffold and often after glycosylation events. Such 
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modifications are often necessary to impart or enhance biological activity (8). The 3-
(dimethylamino)-3,4,6-trideoxy sugar desosamine (or mycaminose) confers biological 
activity to a number of macrolide antibiotics such as erythromycin, troleandomycin, 
mycinamicin, megalomicin (desosamine), tylosin, carbomycin, and spiramycin 
(mycaminose) and is the only glycoside present on pikromycin, methymycin, and the 
highly potent semisynthetic ketolide telithromycin (9). 
Both macrolides and ketolides were shown crystallographically to bind in a 
specific pocket in the ribosomal tunnel via interactions with 23 S rRNA and act to block 
sterically egress of the nascent protein chains (10). The desosamine sugar (or 
mycaminose) attached to C5 of the 14-, 15-, and 16-membered ring macrolactones 
extends up the tunnel toward the peptidyl transferase center. Interactions between 
desosamine and the ribosome play a key role in both macrolide selectivity and macrolide 
resistance (11). 
Previous studies have shown that metabolic engineering approaches can provide 
structurally variable macrolactones (12, 13) and/or extend a repertoire of deoxysugars 
coupled to macrolide aglycones (14-18). The Pik biosynthetic gene cluster of 
Streptomyces venezuelae represents an effective system for the synthesis of novel 
polyketide antibiotics due to (i) its ability to generate two macrolactone ring systems; (ii) 
the presence of a flexible desosaminyl transferase (DesVII) that is tolerant of changes in 










































































































































Figure 2-1. Catalytic roles of PikC. Hydroxylated natural products obtained from the Pik 
pathway are shown. 10-dml, 10-deoxymethynolide. Solid arrows indicate reactions leading to 
the primary products. Dashed arrows indicate minor reactions. 
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17); and finally, (iii) the unusual P450 monooxygenase (CYP) PikC (CYP107L1), 
responsible for the diverse pattern of hydroxylated natural products obtained from the Pik 
pathway (Fig. 2-1). 
A series of particularly intriguing observations were made several years ago 
regarding the substrate selectivity of PikC that appeared to correlate directly with 
hydrogen bond functionality at the C3' position of the glycoside, with no tolerance for 
modifications at C4' (14-17). Such a stringent requirement toward sugar structure 
contrasts with the apparent flexibility of PikC toward the macrolactone core of a 
substrate. Thus, PikC is able to catalyze mono-hydroxylation at either C10 or C12 of the 
12-membered ring macrolactone of YC-17, giving rise to methymycin and 
neomethymycin, respectively, as well as at C12 of the 14-membered ring of narbomycin, 
giving rise to pikromycin (20). Hydroxylation at the C14 position of pikromycin, giving 
rise to neopikromycin, occurs with a very low yield, which precluded isolation and 
characterization of this metabolite until recently (21). Dihydroxylation of YC-17 results 




in novamethymycin (Fig. 2-1), a product that is found in small quantities in vivo and 
appears to be converted from methymycin in vitro (22). Dihydroxylation of narbomycin 
results in a very low but detectable production of novapikromycin (21). 
Here we provide new information regarding the diverse hydroxylation pattern of 
the PikC monooxygenase by determining its crystal structure in a variety of forms, 
including ligand-free and bound to endogenous substrates YC-17 and narbomycin (see 
Table 2-1). This series of crystal structures has revealed that in the absence of a substrate, 
PikC adopts both "open" and "closed" conformations due to repositioning of the BC-loop 
and the F and G helices. This dynamic process appears to enable substrate access to the 
active site; however, it does not account for PikC substrate flexibility, which is largely 
due to the combination of a single macrolactone binding site with two alternative 
desosamine binding pockets. In both pockets, the desosamine C3' dimethylamino group is 
sandwiched between two carboxyl-containing (Glu, Asp) amino acids found in the BC-
region, forming a salt bridge to the more proximal carboxyl group. Site-directed 
mutagenesis revealed that formation of this salt bridge is essential for PikC function. 
 
2.2 Results and Discussion 
2.2.1 Ligand-free PikC 
The crystal structure of the ligand-free form of PikC revealed that two molecules 
in an asymmetric unit adopt two different conformations, referred to as open and closed 
depending on the position of the F and G helices and the BC-loop, the latter being 
partially disordered in the open conformation (Fig. 2-2). These regions are generally 
flexible in P450s and readily reposition in response to inhibitor or substrate binding in the 
active site (23-25). To our knowledge, this is the first time that a P450 demonstrates such 
protein dynamics (linear repositioning of the FG-loop in the ligand-free PikC is within 12 
Å) in the absence of a bound ligand, probably as a result of natural motions, although the 
first structural indications of open/close differences in the FG-region were noticed for a 
ligand-free P450BM3 (26). The most compelling need for such protein dynamics is to 
allow substrate access to the active site and subsequent product release. A water molecule 
is bound as the sixth ligand to the hexa-coordinated heme Fe3+ atom. Scattered electron 
density accommodates a few additional water molecules that together form a hydrogen 
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bond network within the active site. Water molecules are displaced upon substrate 
binding. 
 
2.2.2 X-ray Structure of Narbomycin-bound PikC 
The 14-membered ring macrolide narbomycin is one of the two endogenous 
substrates for PikC (20). Hydroxylation of narbomycin at C12 (Fig. 2-1) of the 
macrolactone ring gives rise to the antibiotic pikromycin. In the co-crystal structure (1.75 
Å resolution), narbomycin is unambiguously positioned in the active site, and its electron 
density is well defined (Fig. 2-3A). Of particular significance are interactions between the 
C3' dimethylamino group of the desosamine sugar and two carboxyl-containing residues 
localized in the BC-region (Glu-85 and Asp-50) (Fig. 2-4A). Although proximal Glu-85 
(3.2 Å distance) provides a salt bridge contact, distal Asp-50 (5.3 Å distance) may 
compensate for a partial positive charge of the protonated tertiary amine. A calculated 
pKa of 8.85 for the desosamine nitrogen atom (calculated by using the on-line program 
 
 
Figure 2-2. Ribbon representation of ligand-free PikC. A, open, and B, closed 
conformations of ligand-free PikC (2BVJ). C, overlay of both conformations, open (cyan) and 
closed (gray), demonstrating that in the open form, the F and G helix are bent away from the 
heme to enable substrate access to the active site. Molecules in C are rotated ~90° toward the 
viewer along a horizontal axis in the plane of drawing when compared with A and B. The F 
helix is not seen in this orientation. Closed conformation is related within r.m.s. deviations of 
0.58 Å for Cα atoms to catalytically relevant YC-17- and narbomycin-bound forms. The heme 
co-factor is shown in red. 
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SPARC (27)) is in good agreement with the values experimentally obtained for 
erythromycin (28), suggesting that at neutral pH, desosamine exists primarily in the 
protonated form. Interestingly, electrostatic interactions involving the C3' dimethylamino 
group are also involved in macrolide recognition in the ribosome tunnel where a positive 
charge is neutralized by a negative charge of an rRNA phosphate group invariantly 
positioned within 5 Å in structurally defined macrolide/ribosome complexes (29-32); 
however, no salt bridge is formed (Fig. 2-4C). In this regard, macrolide resistance in 
bacterial pathogens is often attributed to mono- or dimethylation at the A2058 N6 
position (Escherichia coli numbering) or to mutations that change nucleotide identity, 
both eliminating interactions with desosamine (11). In addition, PikC amino acid side 
chains Phe-178, Ala-187, Gln-188, Met-191, and Tyr-295 are within4Åofthe desosamine 
 
 
Figure 2-3. Substrate binding in the PikC active site. Stereo views of narbomycin (2C7X) 
(A) and YC-17 (2C6H) (B) bound in the active site of PikC are shown. Amino acid residues 
within 4.0 Å (labeled in black) are also shown. Carbon atoms are labeled in red. Fragments of 
2Fo - Fc electron density composite omit map contoured at 0.8 σ are in blue. To avoid 
excessive cluttering of stereo views with the electron density bulks, a number of residues, 
including heme and those that project on top of the substrate or each other, are excluded from 
the map calculation. Excluded in addition to heme in panel A are: Val-179, Ile-239, Val-242, 
Asn-392, and Ile-395; Excluded in addition to heme in panel B are: His-238, Val-242, Ala-
243, and Met-394. 
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moiety (Fig. 2-3A and 2-4A). Although substrate anchoring by a biosynthetic P450 
involving desosamine is unique, another type of anchoring mechanism was observed 
previously for the epothilone P450 EpoK from Sorangium cellulosum. In EpoK, a 
pendant thiazole moiety linked to the macrolactone ring system is involved in π-π 
interactions with two aromatic amino acids that determine substrate specificity (33). 
Significantly, the macrolactone ring of narbomycin is bound almost entirely via 
hydrophobic interactions with amino acid side chains Leu-93, Phe-178, Val-179, Ile-239, 
Val-242, Ala-243, Thr-247, Thr-294, Met-394, and Ile-395 plus three hydrophilic ones, 
Glu-246, His-238, and Asn-392, but no hydrogen bonding is involved. The Thr-247 
hydroxyl is involved in hydrogen bonding with the I helix main chain atoms, causing a 
local distortion observed in many if not all structurally defined P450s. The Glu-246 side 
chain is in a conformation that is flipped away from the substrate (Fig. 2-3A). These two 
I helix residues, Glu-246 and Thr-247, are highly conserved among P450s and play an 
important part in activation and delivery of protons to the iron-linked dioxygen (34). 
Surprisingly, the allylic C12 carbon (analog of C10 in YC-17) is positioned 7.1 Å away 
from the heme iron, whereas the distance between methylene C14 carbon (analog of C12 
in YC-17) and the heme iron is only 5.3 Å (Fig. 2-4A). Despite this distance differential 
that would appear to favor hydroxylation of the more proximal C14 atom, hydroxylation 
 
 
Figure 2-4. Desosamine anchoring. Desosamine interactions in narbomycin (A) and YC-17 
(B) binding sites of PikC are shown. Amino acid residues within 4.0 Å from desosamine are 
also shown. C, erythromycin (in green) is shown bound to the large ribosomal subunit from 
eubacteria Deinococcus radiodurans (1JZY) (35). The phosphate group of G2484 (G2505) 
interacts with the dimethylamino group of desosamine. Nucleotide numbering according to the 
E. coli sequence is indicated by parentheses. Hydrogen bonds are highlighted in green, salt 
bridges are highlighted in magenta, and the distances are in Angstroms. 
 22 
of narbomycin at this position occurs with very low yield (~40:1 ratio in vivo) (21). The 
structure suggests that unfavorable stereochemistry of the C-H bonds at C14 (pointing 
away from the oxygen scission site) is the basis for this, which could be due to rotation of 
the C14-C15 bond toward the heme iron, possibly to avoid steric interference with the 
side chains of amino acids Leu-93 and Thr-294 (Fig. 2-3A). In contrast, a C-H bond at 
C12 is positioned favorably toward the oxygen scission site. Whether hydroxylation is 
controlled by regio- and stereochemistry of the C-H bond, by distance to the heme iron, 
or by the iron-oxo reactive intermediate (or a combination of these variables) remains to 
be elucidated. It is also possible that Fe+3 reduction followed by oxygen binding might 
result in repositioning of narbomycin, as is indicated by NMR paramagnetic relaxation 
studies on the P450BM3-laurate complex, in which 6 Å movement of the substrate into 
the correct position for hydroxylation has been detected (35). 
Alternatively, hydroxylation at the 7 Å remote allylic C12 atom in narbomycin 
may result from the iron-peroxo intermediate Fe+3-OO- (or its protonated form) as an 
"active oxygen" as opposed to a widely accepted P450 oxidant oxo-ferryl radical, 
 
 
Figure 2-5. Two desosamine anchoring modes in PikC. A stereo view of overlaid YC-17 
and narbomycin bound in the PikC active site is shown. Narbomycin is in green, and YC-17 is 
in cyan. The S-configuration observed for the C6 atom of YC-17 in the crystal structure 
conflicts with the R-configuration derived based on the methymycin, neomethymycin, 
narbomycin, and pikromycin structures (42-44). Formation of this unnatural stereoisomer may 
have been a result of adventitious epimerization at C6 via the enol intermediate during long-
term storage of 10-deoxymethynolide. 
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compound I (36). This frequently discussed alternative pathway requires a homolytic O-
O bond cleavage and is generally not thought to be involved in the normal 
monooxygenation process (37). Classical examples of the role of a nucleophilic iron-
peroxo species in P450 catalysis are the oxidative decarbonylation of aldehydes and the 
final step of the aromatization reaction of androstenedione to estrone catalyzed by human 
aromatase (38). However, growing evidence supports the active role of peroxy-iron as an 
electrophilic oxidant in hydroxylation of C-H bonds in the hypersensitive cyclopropane 
probe (39) and epoxidation of olefins (40, 41). In narbomycin and YC-17, the allylic C-H 
bond is weaker than an alkanyl C-H by about 16 kcal/mol (36). In addition, the C10=C11 
double bond in narbomycin and YC-17 is conjugated to the carbonyl group, which leads 
to a polarization of the double bond and draws electron density toward the oxygen atom 
away from the conjugated system. This serves to further weaken the allylic C-H bond, 
thus decreasing the barrier for its activation. 
 
2.2.3 X-ray Structure of YC-17-bound PikC  
The smaller 12-membered ring macrolide YC-17 is the second endogenous 
substrate of PikC (20). In contrast to narbomycin, it is hydroxylated in vivo and in vitro at 
two different positions (~1:1 ratio). Modification at allylic C10 results in methymycin, 
whereas modification at methylene C12 results in formation of neomethymycin (Fig. 2-
1). In the co-crystal structure determined to 2.35 Å resolution, YC-17 is unambiguously 
positioned in one orientation within the active site, and its electron density is well defined 
(Fig. 2-3B). As observed with narbomycin, the macrolactone ring of YC-17 is bound 
almost entirely via hydrophobic interactions projecting the more hydrophilic surface of 
the lactone toward the I helix and is devoid of hydrogen bonding. The binding site for the 
12-membered ring lactone overlaps the entire binding site for the 14-membered ring 
macrocycle plus an extra amino acid residue, Val-290. As observed for narbomycin, the 
C3' dimethylamino group of the desosamine moiety in YC-17 is sandwiched between two 
carboxyl groups (Glu-85 and Glu-94) in a different binding pocket (Fig. 2-5) that is more 
buried in the protein interior when compared with the narbomycin desosamine binding 
site (Figs. 2-3B and 2-4B). Although proximal Glu-94 (2.7 Å distance) provides a salt 
bridge, distal Glu-85 (5.8 Å distance) may potentially compensate for the partial positive 
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charge at the desosamine tertiary amine. Trp-74, Asn-91, and Glu-94 participate in a 
network of hydrogen bond contacts with the desosamine moiety (Fig. 2-4B). The BC-
loop is more extensively involved in interactions with desosamine in this binding pocket, 
providing additional hydrophobic contacts via Trp-74, Leu-81, and Leu-88. The 
remaining desosamine-protein interactions are via Met-191 and His-238. Interestingly, 
the desosamine interaction pattern with amino acid residues in the PikC active site 
mimics interactions of desosamine with the bacterial ribosome drug target, although these 
involve specific RNA nucleotides and the phosphate backbone (Fig. 2-4C). 
Both YC-17- and narbomycin-bound PikC differ slightly (~2 Å) in positioning of 
the FG-region, which is most dynamic in the absence of substrate. Overall r.m.s. 
deviation between the two complexes is 0.51 Å and is almost the same (0.6 Å) for 
carboxyl residues anchoring desosamine. This indicates that specific substrate-anchoring 
modes largely account for the diversity of PikC products rather than an induced fit 
mechanism. 
The two YC-17 hydroxylation sites, allylic C10 and methylene C12 atoms, are 
within 7.5 and 5.3 Å from the heme iron, respectively (Figs. 2-3B and 2-4B). However, 
the C12-C13 bond of YC-17 is rotated slightly away from the heme iron, thus presenting 
a C-H bond at C12 for catalysis. This favorable stereochemical arrangement in 
combination with the 5.3 Å distance to the heme iron apparently leads to hydroxylation 
of YC-17 at C12, giving rise to neomethymycin (Fig. 2-1). However, the question 
remains whether the C10 position in YC-17 is hydroxylated from this same binding 
orientation and/or via the same mechanism since it is separated by > 7 Å from the heme 
iron atom. 
 
2.2.4 Site-directed Mutagenesis in Desosamine Binding Pockets 
To investigate directly the role of carboxyl functionalities in the desosamine 
binding pockets, site-directed mutagenesis was performed to replace Asp-50, Glu-85, and 
Glu-94 with alanine or glutamine/asparagines (Fig. 2-6). Functional activity of the mutant 
enzymes was assessed in vitro. Reaction products were analyzed by high pressure liquid 
chromatography. Substitution of the proximal carboxyl group forming a salt bridge to the 
C3' dimethylamino group, Glu-94 for YC-17 and Glu-85 for narbomycin, almost entirely 
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abolishes conversion of the corresponding substrate, indicating that both charge and 
hydrogen-bonding capacities in the proximal position are essential for desosamine 
anchoring. This result is in agreement with a stringent requirement of hydrogen-bonding 
functionality in the C3' position in genetically modified sugars (14-17). Substitution of 
the carboxyl at distal amino acid groups (Glu-85 for YC-17 and Asp-50 for narbomycin) 
generated PikC mutants that retain partial to complete catalytic activity, indicating that 
the negative charge of the distal carboxyl is dispensable. Interestingly, the E85Q mutant, 
which lacks a negative charge but retains a hydrogen-bonding capability, shifts the 
product ratio of YC-17 hydroxylation toward methymycin (Fig. 2-6). This change in 
product profile does not rule out the possibility of interchangeable roles of proximal and 
 
 
Figure 2-6. Functional activity of PikC mutants. High pressure liquid chromatography 
analyses of PikC-catalyzed reactions using YC-17 (A series) and narbomycin (B series) as 
substrate are shown. A1/B1, negative control in the absence of PikC. A2/B2, PikC wild type 
(PikC-wt). Mutants are used as indicated in the figure. Compound identities are as follows: 1, 
YC-17; 2, neomethymycin; 3, methymycin; 4, narbomycin; 5, pikromycin. Conversion of 
narbomycin at low efficiency is probably due to use of exogenous redox partners (e.g. spinach 
ferredoxin reductase) in P450 reconstitution assays. 
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distal carboxyl groups in desosamine binding, which may result in realignment of YC-17 
in the active site, bringing C10 closer to the heme iron. Substitution of a third residue not 
participating in binding, Asp-50 for YC-17 and Glu-94 for narbomycin, allows full (YC-
17) or significant residual (narbomycin) conversion to occur. It is particularly interesting 
that the D50N mutant provides more efficient hydroxylation of both macrolide substrates 
when compared with native PikC. Double mutant E85A/E94A is catalytically 
incompetent toward both endogenous macrolactone substrates (not shown). 
 
2.3 Summary 
In summary, we have determined four x-ray structures for the PikC P450 
monooxygenase that catalyzes hydroxylation of two macrolide substrates, leading to four 
dominant reaction products. Based on these data, a unique anchoring mechanism has 
been identified that involves a specific salt bridge of glutamate amino acid residues to the 
C3' dimethylamino group of the deoxysugar substituent. Site-directed mutagenesis of 
Glu-85, Glu-94, and Asp-50 amino acid residues in the substrate binding pocket were 
conducted to confirm the role of each in desosamine anchoring and their impact on the 
product ratio. Formation of a salt bridge between the protein carboxyl group and 
desosamine dimethylamino group is essential for catalytic conversion of each substrate. 
The data suggest that substrate tolerance and diverse product distribution occur from two 
specific anchoring orientations rather than induced fit mechanisms. The 12- and 14-
membered ring macrolactone portions of both macrolide substrates bind in the active site, 
utilizing virtually the same set of protein-substrate interactions. In contrast, the 
desosamine group binds in two alternative binding pockets, each providing two carboxyl 
residues, one of which involves a salt bridge to a C3' dimethylamino group of 
desosamine. Moreover, the presence of two desosamine binding pockets provides a 
unique opportunity to develop rational design of unnatural glycosylated substrates for 
PikC. It also enables selection of one of the two desosamine binding sites by site-directed 
mutagenesis to shift reaction product distribution toward a single desirable bioactive 
metabolite. It is particularly intriguing that the "acceptor" carbon atoms are located in 
non-equivalent positions with respect to the heme iron. Based on the x-ray structure, 
there is a ~5 Å distance between the heme iron atom and the corresponding reactive 
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methylene C atom that results in hydroxylation of analogous positions, C12 in YC-17, 
leading to neomethymycin, and C14 in narbomycin, leading to neopikromycin (Fig. 2-1). 
The latter hydroxylation product is formed in very low amounts, which might be due to 
the unfavorable stereochemistry of the C14-C15 bond that points toward the heme iron 
with both C14-H bonds directed away from the oxygen scission site. Two other 
analogous allylic hydroxylation sites, C10 in YC-17 and C12 in narbomycin, are both 
within 7.5 Å from the heme iron. This is far enough to raise questions about the ability of 
these positions to be hydroxylated (i) from this same substrate orientation as opposed to 
an alternative, as yet uncovered substrate orientation or (ii) via an oxo-ferryl P450 
intermediate as opposed to a peroxy-iron species. 
 
2.4 Experimental Procedures 
Expression and Purification of PikC — The PikC expression vector (20) was used for 
site-directed mutagenesis according to the QuikChange (Stratagene) protocol and for 
protein expression. The desired mutations were confirmed by DNA sequencing. Proteins 
were expressed in HMS174 (DE3) E. coli strain at 20 °C with an induction period of 20 
h. Purification on nickel-nitrilotriacetic acid resin (Qiagen) was followed by flow-through 
chromatography on S-Sepharose (Amersham Biosciences) and binding to Q-Sepharose 
(Amersham Biosciences), from which PikC was eluted by a NaCl gradient, 0-0.5 M. 
Protein was concentrated to 1 mM by using a Centriprep concentrating device. Quality 
and quantity of purified protein were accessed by SDS-PAGE and CO-reduced difference 
spectra (45). 
 
Crystallization and Diffraction Data Collection — Purified PikC with the His tag at 
0.2 mM concentration was either subjected to crystallization alone or mixed with 
substrate at 2 mM concentration (1:10 ratio) and then subjected to crystallization. In all 
cases, prior to crystallization, the protein was incubated for 1 h on ice with 1 mM 
dithiothreitol to prevent dimerization via Cys-375, which is readily observed during 
prolonged storage of PikC. Co-crystallization with ligands, either inhibitor or substrates, 
resulted in crystals of different size and morphology grown by vapor diffusion hanging 
drop method from a variety of crystallization conditions as indicated in Table 2-1. 
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Ligand-free PikC crystals grew in the presence of 5 mM azole inhibitor 4-
phenylimidazole (not found in the final crystal structure). All diffraction data were 
collected at 100-110 K at the Southeast Regional Collaborative Access Team (SER-CAT) 
22ID and Structural Biology Center 19ID beamlines, Advanced Photon Source, Argonne 
National Laboratory, Argonne, IL. Glycerol mixed with the reservoir solution was used 
as a cryoprotectant at concentrations ranging from 18 to 25%, which have been 
determined empirically for each crystal type. The images were integrated and the 
intensities were merged by using HKL2000 (46). 
 
Crystal Structure Determination — Molecular replacement was used to determine all 
crystal structures (Table 2-1). The ligand-free form of PikC was initially determined 
using the program CNS (47) and EryF (46% sequence identity) coordinates (48) as a 
search model. Crystal structures of YC-17- and narbomycin-bound PikC were similarly 
determined by molecular replacement using CNS (47), with ligand-free PikC coordinates 
as a search model. All reflections were used for refinement. The final atomic models 
(Table 2-1) were obtained after a number of iterations of refinement (CNS (47)) and 
manual model building with the program O (49). Ramachandran statistics (50) (Table 2-
1) indicate no outliers with an exception of one residue, Pro-181, in the narbomycin-
bound PikC structure (Protein Data Bank ID 2C7X). From 10 to 13 N-terminal residues, 
depending on the crystal form, are missing in all protein chains due to insufficient 
electron density in this region. Also, six BC-loop residues are missing in an open ligand-
free form due to the same reason. 
 
PikC Product Profile Analysis — The enzymatic conversions of YC-17 or narbomycin 
in vitro were carried out using a previously developed assay (20). The standard reaction 
contained 1 µM PikC (native enzyme or mutants), 0.5 mM YC-17 or narbomycin, 3.5 
µM spinach ferredoxin, 0.01 units of spinach ferredoxin-NADP+ reductase, and 1 mM 
NADPH in 200 µl of 50 mM Na-PO4 (pH 7.3), 1 mM EDTA, 0.2 mM dithiothreitol, 
10% (v/v) glycerol. The reaction was terminated after 40 min of incubation at 30 °C by 
the addition of 300 µl of chloroform, and products were subsequently extracted, dried, 
dissolved in 120 µl of methanol, and analyzed by reverse-phase (C18) high pressure 
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liquid chromatography (Waters Corp., Milford, MA) by using a linear gradient (0-100%) 
of water : trifluoroacetic acid : triethylamine (99.8 : 0.1 : 0.1) /acetonitrile : trifluoroacetic 
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Analysis of Transient and Catalytic Desosamine-binding 




Macrolides are a large family of secondary metabolites belonging to the 
polyketide class of natural products generated by diverse genera of actinomycetes 
bacteria. The large macrolactone ring systems are derived from polymerization of simple 
carboxylic acid precursors catalyzed by modular polyketide synthases and often require 
further modification by specific tailoring enzymes (1) to acquire or enhance biological 
activity. The modular architecture of polyketide synthase gene clusters has led to the 
development of combinatorial biosynthetic approaches that aim to generate novel 
secondary metabolites through rational engineering of new combinations of polyketide 
synthase modules (2–4). Tailoring enzymes, including cytochrome P-450 
monooxygenases (P-450) (2) are usually encoded within macrolide biosynthetic 
pathways (5). P-450 enzymes mainly serve to introduce hydroxyl or epoxide functional 
groups to nascent macrolactone structures or their glycosylated products (1, 3). To date, 
only three macrolide P-450 monooxygenases including EryF, EpoK, and PikC have been 
studied at both enzymatic and structural levels. Therefore, the principles of substrate 
recognition and regio- and stereochemical selectivity are just beginning to emerge for this 
intriguing group of biosynthetic enzymes. 
Streptomyces venezuelae P-450 PikC displays a relatively broad substrate and 
regiospecificity compared with EryF (6) and EpoK (7). This characteristic combined with 
robust catalytic efficiency as a single component engineered biocatalyst (8) has motivated 
us to further its development as a prototype P-450 monooxygenase directed toward 
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metabolic engineering and synthetic chemical applications (3). Thus, PikC performs 
multiple hydroxylations of structurally variant macrolides including the 12-membered 
ring YC-17 and 14-membered ring narbomycin, leading to methymycin/neomethymycin 
and the natural ketolide antibiotic pikromycin, respectively (10) (Fig. 3-1). Ketolides are 
macrolide derivatives characterized by a C-3 keto group that have received significant 
attention recently because of their enhanced activity against drug-resistant microbial 
pathogens (11). 
Both endogenous PikC substrates are glycosylated with the 3-(dimethylamino)-
3,4,6-trideoxy sugar desosamine that confers antibiotic activity to a number of macrolide 
antibiotics such as erythromycin, troleandomycin, mycinamicin, megalomicin 
(desosamine), tylosin, carbomycin, spiramycin (mycaminose, having an additional 
hydroxyl group at the C-4 position of the sugar ring), and a highly potent semisynthetic 
ketolide telithromycin (11–13). PikC catalyzes hydroxylation of variant macrolide 
substrates modified with altered sugar moieties through metabolic engineering (14–18) or 
with unnatural macrolactone ring systems (19, 20). PikC has also been shown to function 
effectively when immobilized on a microfluidic biochip (21), and when fused to a 
heterologous electron donor (8), the reductase domain of a self-sufficient P-450RhF from 
Rhodococcus sp. NCIMB 9784 (22). 
 
 
Figure 3-1. Structures of the PikC native substrates and their hydroxylated products. 
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Recent analysis of the x-ray crystal structures (23) revealed that YC-17 and 
narbomycin bind in the PikC active site via overlapping modes sharing the macrolactone-
binding site and utilizing distinct desosamine binding regions, including buried and 
surface-exposed pockets, respectively. In both modes, the protonated dimethylamino 
group of desosamine binds between two negatively charged carboxyl groups of amino 
acid residues forming a salt bridge with the proximal (relative to the dimethyamino 
moiety) carboxyl and an ionic contact with the distal one. The triad of carboxylate 
residues Asp50, Glu85, and Glu94 located in the BC loop provides this set of 
interactions. Elimination of the negative charge at Glu85 or Glu94 by site-directed 
mutagenesis virtually inactivates (Glu94) or substantially reduces (Glu85) conversion of 
both substrates (23). In contrast, elimination of the surface-exposed negative charge at 
Asp50 via substitution of this residue with asparagine significantly enhances catalytic 
activity of PikC. To address the specific role for each desosamine-binding pocket, we 
analyzed the x-ray structures of the catalytically superior PikCD50N mutant co-crystallized 
with narbomycin or YC-17. In PikCD50N, YC-17 adopts the same binding mode as 
observed previously in the wild type, with desosamine bound in the buried pocket. In 
contrast to the previously observed binding mode in wild type PikC, narbomycin was also 
found predominantly in the buried pocket in the corresponding D50N mutant form, 
suggesting the possibility of initial substrate recognition in the "surface-exposed site," 
with subsequent relocation to the catalytic "buried site." We herein report PikC substrate 
binding, enzyme mutagenesis, and kinetic data to support this hypothesis and provide 




3.2.1 Substrate Binding 
Binding affinities of PikC wild type and the mutants for the native substrates, YC-
17 and narbomycin, and their aglycone precursors, 10-deoxymethynolide and 
narbonolide, were deduced from a low to high spin iron spectral shift, known as type I 
binding (24). Both narbonolide and 10-deoxymethynolide bound PikC with the 
significantly reduced affinities compared with the corresponding glycosylated substrates 
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(Table 3-1), which may explain, at least in part, lack of hydroxylation by PikC. Binding 
affinity for YC-17 (KD = 98.9 µM) was 2.3 times higher than narbomycin (KD = 234.5 
µM) (Fig. 3-2, panels A1 and B1). Compared with wild type enzyme, binding affinities 
of the catalytically more active PikCD50N increased about 4-fold for YC-17 (27.2 µM) and 
1.3-fold for narbomycin (171.9 µM) (panels A2/B2). PikCE85Q had reduced binding 
affinities for both substrates compared with wild type enzyme (panels A3/B3). Binding 






Figure 3-2. Binding of YC-17 and narbomycin to PikC. The concentration dependence of 
YC-17 (A panels) and narbomycin (B panels) binding deduced from the difference absorption 
changes (shown in insets) obtained from titration of PikC wild type or mutant enzymes, as 
indicated in each panel with increasing concentrations of substrates, as shown. Titration 
experiments were performed in 50 mM sodium phosphate, pH 7.3, 1 mM EDTA, 0.2 mM 
dithioerythritol, and 10% glycerol. The absence of the fitting curves in panels A4 and A6 
indicates an unsuccessful fit caused by a lack of enzyme saturation. The values for the binding 
constants obtained from the curve fitting are presented in Table 3-1. 
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affinities for PikCE94Q were even further reduced (panels A4/B4), although the KD values 
could not be determined for YC-17 because saturation of enzyme could not be 
approached because of both low binding affinity and limited substrate solubility. 
Additionally, D50N substitution did not significantly affect binding in the double mutants 
(Table 3-1 and Fig. 3-2, panels 5 and 6). 
 
3.2.2. Kinetics of Narbomycin Binding 
Binding of narbomycin to PikC wild type and the PikCD50N and PikCE85Q mutants 
was addressed by stopped flow UV-visible spectroscopy. Binding kinetics were biphasic 
and accurately described by a double exponential function revealing a fast first phase 
followed by a slow second one (Fig. 3-3). The kinetic rate of the first binding step 
(accounting for ~50% of the reaction amplitude) was fast and protein-dependent (Table 







Figure 3-3. Kinetics of narbomycin binding. Typical kinetic transient of narbomycin 
binding (black) fitted to a double exponential function (red) is shown for PikCD50N. Stopped 
flow experiments were conducted in 50 mM Tris-HCl, pH 7.5, 0.5% Me2SO, and 0.5 mM 
EDTA. 
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3-2). The rate of the second step was slow, 13 s–1, and virtually identical between the 
wild type and both mutant forms (D50N and E85Q) of PikC. The first binding rate of the 
catalytically superior PikCD50N was twice as fast as that of the mutant PikCE85Q with low 
activity: 822.8 ± 21.8 s–1 versus 421.4 ± 18.4 s–1, respectively, with the wild type 
determined to be more similar to the D50N mutant at 703.0 ± 29.1 s–1. We assume that 
the first binding step represents a pseudo first order reaction of the bimolecular encounter 
between PikC and narbomycin, whereas the second slow step may reflect monomolecular 
conformational adjustments of substrate position in the active site assisted by PikC 
dynamics (23). Because of small changes in the absolute spectra used to monitor the 
reaction and the limited solubility of narbomycin, we were unable to accurately estimate 
the kon from the concentration dependence of the observed rates. In addition, the pseudo 
first order rate for PikCD50N may be underestimated because of instrument limitations for 
monitoring fast reactions. 
 
 
3.2.3 X-ray Structure of the PikCD50N-YC-17 Complex 




The crystal structure of the PikCD50N-YC-17 complex was determined to a 
resolution of 3.2 Å (Table 3-3). Although determined at relatively low resolution, the 
electron density for YC-17 in both protein monomers in an asymmetric unit was well 
defined, showing no ambiguity for macrolide binding (Fig. 3-4). In both monomers 
(superimposable with the root mean square deviation of 0.43 Å), YC-17 was bound in the 
active site with desosamine positioned in the buried pocket anchored via the 
dimethylamino group to the side chain of Glu94 and Glu85, similar to what has been 
observed for wild type PikC (23). 
 
3.2.4 X-ray Structure of the PikCD50N-Narbomycin Complex 
Although they share the same space group and the unit cell dimensions as the 
PikCD50N-YC-17 (Table 3-3), PikCD50N-narbomycin crystals diffracted to a higher 
resolution (1.85 Å), revealing new details of the protein-substrate interactions. Although 
two protein monomers in the asymmetric unit had virtually identical overall 
conformations (root mean square deviation of 0.34 Å), the desosamine moiety of 
narbomycin was found in both alternative pockets. In the chain B form, desosamine was 
unambiguously bound in the buried pocket with the dimethylamino group positioned 
between the Glu94 and Glu85 side chains (Fig. 3-5A). This binding mode has been 
previously characterized for YC-17 but not for narbomycin (23). In the chain A form, 
 
 
Figure 3-4. YC-17 binding in PikCD50N. Stereo view of YC-17 (highlighted in cyan) bound 
in the active site of PikCD50N (Protein Data Bank code 2VZ7, chain A) surrounded by heme 
and amino acid side chains (green) within 4 Å plus N50 is shown. Fragments of the 2Fo – Fc 
electron density composite omit map contoured at 0.8 σ are shown as gray mesh. Heme is 
orange, nitrogen atoms are blue, and oxygen atoms are red. The image was generated using 
PYMOL program (30) 
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electron density for the macrolactone ring of narbomycin was clearly defined, whereas 
electron density for desosamine was split between both buried and surface-exposed 
pockets, suggesting two alternative conformations (Fig. 3-5B), each refined with the 
occupancy of 0.5. The buried conformation (cyan in Fig. 3-5B) superimposed well 
between the A and B monomer, whereas the surface-exposed conformation in monomer 
A (pink) superimposed with the position observed for narbomycin in the wild type 
enzyme (23). Interestingly, in the surface-exposed pocket of PikCD50N, the dimethylamino 
group of desosamine was located between the carboxyl group of Glu85 and the 
carboxamide group of Asn50 substituting for Asp50. In addition, subtle differences were 
observed for the macrolactone portion of narbomycin between the two binding modes 
(Fig. 3-5B). 
 
3.2.5 Catalytic Activity of PikC Mutants  
The catalytic activity of the double mutants PikCD50N/E94Q and PikCD50N/E85Q was 
addressed simultaneously with the panel of single PikC mutants characterized previously 
 
 
Figure 3-5. Narbomycin binding in PikCD50N. Stereo views of narbomycin (cyan or pink) 
bound in the active site of PikCD50N (Protein Data Bank code 2VZM) (A) in the chain B and 
(B) in the chain A are shown. Selected amino acid side chains (green) are within 4 Å. In A, 
alternative conformations for Met191 are shown. Heme is in orange, nitrogen atoms are in 
blue, oxygen atoms are in red, and sulfur atoms in yellow. Fragments of the 2Fo – Fc electron 
density composite omit map contoured at 0.8 σ are shown as gray mesh. 
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(23). Enhanced catalytic activity for PikCD50N and attenuated catalytic activity for 
PikCE94Q were confirmed (Fig. 3-6 and Table 3-4). As before, residual catalytic 
conversion by PikCE94Q was observed for narbomycin, 5.4% versus 35.0% for the wild 
type, but not for YC-17 (Fig. 3-6, panels A5 and B5 and Table 3-4). In accord with 
previous results (23), E85Q substitution notably reduced but did not entirely eliminate 
both catalytic activities (Fig. 3-6, panels A4/B4, and Table 3-4). Significantly, 
introduction of the D50N substitution failed to rescue catalytic activity of the double 
 
 
Figure 3-6. Catalytic activity of PikC mutants. High pressure liquid chromatography 
analysis of PikC-catalyzed reactions using YC-17 (A panels) and narbomycin (B panels) as 
substrate are shown. A1/B1, negative control in the absence of PikC. A2/B2, PikC wild type 
(PikC-wt). The mutants are used as indicated in the figure. The compound identities are as 
follows: 1, YC-17; 2, neomethymycin; 3, methymycin; 4, narbomycin; 5, pikromycin. The 
peak identity in each HPLC trace was determined by mass spectrometry and compared with 
authentic compounds with respect to HPLC retention time and UV spectrum. The area under 
each peak was quantified, and the results for each chromatogram are presented in Table 3-4. 
 





mutants (Fig. 3-6, compare panels 4 and 5 with panels 6 and 7, respectively), revealing 
the dominant impact of the E94 interaction for PikC function. 
 
3.3 Discussion 
Desosamine plays a fascinating parallel role both in targeting macrolide 
molecules to the 50 S bacterial ribosomal subunit (25, 26) and in tailoring of these 
important antibiotics by biosynthetic P-450 enzymes. In each case, the N,N-
dimethylamino group of the sugar provides a key interaction for anchoring the 
macrolactone in its specific binding site. Antibiotic action is achieved through blockage 
of the peptide exit site resulting from precise macrolide interactions (27). Sugar 
anchoring also provides the basis for hydroxylation in the active site of P-450 
monooxygenases PikC (23), EryK (28), MycCI, and MycG (29). As shown previously for 
PikC, the specific interactions between the protonated dimethylamino group of 
desosamine and the carboxyl-containing residues in the binding site are required for the 
catalytic activity. Non-glycosylated substrate precursors narbonolide and 10-
deoxymethynolide, are very weakly bound with KD values in the millimolar range (Table 
3-1) and do not serve as substrates for PikC. Thus, given the importance of negative 
charges associated with Glu85 and Glu94, the enhancement of catalytic activity in 
PikCD50N was surprising. 
In a search for determinants of improved catalytic function of PikCD50N, we have 
determined the x-ray structures for this mutant complexed with the native substrates YC-
17 and narbomycin. Although YC-17 showed no binding ambiguity (Fig. 3-4), 
narbomycin adopted two alternative conformations in the active site of the mutant 
enzyme (Figs. 3-5 and 3-7). Moreover, for the 14-membered ring macrolide, 25% of 
protein molecules in the PikCD50N-narbomycin crystals had desosamine bound in the 
surface-exposed pocket, whereas the remaining molecules revealed desosamine 
associated with the buried pocket. The latter binding mode has not been observed for 
narbomycin previously. In the surface-exposed pocket of PikCD50N, the dimethylamino 
group of desosamine formed a salt bridge to the proximal Glu85 residue as it does in the 
wild type. However, the original ionic contact with the distal Asp50 was no longer 
available because of removal of the negative charge through asparagine substitution. We 
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surmised that the loss of an electrostatic component might weaken protein-desosamine 
interactions in the surface-exposed pocket and facilitate desosamine relocation to the 
buried position, suggesting a catalytic role for this site. If so, the PikCD50N/E94Q double 
mutant should remain sensitive to the E94Q substitution. Alternatively, if D50N 
substitution favors hydroxylation from the surface-exposed pocket (given that the 
macrolactone is positioned similarly in respect to the iron center in both binding modes 
(Fig. 3-5B)), PikCD50N/E94Q should be insensitive to the E94Q mutation. To test both 
hypotheses, the catalytic activities of two double mutants, PikCD50N/E94Q and 
PikCD50N/E85Q, were analyzed. The D50N substitution could not rescue or even affect the 
functional activity of the double mutants (Fig. 3-6 and Table 3-4), supporting the 
facilitated relocation to the buried pocket as a factor that favors catalysis. 
Both the PikC mutagenesis studies and the crystal structure analysis suggest a 
two-step substrate binding mechanism whereby desosamine of the macrolide substrate 
initially binds to the surface-exposed pocket (Fig. 3-7A) and then relocates to the 
catalytic buried site (Fig. 3-7B). Because narbomycin is comprised of a 14-membered 
macrolactone ring, it could have a higher energetic barrier for conversion from one site to 
another and therefore was trapped entirely in the surface-exposed pocket in the crystals of 
 
 
Figure 3-7. Transient and catalytic desosamine-binding pockets. (A) Narbomycin in the 
surface-exposed pocket is highlighted in pink. (B) Narbomycin in the buried pocket is 
highlighted in cyan. Zoomed images in (A) and (B) are shown in perspective. (C) Semi-
transparent surface of the PikCD50N shows overall disposition of the negatively charged 
residues. Heme (orange) is shown as van der Waals' spheres. N atoms of desosamine are blue, 
O atoms red. Carboxylic residues Asp50, Glu85, and Glu94 are shown as red sticks. Images 
were generated using VMD program (9). 
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the wild type enzyme (23) and partially in the crystals of the PikCD50N mutant. The 
hampered relocation to the buried pocket might explain the reduced binding affinity of 
narbomycin compared with YC-17: 234.5 ± 15.0 µM versus 98.9 ± 1.9 µM (Table 3-1), 
because the substrate is presumed to be more easily released from the surface-exposed 
pocket than the buried one. Accordingly, the affinity of PikCD50N is higher toward both 
substrates because of facilitated access for desosamine to the buried pocket, which 
reduces dissociation of substrate from the surface-exposed site. Thus, the residual level of 
the PikCE94Q catalytic activity toward narbomycin (Fig. 3-6, panel B5, and Table 3-4) is 
readily explained by marginal hydroxylation from the surface-exposed pocket. In 
contrast, YC-17 is not hydroxylated by this mutant (Fig. 3-6, panel A5) because of rapid 
relocation to the buried pocket, where catalytic activity depends entirely on the 
interactions with Glu94. 
The residual level of hydroxylation demonstrated by PikCE85Q toward both 
substrates (Fig. 3-6, panels A4 and B4, and Table 3-4) suggests that relocation of each 
macrolide is affected in this mutant. Glu85 is centered between the two pockets (Fig. 3-7) 
and therefore may serve as a pivot in the transition of desosamine, because the latter may 
remain electrostatically "tethered" to the Glu85 carboxylate group during the relocation. 
Because introduction of the D50N substitution could not rescue catalysis (Fig. 3-6, panels 
A6 and B6, and Table 3-4), the residual hydroxylation by PikCE85Q is likely to occur from 
the surface-exposed pocket as well. 
Because of the dynamic constraints imposed upon narbomycin, we were able to 
assess kinetic binding rates between the PikC mutants by UV-visible spectroscopy 
combined with stopped flow kinetic studies. The kinetic trends were consistent with the 
equilibrium binding and functional data, because the catalytically superior PikCD50N 
bound narbomycin twice as fast as the poorly active PikCE85Q mutant enzyme under the 
same experimental conditions (Table 3-1). This observation suggests that the first kinetic 
rate likely reflects formation of the final buried complex rather than a transient one, and 
hence, transition from the surface-exposed to the buried site is the rate-limiting step of 
the substrate binding reaction. 
The regiospecificity of PikC is a particularly interesting characteristic of this 
enzyme. In all PikC/substrate co-crystal structures reported to date, the allylic carbon 
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hydroxylation center in YC-17 (C-10) and narbomycin (C-12) is >7 Å away from the 
iron. The allylic C-H bond is the predominant hydroxylation site in narbomycin and one 
of two equally hydroxylated sites in YC-17, the second (methylene at C-12) positioned 
within 5 Å from the iron. Differences in the ratio of the YC-17 hydroxylation products 
between PikCD50N, PikCE85Q, and the wild type (Fig. 3-6 and Table 3-4) may be explained 
by dynamic variations in substrate binding making one site more favorably positioned for 
hydroxylation. At the same time, despite its 5 Å proximity to the iron reaction center, we 
have not observed hydroxylation of the methylene C-14 site in narbomycin by any PikC 
form in vitro, suggesting the possibility of additional steric or electronic factors that shift 
hydroxylation to the allylic C-12 site exclusively. 
Collectively, our data indicate that each of the triad carboxylic acid residues 
interacting with the positive charge of desosamine plays a particular role in PikC 
catalysis; surface-exposed Asp50 appears to function as a gate for substrate access to the 
active site through kinetic control over substrate dissociation in solution from the 
transient site versus transition to the catalytic buried site. Glu85 centered between two 
desosamine-binding pockets may serve as a pivot in desosamine relocation. Finally, 
Glu94 evidently plays a major role in tuning substrate orientation for effective catalysis. 
 
3.4 Experimental Procedures 
Preparation of Protein Samples — Expression vectors for PikC wild type and mutants 
were used to transform Escherichia coli strain HMS174 (DE3) to express and 
subsequently purify proteins according to the protocol described elsewhere (23). The 
double mutants PikCD50N/E94Q and PikCD50N/E85Q represent new constructs prepared in this 
study. The quality of the purified proteins was assessed by the SDS-PAGE and UV-
visible spectroscopy, and the concentration was determined at 450 nm from the 
difference spectra between the carbon monoxide-bound ferrous and water-bound ferric 
forms using the extinction coefficient of 91,000 M–1 cm–1 (31). 
 
Preparation of Substrates — Substrates YC-17 and narbomycin were obtained from the 
pikC knock-out strain S. venezuelae AX-906 (10). Alternatively, narbomycin was 
harvested from fermentation culture of Streptomyces narbonensis NRRL B-1680 in 
 45 
soluble complete medium, containing 15 g of soluble starch, 20 g of soytone, 1.5 g of 
yeast extract, 10.5 g of MOPS, 0.1 g of CaCl2 at pH 7.2, per 1 liter of deionized water. 
 
Equilibrium Binding Assay — Spectroscopic substrate binding assay was carried out at 
room temperature using a UV-visible spectrophotometer 300 Bio (Cary). Protein 
dissolved in 50 mM sodium phosphate, pH 7.3, 1 mM EDTA, 0.2 mM dithioerythritol, 
and 10% glycerol at concentrations ranging from 1 to 2 µM was titrated with the 
substrate dissolved in Me2SO (20 mM) in 1-µl aliquots. The same amounts of Me2SO 
alone were added to the protein in the reference cuvette followed by recording of the 
difference spectra. Absorbance differences ∆A (Apeak 389 nm – Atrough 422 nm) were plotted 
versus substrate concentration, and data from duplicated experiments were fitted to the 
hyperbolic function ∆A = Amax•S/(KD + S), where S is the total ligand concentration, 
Amax is the maximal absorption shift at saturation, and KD is the apparent dissociation 
constant for the enzyme-ligand complex. 
 
Catalytic Activity Assay — Enzymatic conversion of YC-17 or narbomycin in vitro 
were performed using a previously developed assay (10). The standard reaction contained 
1 µM PikC (wild type or mutant form), 0.5 mM YC-17 or narbomycin, 3.5 µM spinach 
ferredoxin, 0.01 units of spinach ferredoxin-NADP+ reductase, and 1 mM NADPH in 100 
µl of 50 mM sodium phosphate, pH 7.3, 1 mM EDTA, 0.2 mM dithioerythritol, and 10% 
(v/v) glycerol. The reaction was terminated after 40 min of incubation at 30 °C by the 
addition of 3 x 300 µl of chloroform. The extractions were subsequently combined, dried, 
and dissolved in 120 µl of methanol and subjected to the reverse phase HPLC using a X-
Bridge C18, 5 µm, 250-mm column (Waters Corporation) in a linear gradient (30–60%) 
of acetonitrile in 10 mM ammonium acetate, pH 8.1, at the flow rate of 1.0 ml/min. 
Detection was at 238 nm. 
 
Pre-steady State Binding Assay — Stopped flow kinetic analysis experiments were 
conducted at 23 °C using a Hi-Tech Scientific instrument equipped with a photodiode 
array detector and controlled by the KinetAsyst software (Bradford on Avon, UK). 
Protein and narbomycin solutions were prepared in 50 mM Tris-HCl, pH 7.5, and 0.5 
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mM EDTA. Narbomycin stock solution was in Me2SO; therefore, solvent concentration 
was adjusted in both syringes and maintained constant (0.5%) throughout the 
experiments. Protein concentration after mixing was 10 µM. To maintain pseudo first 
order reaction conditions, all of the measurements were carried out in 10-fold excess of 
narbomycin over the protein. Kinetic transients were recorded for 0.5 s at 390 nm 
corresponding to the peak of the difference spectra between the high spin substrate-bound 
and the low spin substrate-free PikC forms. Multiple kinetic traces for each sample were 
measured and averaged prior to data analysis. The data points from 2 to 500 ms were 
fitted to a standard double exponential function using SPECFIT software. 
 
Crystallization and Data Collection — PikCD50N from the 1 mM frozen stock stored at 
–80 °C in 20 mM Tris-HCl, pH 7.5, 200 mM NaCl, and 0.5 mM EDTA was mixed with 
either YC-17 or narbomycin, both dissolved in Me2SO at 50 mM stock concentration, to 
final concentrations of 0.2 mM for protein and 2 mM for the ligand. The mixtures were 
subjected to the automated screening of crystallization conditions (hanging drop 
crystallization protocol) using a nanoliter drop setter Mosquito (TTP LabTech) and 
commercial high throughput screening kits purchased from Hampton Research and 
Qiagen. Crystallization conditions generating crystals were identified and optimized 
further in 24-well crystallization plates. The crystals used for x-ray data collection were 
obtained at 23 °C for the PikCD50N-YC-17 complex from 20% polyethylene glycol 4000, 
0.1 M Bis-Tris, pH 6.5, and 0.2 M Li2SO4, and for the PikCD50N-narbomycin complex 
from 16% polyethylene glycol 8000, 0.1 M sodium cacodilate, pH 6.5, and 0.15 M 
Li2SO4. Prior to data collection, the crystals were cryo-protected by plunging into a drop 
of reservoir solution supplemented with 20% glycerol and flash frozen in the liquid 
nitrogen. Diffraction data were collected at 100–110 K at beamline 8.3.1, Advanced 
Light Source, Lawrence Berkeley National Laboratory. The images were integrated, and 
the intensities were merged by using the HKL2000 software suite (32). 
 
Structure Determination and Refinement — Structures were determined by molecular 
replacement using the CCP4 (33) program suit and an A chain of the YC-17-bound PikC 
(Protein Data Bank code 2C6H) as a search model. Model building was performed with 
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the programs COOT (34, 35) and O (36) and refined using REFMAC5 (33, 37). 
Simulated annealing was performed, and electron density composite omit maps were 
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Engineering and Analysis of a Self-Sufficient Biosynthetic 




Cytochrome P450 enzymes (P450s) are highly attractive biocatalysts due to their 
ability to catalyze a variety of regio- and stereospecific oxidation reactions of complex 
organic compounds. These reactions occur under mild conditions by taking advantage of 
the two-electron activated dioxygen that is often challenging in organic synthesis (1, 2). 
To activate molecular oxygen, redox partners are required to sequentially transfer two 
reducing equivalents from NAD(P)H to P450 (3). Classically, there are two major redox 
partner systems, including an FAD containing reductase with a small iron−sulfur (Fe2S2) 
redoxin for most bacterial and mitochondrial P450s (class I) and a single FAD/FMN 
containing flavoprotein for eukaryotic microsomal P450s (class II) (4, 5). The inherent 
requirement of cytochome P450s for separate protein partner(s) significantly limits their 
application in biotechnology. 
The discovery of the first self-sufficient P450BM3, which is naturally fused to a 
eukaryotic-like reductase, represents an effective solution to this limitation (6, 7). The 
fusion nature of this enzyme dramatically improves electron-transfer efficiency and 
coupling with the oxidative process, enabling it to be the most efficient P450 enzyme 
characterized to date (8). Based upon the self-sufficiency of this naturally fused enzyme, 
a number of engineered proteins of diverse eukaryotic P450s bearing a reductase domain 
from P450BM3 have been generated with in vitro activities (9, 10). This provides ready 
access to the great catalytic versatility of the membrane-bound eukaryotic P450s. In 
contrast, the biosynthetic P450s (class I) lack such a universal reductase that can be used 
 51 
to engineer diverse self-sufficient P450s for either functional identification or potential 
industrial application. 
Recently, a new class of self-sufficient cytochrome P450s exemplified by P450RhF 
from Rhodococcus sp. NCIMB 9784 was discovered to be naturally fused to a novel 
FMN/Fe2S2 containing reductase partner (11, 12). Although the physiological function 
of P450RhF remains unknown, its reductase domain (RhFRED), which is similar to the 
phthalate family of dioxygenase reductases, is capable of transferring electrons from 
NADPH to the heme domain of the monooxygenase, supporting 7-ethoxycoumarin 
dealkylation activity (13, 14). Moreover, recent reports from Misawa et al. demonstrated 
that this reductase domain could be used to reconstitute the catalytic activities of various 
class I P450s in vivo through expression of corresponding genes fused to RhFRED in 
Escherichia coli cells (15, 16). This suggests that RhFRED might be developed into a 
generally effective redox partner for biosynthetic bacterial P450s. However, the lack of 
corresponding in vitro data could not unambiguously exclude in trans involvement of 
additional cellular redox partners. 
 
4.2 Results and Discussion 
Herein, we describe the first in vitro characterization of a single component 
bacterial biosynthetic cytochrome P450 fused to RhFRED that demonstrates high 
catalytic efficiency. The PikC cytochrome P450 in this study is involved in the 
 
 
Figure 4-1. Major Physiological Reactions Catalyzed by PikC 
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pikromycin biosynthetic pathway of Streptomyces venezuelae (17). PikC catalyzes the 
final hydroxylation step toward both the 12-membered ring macrolactone YC-17 (1) and 
the 14-membered ring macrolactone narbomycin (4) to produce 
methymycin/neomethymycin (2/3) and pikromycin (5) as major products (Fig. 4-1) (18, 
19). Recently, we elucidated the structural basis for the remarkable substrate flexibility 
by analyzing ligand-free and substrate-bound structures of PikC (20). However, since the 
native redox partner of PikC remains unknown, its in vitro activity has depended on 
expensive spinach ferredoxin reductase (Fdr) and ferredoxin (Fdx) (Fig. 4-2A), as are 
many other biosynthetic P450s (21-23). To investigate an alternative electron-transfer 
pathway mimicking the fusion organization in P450RhF (Fig. 4-2B), pikC was linked to 
the RhFRED gene including the native 16 amino acid linker sequence (Fig. 4-S1). The 
hybrid sequence was cloned into pET28b(+), and overexpressed in E. coli BL21 (DE3) to 
generate N-terminal His6-tagged PikC-RhFRED (Fig. 4-S2). After Ni-NTA 
chromatography, the purified red-colored recombinant P450 displayed (upon reduction) 
the signature peak at 450 nm in the CO-difference spectrum (Fig. 4-S3). Interestingly, gel 
filtration chromatography (Fig. 4-S4) indicated that PikC-RhFRED predominantly 
dimerizes in storage buffer solution containing 0.2 mM dithioerythritol (DTE). In 
contrast, wild type (wt) PikC was shown to be monomeric under the same conditions. It 
was thus unclear whether the intermonomer electron transfer could occur in the dimeric 
PikC-RhFRED as in P450BM3 (24). 
We next tested the ability of PikC-RhFRED to hydroxylate 1 and 4 in vitro when 
provided electron donor NADPH. We were gratified to observe that this chimeric protein 




Figure 4-2. Two redox partner systems (electron transfer pathways) used in this study 
for PikC.  A, three-components system; B, one-component RhFRED system. 
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exogenous redox partners (spinach Fdr and Fdx), producing higher yields of 2/3 and 5 
under identical reaction conditions (Fig. 4-3). This result unambiguously confirms that 
PikC-RhFRED is a self-sufficient P450 enzyme. Interestingly, we also constructed the 
pET21b(+)-pikC-RhFRED and obtained the purified C-terminal  His6-tagged PikC-
RhFRED. This protein showed a similar CO-difference spectrum as its N-terminal His6-
tagged counterpart. However, it lacks catalytic activity, which is consistent with a similar 
C-terminal His6-tagged form of original P450RhF (13, 14). This provides additional 
evidence for the importance of the C terminus of RhFRED for electron transfer. 
As mentioned above, one benefit of the fusion arrangement is that the covalent 
linkage presumably stabilizes the interaction between the P450 and redox partner, thus 
enhancing electron-transfer efficiency. As such, one would expect this to improve the 
catalytic activity in terms of kcat, whereas the substrate specificity would not be changed 
significantly (25, 26). To test whether this also applies to PikC-RhFRED, we first 
determined the substrate binding affinity of 1 and 4 toward both PikC and PikC-




Figure 4-3. HPLC analysis of reactions (1 h) catalyzed by wt PikC and fusion enzyme 
PikC-RhFRED. a) Negative control of 1 in absence of P450. b) 1 with wt PikC in presence of 
Fdr, Fdx, and NADPH. c) 1 with PikC-RhFRED in presence of only NADPH. d) Negative 
control of 4 in absence of P450. e) 4 with wt PikC in presence of Fdr, Fdx, and NADPH. f) 4 
with PikC-RhFRED in presence of only NADPH. 
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and 215.0 ± 4.2 µM, respectively, which are similar to 112.9 ± 1.9 µM (1) and 288.3 ± 
7.1 (4) toward wt PikC (Fig. 4-S5). This indicates that attachment of the heterologous 
reductase domain has no significant impact on substrate binding to PikC. Subsequently, 
we compared the kinetic parameters of PikC-RhFRED with those of the PikC-Fdr-Fdx 
three-component system. As previously reported (18, 27), substrate inhibition was 
observed in all cases when substrate concentration was greater than 250 µM. Moreover, 
the solubility limitation (less than 500 µM) of macrolides in aqueous solution prevented 
us from deducing the Ki value. Therefore, we determined the apparent specificity 
constants (kcat/Km) by fitting the low-concentration data to the linear region of the 
Michaelis−Menten curve (Fig. 4-S6). By directly monitoring the substrate consumption 
by HPLC, the kcat/Km values of PikC-RhFRED were determined to be 0.96 and 1.20 µM-
1·min-1 for 1 and 4, respectively. In contrast, the specificity constants of wt PikC 
partnered by Fdr and Fdx were 0.24 µM-1·min-1 for 1 and 0.31 µM-1·min-1 for 4. It is 
evident that the fusion enhanced catalytic activity approximately 4-fold for both 1 and 4. 
Notably, the kinetic parameters of wt PikC differ significantly from those previously 
determined indirectly, using a NADPH depletion assay (18, 19, 27), suggesting that the 
stoichiometric ratio between NADPH and substrate hydroxylation could not be 1:1. The 
presumed decoupling between electron transfer and hydroxylation might account for this 
difference. 
Finally, when RhFRED was fused to another prototype biosynthetic P450 EryF 
(21, 22), a more active self-sufficient biocatalyst was obtained once again (Fig. 4-S7). 
Together with previous in vivo work (15, 16), our studies demonstrate that further 
development of RhFRED as the basis for an efficient cost-effective redox partner for 
bacterial biosynthetic P450s is warranted. Further efforts to understand this unique 
reductase, especially the electron-transfer process involving heterologous fusion systems, 
are now in progress. 
 
4.3 Experimental Procedures 
Molecular cloning — The gene encoding the reductase domain of P450RhF (RhFRED) 
and the linker sequence was amplified by PCR under standard conditions using forward 
primer: 5’-GGGAATTCGTGCTGCACCGCCATCAACCG-3’ (the italic bases represent 
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EcoRI restriction site), reverse primer 1: 5’-
TTAGAGCTCCAGAGGCGCAGGGCCAGGCG-3’ (the SacI cutting site is underlined) 
for amplifying RhFRED gene without the stop codon, and reverse primer 2: 5’-
ACATCAAGCTTTCAGAGGCGCAGGGCCAG-3’ (the HindIII cutting site is 
underlined) for cloning RhFRED gene retaining the stop codon. The cDNA without and 
with the stop codon were digested by NdeI/SacI and NdeI/HindIII restriction enzyme 
pairs, respectively, and then ligated into the NdeI/SacI digested pET21b(+) (Novagen) 
and NdeI/HindIII digested pET28b(+) (Novagen) correspondingly, generating the 
recombinant plasmid pET21b(+)-RhFRED and pET28b(+)-RhFRED. On the other hand, 
using previously prepared plasmid pET28a-pikC (18) as template, the pikC gene with 
stop codon removed was amplified by PCR under standard conditions using a pair of 
primers as follow: forward, 5’-GGAGTTCCATATGCGCCGTACCCAGCAG-3’, 
reverse: 5’-GATAGAATTCACCGGTACGGCGGCCCGC-3’ (The italic and underlined 
bases represent the introduced NdeI and EcoRI restriction sites for following cloning 
manipulation). The NdeI/EcoRI double digested pikC gene was then ligated into the 
previously NdeI/EcoRI-digested pET21b(+)-RhFRED and pET28b(+)-RhFRED to 
generate vectors pET21b(+)-pikC-RhFRED and pET28b(+)-pikC-RhFRED (Fig. 4-S1) 
for overexpressing C-His6-tagged and N-His6-tagged fusion protein PikC-RhFRED. 
 
Overexpression and purification of fusion proteins — The E. coli BL21 (DE3) 
transformant carrying certain overexpression vector was grown at 37 oC overnight in LB 
media containing 50 µg/ml of kanamycin (or ampicillin), then 10 ml of culture was used 
to inoculate 1 liter of LB media containing certain selective antibiotic (50 µg/ml), thiamin 
(1 mM), 10% glycerol and a rare salt solution. Cells were grown at 37 oC for 3~4 h until 
A600 reached 0.6~1.0. Then, isopropyl β-D-thiogalactoside (IPTG, 0.1 mM) and δ-
aminolevulinic acid (1 mM) were added, and the cells were cultured at 18 oC overnight. 
The following protein purification was carried out according to previously developed 
procedure (18). 
 
Spectral substrate binding assay — Spectral substrate binding assay was carried out on 
UV-visible spectrophotometer 300 Bio (Cary) at room temperature by titrating 30 mM 
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substrate DMSO solution (blank DMSO for reference group) into 1 ml of 1 µM P450 
sample in 1 µl aliquots, leading to substrate concentration ranging from 30 to 360 µM. 
The series of Type I difference spectra were used to deduce ΔA (Apeak(389)-Atrough(424)). 
Then, the data were fit to Michaelis-Menten equation to obtain the dissociation constant 
Kd. 
 
HPLC analysis of reactions catalyzed by PikC enzymes — The reactions for PikC 
enzymes were carried out using previously developed assays with minor modifications 
(18). The typical assay contains 1 µM PikC-RhFRED (or 1 µM PikC with 3.5 µM 
spinach ferredoxin and 0.1 U/ml spinach ferredoxin-NADP+ reductase), 200 µM YC-17 
(1) or narbomycin (4), and 0.5 mM NADPH in 100 µl of desalting buffer (50 mM 
NaH2PO4, pH 7.3, 1 mM EDTA, 0.2 mM dithioerythritol, 10% glycerol). The reaction 
was stopped and extracted after 1 h of incubation at 30 oC by addition of 2×200 µl of 
chloroform. The extracts were dried, dissolved in 120 µl of methanol and analyzed by 
Xbridge C18 5 µm 250 mm reverse-phase column at 230 nm, using 10-70% solvent B 
(A: deionized water + 10 mM ammonium acetate, B: acetonitrile) at 1 ml/min over 30 
min. The peak identity in each HPLC trace was determined by mass spectrometry and 
comparison with authentic compounds regarding HPLC retention time and UV spectrum. 
 
Steady-state kinetics — The standard reaction contains 100 nM of PikC-RhFRED (or 
150 nM of wt-PikC with 3.5 µM spinach ferredoxin and 0.1 U/ml spinach ferredoxin-
NADP+ reductase), 20~250 µM substrate in 200 µl of desalting buffer (50 mM NaH2PO4, 
pH 7.3, 1 mM EDTA, 0.2 mM DTE, 10% glycerol). After pre-incubation at 30 oC for 5 
min, the reaction was initiated by adding 1 µl of 50 mM NADPH and 50 µl aliquots were 
taken at 0s, 20s, and 40s (or 0s, 30s, and 60s when substrate concentration greater than 
100 µM) to thoroughly mix with 2×100 µl of chloroform. The nitrogen-dried samples 
were redissolved in 150 µl of methanol for subsequent HPLC analysis. The HPLC 
conditions were: Xbridge C18 5 µm 250 mm reverse-phase column, 20-80% solvent B 
(A: deionized water + 0.1% trifluoroacetic acid, B: acetonitrile + 0.1% trifluoroacetic 
acid) at 0.8 ml/min over 20 min, UV wavelength 230 nm. The initial velocity of substrate 
consumption was deduced from decreased area under the curve (AUC) of specific 
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4.4 Supplementary Information  
 




















Figure 4-S2.  SDS-PAGE analysis of functional N-terminal His6-tagged PikC-RhFRED. The 
















Figure 4-S3. UV-visible absorption spectra for purified N-terminal His6-tagged PikC-
RhFRED (~1.6 µM): oxidized (solid line), sodium dithionite reduced (dotted line), and CO-
reduced (dashed line) are shown. The CO-bound reduced difference spectrum is shown in inset. 
This assay is also employed to determine the concentration of functional P450 enzyme using the 















Figure 4-S4.  The calculation of the apparent molecular mass of wt-PikC and PikC-
RhFRED on the basis of the gel-filtration standard curve. The deduced molecular mass of wt-
PikC and PikC-RhFRED is approximately 55 kDa and 150 kDa, respectively, suggesting the 
monomeric (wt) and dimeric (fusion) form in 50 mM sodium phosphate pH 7.3 buffer containing 




Figure 4-S5.  The substrate binding affinity (Kd) of YC-17 (1) and narbomycin (4) toward 
wt-PikC (A) and PikC-RhFRED (B). The insets show the Type I binding spectra. All 



























   
 
   
 
Figure 4-S6. Michaelis-Menten curves of PikC-RhFRED (A) and wt-PikC (B) using YC-17 
(1) or narbomycin (4) as substrate. The apparent Km and kcat values are deduced from the 
unsaturated Michaelis-Menten curve. The kcat/Km values deduced from the linear fit of low-




















Figure 4-S7. LC-MS analysis of in vitro activity of EryF-RhFRED. A1. Negative control of 6-
deoxyerythronolide B (6) in absence of P450. A2. 6 with wt EryF in presence of Fdr, Fdx, and 
NADPH. A3. 6 with EryF-RhFRED in presence of only NADPH. B1. Mass spectrum of 6. B2. 
Mass spectrum of erythronolide B (7). The sample preparation was similar to that for typical PikC 
assay. The LC conditions were: Xbridge C18 3.5 µm 150 mm reverse-phase column, 20-100% 
solvent B (A: deionized water + 0.1% formic acid, B: acetonitrile + 0.1% formic acid) at 0.2 
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Selective Oxidation of Carbolide C-H Bonds by an Engineered 
Macrolide P450 Monooxygenase (PikCD50N-RhFRED) 
 
5.1 Introduction 
The superfamily of cytochrome P450 (CYP450) enzymes (monooxygenases) is 
involved in diverse oxidative processes including xenobiotic catabolism, steroid 
synthesis, and biosynthetic tailoring of diverse natural products (1-3). Among various 
reactions catalyzed by P450 enzymes, the regio- and stereoselective oxidation of an 
unactivated sp3 C-H bond represents a central challenge in organic chemistry (4-8). 
Considerable effort has been devoted to identifying biological catalysts or simpler 
mimics that function by mechanisms typically involving a metal oxo reactive site (9). 
Alternatively, transition metal complexes have been identified for C-H bond oxidations 
that proceed through mechanisms completely distinct from biological systems. A key 
challenge in developing useful C-H oxidation procedures is the control of site-selectivity 
among similar C-H bonds. Successful approaches have typically involved either relying 
on the inherent reactivity differences of various C-H bonds based on steric and electronic 
considerations (10-15), or the incorporation of directing groups that orient the catalyst 
active site towards a specific C-H bond (16-18). The selective oxidation of a C-H bond 
that is neither inherently more reactive than alternate sites nor positioned adjacent to a 
directing group poses the most difficult application in site-selective C-H bond 
functionalization.  
Recent reports have shown that supramolecular organometallic assemblies can 
provide some success in this challenge for synthetic chemistry (19-24). Alternatively, 
biological catalysts may provide unique potential to selectively oxidize bonds that are 
chemically similar, yet remote from directing influences. Thus, we were drawn to 
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investigate the potential role of biosynthetic CYP450 monooxygenases despite their 
fundamental dependence on substrate-enzyme complementarity, which might limit their 
application in synthetic chemistry (25). A number of previous efforts have sought to 
overcome this limitation by employing protein engineering strategies, including scanning 
chimeragenesis (26, 27) and directed-evolution (28-31) to generate non-natural 
cytochrome P450s (e.g., P450BM3) with novel substrate specificities and abilities to 
selectively oxidize target substrates.  
Based on a series of investigations involving CYP450 monooxygenases with 
remarkable substrate flexibility in macrolide biosynthetic systems (32, 33), we were 
motivated to explore their potential value in selective C-H bond activation reactions (25). 
Their unique requirement for a sugar-appended substrate lead us to assess an 
underexplored strategy involving “substrate engineering” (Fig. 5-1) that offers another 
way to broaden the substrate landscape of biological catalysis (34, 35). Our 
anchoring/tethering approach was inspired by an earlier observation that certain 
functional groups facilitate enzyme-substrate interactions, where a direct functional group 
linkage (termed anchoring group in this study) to previously inaccessible compounds 
enables selective oxidation of the modified substrates in vivo (36, 37). However, due to 
the complexity of the cell-based system, the precise mechanism behind the substrate 
 
 
Figure 5-1. Schematic strategy of substrate engineering. 
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engineering approach has remained unclear. An initial application (36) hypothesized that 
the anchoring group might be involved in substrate recognition, productive binding, or 
control of binding orientation in the active site of certain oxidative enzymes (e.g. 
monooxygenases).  
Herein, we report the first in vitro implementation of substrate engineering for 
selective C-H bond oxidations by using an optimized form of the macrolide CYP450 
monooxygenase PikC (32, 38). For this study, a series of carbocyclic rings linked to the 
desosamine glycoside (referred to as carbolides) were effectively hydroxylated in a 
regioselective manner.  Furthermore, analysis of a series of high-resolution enzyme-
substrate co-crystal structures provided significant new insights into the function of the 
aminosugar-derived anchoring group for control of reaction site selectivity.  Finally, 
unexpected biological activity of a select number of these carbolide systems revealed 
their potential as a new class of antibiotics. 
 
5.2 Results and Discussion 
5.2.1 The Engineered PikCD50N-RhFRED Is Capable of Hydroxylating Carbolides 
Effectively and Regioselectively.  
PikC is the cytochrome P450 involved in pikromycin biosynthesis from 
Streptomyces venezuelae (32, 39). The physiological function of this monooxygenase is 
to hydroxylate both the 12-membered ring macrolide YC-17 1 and the 14-membered ring 
 
 
Figure 5-2. Major physiological reactions catalyzed by PikC. 
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macrolide narbomycin 4, giving rise to methymycin/neomethymycin 2/3 and pikromycin 
5, respectively, as major products (Fig. 5-2). Recent analysis of x-ray co-crystal 
structures of PikC (40, 41) involving endogenous substrates revealed that the 
macrolactone ring contacts the active site residues entirely via nonspecific hydrophobic 
interactions, likely accounting for the tolerance of PikC toward the variant macrolactone 
ring size and functionalization. In contrast, the desosamine sugar employs two distinct 
binding pockets and anchors the substrate through a number of hydrogen bonds and ionic 
interactions, in particular, a unique salt bridge between the protonated dimethylamino 
group of desosamine and a glutamate residue, either Glu94 or Glu85 in the B/C loop 
region. Based on these previously recognized molecular interactions that specify 
substrate binding affinity and orientation in the binding pocket, we reasoned that 
desosamine could be an effective anchoring group to direct positioning of various 
unnatural molecules in the active site of PikC for selective C-H bond hydroxylations. 
To test this hypothesis, we synthesized the unnatural cyclic carbolide substrate 
desosaminyl cyclododecane 6 to mimic the structure of the natural substrate 1 (YC-17) 
using a recently developed synthetic strategy (33), which was subsequently employed as 
a general approach to derivatize diverse alcohols with desosamine (Fig. 5-S1). An 
enzyme-substrate analysis showed that 6 binds to wild type PikC (PikCwt) with a 
dissociation constant (Kd) of 1,379 µM, about 12 times higher than the Kd value (116 
µM) of 1. The decreased binding affinity of 6 could result from 1) an entropic penalty 
upon binding due to high conformational freedom of the saturated ring system, 2) lack of 
hydrophobic interactions between the functional groups on the macrolactone ring of 1 
and PikC active site residues, and/or 3) loss of some specific interactions with 
desosamine as observed in the co-crystal structure with PikC (see below). When using the 
more active PikCD50N mutant (40, 41), the binding affinities of both carbolide 6 and 
macrolide 1 were shown to be approximately four times higher with Kd values of 390 and 
32 µM, respectively. Moreover, we recently engineered a self-sufficient fusion enzyme 
PikC-RhFRED (38) that displayed approximately 4-fold enhanced catalytic activity (kcat) 
compared to PikCwt. Combining these two beneficial properties, the resulting engineered 
form of the P450 enzyme PikCD50N-RhFRED (kcat/Km = 7.44 µM-1•min-1 for 1, Fig. 5-S2) 
is approximately 13 times more active than PikCwt (38). Interestingly, 1 and 6 bound to 
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this mutant enzyme with slightly improved Kd values of 19 and 309 µM (Table 5-1), 
respectively. Due to enhanced substrate conversion and ease of use in the absence of 
expensive exogenous redox partners, we elected to employ PikCD50N-RhFRED to 
hydroxylate carbolide 6 and all other substrates for this work. 
LC-MS analysis (Fig. 5-3A) of the extract obtained following reaction with 
PikCD50N-RhFRED showed that 47% of carbolide 6 was converted into seven different 
monohydroxylated products 7a-g (no multi-hydroxylated products were observed) with 
expected m/z = 358.19 for [6 + OH + H]+ using 5 µM of PikCD50N-RhFRED in 3 h (the 
Table 5-1. The activity of PikCD50N-RhFRED toward various substrates. 
 
Substratesa Kd (µM) Yield
b Number of productsc 
    
    
 19 >99% 2 









   
 309 47% 7 





    
 218 65% 6 





    
 289 63% 6 





    
 243 35% 9 





    
 NBd 0 0 







   
 NB 0 0 








    
 NB < 1% 0 










    
 NB 0 0 








   
 2,900 8% 5 








   
 2,300 14% 7 







   
 >5,000 4% 1 







    
aRacemic cis-decahydro-1-naphthol was used in preparation of 14, leading to the structure shown and its diastereomer. The 
mixture of diastereomers was subjected to the PikC oxidation reaction. 
bThe yield shown is based on product formation calculated with AUCtotal products / (AUCtotal products + AUCunreacted substrate) by assuming 
ionization efficiency of substrate and various hydroxylated products are same since the ionization site of this series of 
desosaminyl derivatives should be the dimethylamino group. The calculated yield is fairly close (difference < ±3%) to the 
substrate conversion ratio calculated by 1 – AUCunreacted substrate / AUCtotal substrate (AUCtotal substrate is derived from the control reaction 
using boiled enzyme under identical conditions), indicating the assumption is correct. (AUC: area under curve of the ion count 
chromatograms as shown in Fig. 5-3). 
cThe number of products refers to the number of distinct peaks seen in the LCMS. Comparison to synthetic standards illustrated a 
few cases where regioisomers or diastereomers were not distinguished by LCMS, so the number provided is a lower limit. See 
supporting information for details.  
dNB: No binding 
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conversion can be driven further by increasing enzyme concentration and/or reaction 
time). All product ions displayed the same MS/MS spectra (Fig. 5-S3) at m/z = 158.02, 
corresponding to [desosamine – OH]+. The unmodified desosamine moiety indicates that 
all hydroxylations occur on the cyclododecane ring. In contrast, cyclododecanol lacking 
an appended desosamine was unable to serve as a substrate for PikC P450 under identical 
conditions. Therefore, it is evident that desosamine is indispensable for this biochemical 
transformation. Notably, PikCwt, PikCD50N, and PikCwt-RhFRED generated similar 
product profiles compared to PikCD50N-RhFRED, albeit with lower efficiency. These 
results indicate that neither the point mutation nor the C-terminal RhFRED-fusion with 
PikC has a significant impact on the binding mode of 6.  
To assess the regio- and stereoselectivity of PikCD50N-RhFRED toward the 
selected substrate, we sought to obtain detailed structural information on the reaction 
products. Challenging preparative-scale separations as well as the high similarity of the 
methylene groups on the cyclododecane ring complicated structure determination of the 
individual compounds by NMR analysis. Due to the large number of potential isomers 
(23 total) that could result from oxidation of the 12-membered ring of 6, it was 
impractical to synthesize all possible products. Therefore, guided by the 2.0 Å co-crystal 
structure of mutant PikCD50N enzyme with 6 (Fig. 5-4), we synthesized a series of 
authentic standards with a hydroxyl group installed at the C7 and C6/C8 position (the two 
diastereotopic carbons were numbered differently for clarity) that were likely to be the 
major reaction products. During the chemical synthesis, but prior to desosamine 
installation, racemic mixtures of two diastereomers of a mono-protected diol leading to 
C6/C8-oxidized authentic materials were prepared. Glycosylation with the glycosyl 
fluoride of acetate-protected desosamine followed by deprotection provided the four 
diastereomers that correspond to C6/C8 oxidized products (see Supplementary 
Information). Similarly, the two diastereomers of C7-oxidized authentic material were 
obtained.  
Through comparison of LC-MS retention times and confirmation by co-injections 
(Fig. 5-S4), six of the seven PikC-derived hydroxylated products of 6 were assigned as 
the C7 and C6/C8 oxidized materials. Since authentic samples of oxidized products were 
prepared as diastereomeric pairs, hydroxyl positioning was determined, but the precise 
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stereostructure was not. The ratio of C7 oxidized products (7b and 7f) to C6/C8 oxidized 
 
 
Figure 5-3. LC-MS analysis of PikCD50N-RhFRED catalyzed reactions using different 
cyclized carbolides as substrates. (Ion count chromatograms are shown) (A) Desosaminyl 
cyclododecane 6 reaction, 7b and 7f correspond to two diastereomers generated by C7 
hydroxylation, 7a, 7c, 7e, and 7g correspond to four diastereomers generated by C6/C8 
hydroxylation; (B) Desosaminyl cyclotridecane 8 reaction, 9a, 9d and 9f correspond to 
diastereomers arising from C6/C9 hydroxylation, 9b and 9c correspond to diastereomers 
originated from C7/C8 or C6/C9 hydroxylation. The number of products that peak 9c contains 
is undetermined due to product overlap; (C) Desosaminyl cyclotetradecane 10 reaction; (D) 
Desosaminyl cyclopentadecane 12 reaction. The details of product assignment for 6 and 8 
based on correlation with synthesized authentic standards regarding retention time and co-
injection confirmation are shown in Supplementary Information. 
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products (7a, 7c, 7e, and 7g) was approximately 1:4 (see Supplementary Information for 
product assignment). Thus, it is evident that PikC catalyzed hydroxylation occurs 
primarily at sites most remote from the desosamine-anchoring group, as predicted by the 
crystal structure (Fig. 5-4). The C7 and C6/C8 oxidized compounds account for 95% of 
the mass of mono-hydroxylated material, and the only unidentified minor product 7d 
(5%) might be one of the C5 hydroxylated products. Considering the abundance of 
secondary C-H bonds on the 12-membered ring with almost equal reactivities, this 
regioselectivity is considerable, but not as strict as that observed toward the native 
macrolide substrates 1 (YC-17) and 4 (narbomycin). 
We next sought to determine if C-H hydroxylation still occurs at the sites remote 
from desosamine in the cases of larger hydrocarbon rings, thus the 13-membered ring 
carbolide 8 was synthesized and treated with PikCD50N-RhFRED in a similar way to 6. 
Consistently, the major peaks 9a-d (accounting for 94% of all products, Fig. 5-3B) were 
determined to be C7/C8 or C6/C9 mono-hydroxylated products (Fig. 5-S6). However, 
due to high structural similarity between these molecules, some synthetic hydroxylated 
authentic standards containing different diastereomeric pairs were not distinguishable 
from one another due to identical retention times (e.g. Fig. 5-S6, traces D and E), which 
prevented determination of the exact number of diastereomers generated in the reaction. 
Furthermore, two larger cyclic carbolides, including the 14-membered ring 10, 
and 15-membered ring 12 were investigated. The reactivity of desosaminyl 
cyclotetradecane 10 was similar to that of 13-membered ring carbolide 8, with 65% 
substrate converted to hydroxylation products 11a-f (Fig. 5-3C). In contrast, the 
desosaminyl cyclopentadecane 12, although having comparable binding affinity with 8 
and 10 (Table 5-1), showed lower conversion (35%) and decreased selectivity reflected 
by the increased number of products (Fig. 5-3D), suggesting that this large cyclic 
substrate might not be located in a suitable position within the PikC active site. 
 
5.2.2 Analysis of PikCD50N-RhFRED Reactivity toward Other Types of Desosaminyl 
Derivatives.  
Due to the surprising activity and regioselectivity that PikCD50N-RhFRED showed 
toward 12-, 13-, and 14-membered ring carbolide derivatives, we decided to investigate 
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the ability of desosamine to function as an anchor for other classes of compounds. Thus, 
the activity of PikCD50N-RhFRED toward additional cyclic and linear synthetic substrates 
(Table 5-1) was assessed. The results revealed that PikC only marginally hydroxylated 
cyclic derivatives 13-15, suggesting that these small ring systems might not be 
accommodated within the active site, or cannot reach the iron-oxo center for catalysis.  
Surprisingly, the linear derivatives 17 and 18 were oxidized to form multiple 
mono-hydroxylated products with 8% and 14% yields, respectively (Table 5-1, Fig. 5-S9 
and 5-S10). The predominant hydroxylation site for 18 was identified as the C9 
propargylic position (Fig. 5-S11). When aromatic derivative 19 was used as substrate 
(Fig. 5-S12), we observed a single oxidized product determined to be the 8-hydroxy 
desosaminyl pyrene (Table 5-S1), albeit with a conversion of 4%. This observation 
suggests that rigidity of the substrate might be a key factor to gain high selectivity when 
using PikC as a biocatalyst for oxidation. The low level of conversion might result from 
its poor binding and/or higher C-H bond dissociation energy in this aromatic ring system. 
Taken together, these data reveal that PikC-catalyzed oxidation occurs primarily at the 
site most remote from the desosamine anchoring group when linear or aromatic substrates 
are used, suggesting a similar mechanism for control of regioselectivity compared to the 
carbolides. 
 
5.2.3 Structural Basis for Regioselectivity of PikC toward 12- and 13-membered 
Ring Carbolides.  
To understand the structural basis for the regioselectivity of PikC and predict the 
hydroxylation sites of the 12- and 13-membered ring carbolides to direct the synthesis of 
authentic standards, we solved the crystal structures (Table 5-S2, Fig. 5-4 and 5-5) of 
PikCD50N in complex with unnatural substrates 6 and 8. 
In the co-crystal structure of PikCD50N and 6, the electron density for 6 is well 
defined in one monomer of the asymmetric unit (Fig. 5-4A). In contrast, the other 
asymmetric unit showed an unambiguously positioned cyclododecane ring, while the 
dispersed electron density for desosamine indicated at least two alternative conformations 
(Fig. 5-4B). A satisfactory fit was achieved when 6 was docked in two flipped 
orientations. Carbolide 6 binds in the active site in the L-shaped conformation bringing 
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four cyclododecane carbons most remote from the desosamine anchoring group within 5 
Å of the Fe reaction center (Fig. 5-4A and 5-4B), revealing that C5, C6, C7, and C8 are 
the likely hydroxylation sites. The observed pattern of regioselectivity could arise from 
sporadic contacts of the desosamine moiety of 6 with a number of amino acid residues 
(Fig. 5-5A). Indeed, the specific salt-bridge involving E94 is found in only one conformer 
(pink in Fig. 5-5A) of 6, and a number of the chain A active site residues (green), 
including F178, I239, V242, and M394, adopt alternative conformations indicative of 
dynamic interactions with the substrate.  In chain B, although the salt-bridge to E94 is 
lost, E246 (ice blue in Fig. 5-5A) is located within electrostatic distance from the 
dimethyamino group of the proximal conformer (cyan). However, the E246 side chain is 
missing from the electron density map of chain A. In addition, the sub-optimal 
regioselectivity could be due to the inherent flexibility of the large cycloalkane ring. 
Since all six diastereomers arising from the C7 and C6/C8 hydroxylated regioisomers 
 
 
Figure 5-4. Multiple binding modes of desosaminyl cycloalkanes. Orientations of 6 in the 
active site of PikCD50N (A) in chain A and (B) in chain B, and orientations of 8 in the active site 
of PikCD50N (C) in chain A and (D) in chain B, as defined by the fragments of the electron 
density map (gray mesh) contoured at 0.8 σ are shown. In (B), 6 is docked in the flipped-over 
orientations allowing hydroxylation on the both sides of the ring. In (C) and (D), 8 is in 
flipped over orientations. Heme is shown in orange. Oxygen atoms are in red, nitrogen in 
blue, iron in orange. Atoms of the cycloalkane ring are labeled in red. Distances are in 
Angstroms. Images are generated using PYMOL. 
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were observed, there is clearly a lack of stereoselectivity from this enzymatic 
transformation. The co-crystal structure suggests that compromised stereoselectivity is 
likely due to flipping (or rotating) of the carbolide substrate in the PikC active site 
resulting in oxidation on both faces of the ring (Fig. 5-4A and 5-4B).  
Further inspection of the co-crystal structures revealed that whereas three 
orientations are distinguishable for 6, only two orientations (one in each protein monomer 
in the asymmetric unit) are observed for 8 in the 2.2 Å x-ray co-crystal structure (Fig. 5-4 
 
 
Figure 5-5. Desosaminyl cycloalkane binding sites. (A) Stereo view of the PikCD50N binding 
site with the three superimposed 6 conformers highlighted in gray (chain A), pink and cyan 
(chain B) surrounded by the chain A amino acid side chains within 5 Å plus E85 (green) is 
shown. E246 of chain B is highlighted in ice blue. To increase clarity, V242 was omitted from 
the drawing. (B) Stereo view of the PikCD50N binding site with two superimposed 8 
conformers highlighted in pink (chain A) and cyan (chain B) surrounded by the chain A amino 
acid side chains within 5 Å plus E85 is shown. F178 of chain B is highlighted in ice blue. 
Heme is shown in orange. Oxygen atoms are in red, nitrogen in blue, iron in orange. Atoms 
of the cycloalkane ring are labeled in red. Distances between tertiary amine and carboxylic 
groups are in Angstroms. Lower-case a in the residue label indicates that alternative 
conformations are shown. 
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and 5-5), suggesting improved complementarity and/or more limited conformational 
freedom of the larger ring in the active site. This could explain the increased binding 
affinity (Kd = 218 µM) and hence reactivity (65% yield) of 8 compared to 6 (Kd = 309 
µM, 47% yield). In one monomer (cyan in Fig. 5-5B), the desosamine moiety is in salt-
bridge contact with E94, while in the other monomer (pink), it is within electrostatic 
distance from both E94 and E85. Amino acid side chains in the active site are stabilized 
in a single conformation, with the exception of F178, which is represented by different 
conformers in chain A (green) and chain B (ice blue) (Fig. 5-5B). Similar to 6, the co-
crystal structure suggests that flipping-over (or rotation) of 8 in the active site could 
enable hydroxylation (likely at C6/C9 or C7/C8) on both faces of the ring. However, a 
more limited resolution of the product profile in the LCMS analysis (Fig. 5-S6) (unlike 
oxidations of compound 6, where oxidation products were better distinguished by LCMS, 
Fig. 5-S4) prevents verification of this prediction, or further evaluation of the reaction 
stereoselectivity.   
Despite previously demonstrated dynamics of PikC (40), no fit-induced 
conformational changes were observed in response to binding of the various carbolides, 
which could potentially prevent the substrate from wobbling in the active site. This 
observation contradicts the concept of “conformational plasticity” applied for mammalian 
P450 enzymes (42), and limits the role of PikC conformational dynamics to substrate 
access to and product release from the active site. 
 
5.2.4 Antibacterial Activities of Synthetic Desosaminyl Derivatives.  
In macrolide antibiotics, desosamine (or a related deoxysugar moiety) has been 
found to play a crucial role in the interaction of these important compounds with the 23S 
ribosomal RNA (the major drug target for macrolides) through a number of specific 
contacts with ribonucleotides in the peptidyl-transferase center (43). Accordingly, we 
surmised that our series of synthetic desosaminyl derivatives might possess antibacterial 
activity. As shown in Table 5-S3, the cyclic carbolides including 6, 8, 10, and 12 
displayed some inhibitory activities against selected microbial targets, while their 
corresponding aglycones were inactive, confirming the significance of desosamine for 
bioactivity. Remarkably, the aromatic derivative 19 showed similar or even higher 
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bioactivity compared to the natural macrolide antibiotics 2 and 5. We also compared the 
bioactivity of 8 with its synthetic hydroxylated products. Unexpectedly, upon installation 
of a hydroxyl group at either the C7/C8 or C6/C9 positions (the four authentic standards, 
each of which contains a pair of diastereomers), the products lost activity. Although 
hydroxylation of 8 had a detrimental impact on biological activity against a limited 
number of microbial targets, installation of this functional group might enable a useful 
chemical handle for further functionalization (44) and subsequent generation of more 
potent therapeutics. Further analysis of these carbolides, and direct investigation of their 
presumed binding to ribosomal targets will provide important insights into the impact of 
PikC-mediated regioselective hydroxylation for development of new small molecules for 
treatment of microbial pathogens and other human diseases. 
 
5.3 Summary 
The work described in this report is based on the innate substrate flexibility of the 
biosynthetic CYP450 PikC enzyme that could be harnessed using a substrate engineering 
strategy in vitro due to its desosamine anchoring functionality. In contrast to previous 
chemical approaches that have exploited proximal directing influences or inherent 
differences in C-H bond strengths, our approach utilizes the interactions of an engineered 
bacterial P450 enzyme with aminosugar (desosamine)-linked substrates that otherwise 
lack all of the functionality of the native biosynthetic intermediates. This approach 
provides the unique opportunity to obtain high resolution crystallographic insights into 
the nature of the substrate-catalyst interactions, which has generally not been available 
with biomimetic and organometallic systems that achieve catalytic oxidation of 
unactivated C-H bonds. Attachment of desosamine to a number of unnatural aglycones 
(esp. cyclized aglycones) via an acetal linkage leads to productive enzyme binding and 
considerable regioselectivity in the hydroxylation reactions. However, the level of regio- 
and stereoselectivity observed for natural macrolide substrate YC-17 1 and narbomycin 4 
was not achieved, which infers synergistic contributions of both desosamine and 
macrolactone portions of these endogenous substrates. Insights gained from structural 
analysis in the current study suggest that selectivity could be improved by (i) rigidifying 
the substrate structure, (ii) limiting conformational freedom by optimizing the 
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complementarity between substrate size/shape and the volume of the active site, and (iii) 
increasing structural complexity of compounds to improve the specificity of their 
binding. 
Currently, further investigations, including the applicability of this approach in 
selective oxidation of complex compounds of medicinal significance, the development of 
alternative and more chemically accessible glycosides as well as alternative molecular 
anchors, and the development of diverse linkage groups, are in progress. Additionally, the 
observed selectivity could be potentially exploited for building libraries of compounds 
with hydroxyl group functional handles for further synthetic transformations. Moreover, 
the ability to obtain enzyme/substrate co-crystal structures offers unique mechanistic 
insights as well as a means to engineer CYP450 enzymes that display greater regio- and 
stereoselectivity. This type of reagent engineering is particularly amenable to biological 
catalysts, and provides effective approaches to tailor the catalytic outcome toward a 
desired synthetic goal.  Finally, these findings suggest that in addition to PikC, diverse 
natural product P450s can be further harnessed for a substrate engineering approach to 
selectively oxidize C-H bonds, and to facilitate further chemical diversification of both 
synthetic and natural product molecules of biological interest.  
 
5.4 Experimental Procedures 
Preparation of PikCD50N-RhFRED — Using previously prepared pET28b-PikC-
RhFRED as a template (38), site-directed mutagenesis was performed by following the 
QuikChange (Stratagene) protocol. The primers for mutagenesis were: forward, 5’-
CACCCCCGAGGGGAATGAGGTGTGGCTGG-3’; reverse, 5’-
CCAGCCACACCTCATTCCCCTCGGGGGTG-3’. Protein expression and purification 
of PikCD50N-RhFRED followed the procedure developed previously (38).  
 
PikCD50N-RhFRED assay — The standard assay contains 5 µM PikCD50N-RhFRED, 0.5 
mM substrate, 2.5 mM NADPH, 0.25 Unit of glucose-6-phosphate dehydrogenase, and 5 
mM glucose-6-phosphate for NADPH regeneration in 100 µl of reaction buffer (50 mM 
NaH2PO4, pH 7.3, 1 mM EDTA, 0.2 mM dithioerythritol, and 10% glycerol).  The 
reaction was carried out at 30 oC for 3 h and terminated by extraction using 3 × 200 µl of 
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CHCl3. The resulting organic extract was dried by N2 and redissolved in 120 µl of 
methanol. The subsequent LC-MS analysis was performed on a ThermoFinnigan LTQ 
linear ion-trap instrument (Department of Pharmacology, University of Michigan) 
equipped with electrospray source and Surveyor HPLC system by using an XBridgeTM 
C18 3.5 µm 150 mm reverse-phase HPLC column under following conditions: mobile 
phase (A = deionized water + 0.1% formic acid, B = acetonitrile + 0.1 % formic acid), 
20% B for 3 min, 20-100% B over 25 min, 100% B for 5 min, 100-20% B over 1 min, 
20% B for 15 min; flow rate, 0.21 ml/min. The substrate binding assays were performed 
following the previous report (38). 
 
Crystallization, data collection and structure refinement — Crystallization conditions 
for PikCD50N complexes with 6 and 8 were identified by using commercial high 
throughput screening kits available in deep-well format (Hampton Research), a nanoliter 
drop-setting Mosquito robot (TTP Lab Tech) operating with 96-well plates, and a 
hanging drop crystallization protocol. Optimization of conditions was carried out 
manually in 24-well plates. The protein from the 1 mM stock was diluted to 0.2 mM by 
mixing with 6 or 8 dissolved at 2 mM in 10 mM Tris-HCl, pH 7.5. Crystals of PikCD50N-6 
complex were obtained from 15% PEG 4000, 0.1 M Tris-HCl, pH 7.5; 200 mM MgCl2. 
Crystals of the PikCD50N-8 complex were obtained from 12% PEG 8000, 0.1 M sodium 
cacodilate, pH 6.5, and 200 mM Li2SO4. Prior to data collection the crystals were cryo-
protected by plunging them into a drop of reservoir solution supplemented with 20% 
glycerol. Diffraction data were collected at 100-110 K at beamline 8.3.1, Advanced Light 
Source, Lawrence Berkeley National laboratory, USA. Data indexing, integration, and 
scaling were conducted using HKL2000 software suite. Crystal structures were 
determined by molecular replacement using the atomic coordinates of the 2C6H (PDB 
ID) as a search model (Table 5-S2). 
 
Antibacterial assay — Two-fold serial dilutions of 40 mM (10 mM for positive control 
erythromycin) DMSO solutions of test compounds with DMSO generated a series of 
stock solutions with concentrations ranging from 0.31 ~ 40 mM. Then, a ten-time dilution 
of each was performed by using dd H2O to make a 31 ~ 4000 µM series. Cultures of 
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target strains were grown in appropriate media at 37 °C (30 °C for Deinococcus 
radiodurans) with shaking (180 rpm). An overnight seed culture was diluted to an OD600 
of 0.05, grown to an OD600 of 0.4 ~ 0.6, back diluted to an OD600 of 0.004, and 45 µL of 
this diluted culture was added to each well of a 384-well microtiter plate that contained 5 
µL of a given dilution of compound in dd H2O.  Plate cultures were grown for 16 h (60 h 
for D. radiodurans) and OD600 measurements were taken. All measurements were 
performed in duplicate. 
 
Steady-state kinetics of PikCD50N-RhFRED — The reaction contains 40 nM of PikC-
RhFRED-D50N with 3.5 µM spinach ferredoxin and 0.1 U/ml spinach ferredoxin-
NADP+ reductase, 10~160 µM substrate in 400 µl of desalting buffer (50 mM NaH2PO4, 
pH 7.3, 1 mM EDTA, 0.2 mM DTE, 10% glycerol). After pre-incubation at 30 oC for 5 
min, the reaction was initiated by adding 4 µl of 50 mM NADPH and 100 µl aliquots 
were taken at 0s, 20s, and 40s (or 0s, 30s, and 60s when substrate concentrations are 
greater than 100 µM) to thoroughly mix with 100 µl of methanol for reaction termination. 
After centrifugation at 13,000 g for 15 min to pellet protein, the supernatants were 
analyzed by HPLC. The HPLC conditions were: Xbridge C18 5 µm 250 mm reverse-
phase column, 20-80% solvent B (A: deionized water + 0.1% trifluoroacetic acid, B: 
acetonitrile + 0.1% trifluoroacetic acid) at 1.0 ml/min over 18 min, UV wavelength 226 
nm. The initial velocity of substrate consumption was deduced from decreased area under 
the curve (AUC) of specific substrate peaks. Finally, the data from duplicated 
experiments were fit to Michaelis-Menten equation. 
 
Preparation of the oxidized product of desosaminyl pyrene 19 — An enzymatic 
reaction containing 0.8 µM PikCD50N-RhFRED, 750 µM glucose-6-phosphate, 0.15 
Unit/ml glucose-6-phosphate dehydrogenase, 500 µM NADPH, and 15 mg 19 in 200 ml 
reaction buffer (50 mM NaH2PO4, pH7.3, 1 mM EDTA, 0.2 mM dithioerythritol, and 
10% glycerol) was carried out at 30 oC for 20 h. The hydroxylated product 20 (yield ~8% 
based on HPLC analysis) was purified by reverse phase C18 preparative HPLC. Upon 
chloroform extraction from the aqueous solution of 20, 0.2 mg of 20 was recovered. The 
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oxidation site was determined based on the 600M 1H NMR and COSY performed by 

















































5.5 Supplementary Information 
 
 
Figure 5-S1. General synthetic strategy for glycosylation of diverse alcohols with 
desosamine. [Ref.: 1. Chen, H., Yamase, H., Murakami, K., Chang, C.-w., Zhao, L., Zhao, Z. and 
Liu, H.-w. (2002) Biochemistry 41, 9165–9183; 2. Anzai, Y., Li, S., Chaulagain, M. R., 


























Figure 5-S3. Mass spectra of 6 (top panel) and its hydroxylated products 7a-g (middle 
panel). The bottom panel shows the MS-MS pattern of one of products. Notably, all desosaminyl 














Figure 5-S4. Structural determination of mono-hydroxylated products of 6 through LC-MS 
comparison of synthetic authentic standards to 7a-g regarding retention times. (A) Product 
profile of PikCD50N-RhFRED reaction using 6 as substrate; (B) Authentic standard containing a 
pair of C6/C8 hydroxylated diastereomers; (C) Authentic standard containing the other pair of 
C6/C8 hydroxylated diastereomers; (D) Authentic standard containing the pair of C7 







































          
Figure 5-S6. Structural determination of mono-hydroxylated products of 8 through LC-MS 
comparison of synthetic authentic standards to 9a-f regarding retention times. (A) Product 
profile of PikCD50N-RhFRED reaction using 8 as substrate; (B) Authentic standard containing a 
pair of C6/C9 hydroxylated diastereomers; (C) Authentic standard containing the other pair of 
C6/C9 hydroxylated diastereomers; (D) Authentic standard containing a pair of C7/C8 
hydroxylated diastereomers; (E) Authentic standard containing the other pair of C7/C8 
hydroxylated diastereomers. The products assignment was further confirmed by co-injections. 
Some diastereomers are not distinguishable due to identical retention times (e.g. traces D and E) 
Notably, to get a better separation of similar diastereomers, an optimized LC condition other than 
the one described in the main text was employed: mobile phase, 10% B for 3 min, 10-80% B over 
25 min, 80-100% B over 1 min, 100% B for 5 min, 100-10% solvent B over 2 min, 10% solvent 
B for 15 min. All other conditions remained the same. 
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Figure 5-S9. (A) Product profile of PikCD50N-RhFRED reaction using linear desosaminyl 
derivative 17 as substrate. (B) Amplified product profile to visualize the hydroxylated products in 


















Figure 5-S10. (A) Product profile of PikCD50N-RhFRED reaction using linear desosaminyl 
derivative 18 as substrate. (B) Amplified product profile to visualize the hydroxylated products in 


















Figure 5-S11. Product identification of desosaminyl derivative 18. (A) Product profile of 
PikCD50N-RhFRED reaction using linear desosaminyl derivative 18 as substrate. (B) Authentic 
standard containing a pair of C9 hydroxylated diastereomers. The products assignment was 
further confirmed by co-injection. The right panel shows the amplified chromatograms to 

























Figure 5-S12. (A) Product profile of PikCD50N-RhFRED reaction using aromatic desosaminyl 
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Table 5-S1. 1H NMR data of 19 and 20 
 
Proton assignment (ppm) in CDCl3  
Proton Position 19 20 
H-2 7.81 (d, J = 8.3 Hz, 1H) 7.78 (d, J = 8.3 Hz, 1H) 
H-3 8.12 (d, J = 8.3 Hz, 1H) 8.02 (d, J = 8.3 Hz, 1H) 
H-5 7.94 (d, J = 9.1 Hz, 1H) 7.95 (d, J = 9.3 Hz, 1H) 
H-6 8.00 (d, J = 9.1 Hz, 1H) 8.17 (d, J = 9.1 Hz, 1H) 
H-8 8.13 (d, J = 7.7 Hz, 1H) - 
H-9 7.96 (t, J = 7.7, 7.7 Hz, 1H) 7.44 (d, J = 8.1 Hz, 1H) 
H-10 8.14 (d, J = 7.7 Hz, 1H) 7.96 (d, J = 8.2 Hz, 1H) 
H-12 8.06 (d, J = 9.1 Hz, 1H) 7.92 (d, J = 9.2 Hz, 1H) 
H-13 8.63 (d, J = 9.1 Hz, 1H) 8.41 (d, J = 9.1 Hz, 1H) 
 
 The assignment of the aromatic protons of desosaminyl pyrene 19 was conducted based 
on a full set of 1D and 2D NMR spectra and consistency with the published 1H NMR data for 1-
hydroxypyrene (Lambert, M., Kremer, S., Sterner, P., and Anke, H. (1994) App. Environ. 
Microbiol,  60, 3597-3601). The structure of 20 was determined based on the 600M 1H NMR and 




































Table 5-S2. Crystallographic data and statistics. 




PDB ID 2WI9 
PikC- 
cyclotridecane 
PDB ID 2WHW 
   
Data collection   
   
Wavelength, Å 1.11587 1.11587 
Resolution, Å 2.0 2.2 
Unique reflections 68456 52386 
Redundancy 3.9 (3.4)a 4.2 (4.3) 
Completeness, % 98.2 (87.7) 100.0 (99.8) 
Space group P212121 P212121 
Cell dimensions (a,b,c), Å 
                           (α, β, γ), ° 
65.3, 109.1, 153.2 
90.0, 90.0, 90.0 
60.2, 109.5, 153.1 
90.0, 90.0, 90.0 
Molecules in asymmetric unit 2 2 
Solvent content, % 55.1 55.2 
Rsymb, % 7.2 (39.0) 9.8 (49.7) 
I/σ 21.2 (2.7) 20.9 (3.6) 
   
Refinement   
   
Reflections used in refinement  49541 
Rcryst(Rfree)c, % 18.9/23.9 17.6/25.6 
No. of atoms 6978 7098 
Protein 6229  
Heme 86 86 
Ligand 72  
Water/ions 576/15 /10 
Wilson plot B-values, Å2 30.0 29.8 
Mean B-factor, Å2 31.2 29.46 
Protein 30.8 27.0 
Heme 16.4 12.6 
Ligand A: 62.9, B: 35.3 A: 65.9, B: 57.0 
Water/ions 34.8/85.3 35.3/84.8 
r.m.s. deviations   
Bond length, Å 0.022 0.024 
Bond angles, ° 1.9 1.9 




aNumbers in parentheses correspond to the highest resolution shell. 
bRsym=Σ|Ii - <I>|/ΣIi, where Ii is the intensity of the ith observation, and <I> is the mean intensity of 
reflection. 
cRcryst=Σ ||Fo|-|Fc||/Σ|Fo|, calculated with the working reflection set. Rfree is the same as Rcryst but calculated 
with the reserved reflection set. 
dProgram PROCHECK (Laskowski, R. A., MacArthur, M. W., Moss, D. S. and  Thornton J. M. 1993, 
PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 
283-291), portions of the protein residues in most favored/additional allowed/generously 
allowed/disallowed regions. 
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Table 5-S3. Antibacterial activities of desosaminyl derivatives against selected strains. 
 
 
a Previously known as Micrococcus luteus ATCC 9341, which is sensitive to macrolide antibiotics. 
bA gift from Prof. Ada E. Yonath (Structural Biology Department, Weizmann Institute of Science, Rehovot, Israel) 
cE. coli W3110 TolC disruption mutant that is more sensitive to antibiotics 
dS. aureus 8325 NorA disruption mutant that is more sensitive to antibiotics 
e8-C6OH-a, b and 8-C7OH-a, b correspond to synthetic C6/C9 and C7/C8 hydroxylated standards of 13-membered 
carbolide, each of  which contains a pair of diastereomers as shown in trace B, C and D, E, respectively in Fig. S6 
fMedia recipe: 10 g  caseine peptone (tryptic digest), 5 g yeast extract,  5 g NaCl and 5 g glucose (add after 
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Functional Analysis of MycCI and MycG,  
Cytochrome P450 Enzymes Involved in Biosynthesis of 




The cytochrome P450 enzymes (P450s) form a very large family of oxidative 
hemeproteins that are responsible for diverse oxidative transformations across most life 
forms (1, 2). These reactions typically involve modification of physiologic and 
xenobiotic compounds and include the biosynthesis of various bioactive compounds (e.g., 
steroids, antibiotics, and signaling molecules). Recent bacterial genome sequencing 
efforts have uncovered an unexpected large number of genes encoding P450 enzymes. 
For example, the model actinomycete Streptomyces coelicolor A3(2) that produces 
actinorhodin and undecylprodigiosin revealed the presence of 18 different P450 genes 
(3), whereas Streptomyces avermitilis MA-4680, an avermectin producer, contains 33 
P450s (4), and Saccharopolyspora erythraea NRRL 23338, the erythromycin-producing 
bacterium, encodes 36 P450s (5). In secondary metabolic pathways, it is typical that P450 
genes are integrated within the biosynthetic cluster, where their products catalyze regio- 
and stereospecific oxidation of precursors leading to structural diversity as well as 
improved bioactivities of these molecules (6, 7). Thus, cytochrome P450 enzymes EryF 
(8) and EryK (9) that are encoded within the erythromycin biosynthetic gene cluster are 
involved in the biosynthesis of erythromycin A. Specifically, EryF hydroxylates the 
macrolactone precursor 6-deoxyerthronolide B, whereas EryK is a macrolide hydroxylase 
resulting in formation of erythromycin D. As prototypic P450 hydroxylases involved in 
secondary metabolism, EryF and EryK exhibit strict substrate specificity. In contrast, 
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PikC cytochrome P450 involved in the methymycin/neomethymycin and pikromycin 
biosynthetic pathway of Streptomyces venezuelae has broader substrate tolerance (10). 
PikC catalyzes the final hydroxylation step toward the 12-membered ring macrolide YC-
17 and the 14-membered ring macrolide narbomycin to produce 
methymycin/neomethymycin and pikromycin as major products. 
Mycinamicins, a series of macrolide antibiotics produced by the rare 
actinomycete Micromonospora griseorubida, have shown impressive activities against a 
spectrum of Gram-positive strains, especially some antibiotic-resistant human pathogens 
(11-13). Stucturally, the major mycinamicin products of wild-type strain M. griseorubida 
 
 
Figure 6-1. Mycinamicin post-PKS biosynthetic pathway and organization of the 
mycinamicin biosynthetic gene cluster. Methyl groups introduced by O-methyltransferases 
and oxidation steps catalyzed by cytochrome P450 enzymes are highlighted in green and red, 
respectively. Bold arrows represent the main pathway, whereas thin arrows indicate a shunt 
pathway. The dashed arrow indicates low-level conversion, as reported elsewhere (17). Color 
codes in the myc gene cluster are as follows: red, cytochrome P450 genes; purple, ferredoxin 
gene; indigo blue, polyketide synthetase genes; blue, glycosyltransferase genes; green, O-
methyltransferase genes; orange, deoxysugar biosynthetic genes; and yellow, self-resistance 
gene (rRNA methyltransferase gene). 
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A11725, including mycinamicin I (M-I), II (M-II), IV (M-IV), and V (M-V) (Fig. 6-1), 
consist of a 16-membered ring polyketide macrolactone substituted with 6-deoxyhexose 
sugars desosamine and mycinose. Partial characterization of the biosynthetic pathway for 
mycinamicins has been obtained through analysis of blocked mutants and corresponding 
bioconversion studies (13, 14). More recently, the nucleotide sequence of the complete 
mycinamicin biosynthetic gene cluster has been reported (15), wherein two putative P450 
genes mycCI and mycG were identified (Fig. 6-1). 
Analysis of the 5′ region of the myc gene cluster upstream from the PKS locus 
revealed that mycCI is located adjacent to mycCII, which encodes a putative ferredoxin 
(15). Since the deduced amino acid sequences of mycCI and mycCII show high sequence 
similarities to TylHI and TylHII (Fig. 6-2), respectively, that are likely responsible for 
hydroxylation at the C23 methyl group of tylactone (16), the function of MycCI and 
MycCII was accordingly proposed to mediate hydroxylation at the analogous C21 methyl 
group of protomycinolide IV (PML-IV) (15) (Fig. 6-1). On the basis of genetic 
complementation analysis of a targeted mutant strain of M. griseorubida, mycG was 
presumed to encode a P450 enzyme that catalyzes both hydroxylation and epoxidation at 
C14 and C12/13 on the macrolactone ring of mycinamicin (13, 17). In the current study, 
mycCI and mycG genes were overexpressed in Escherichia coli, and the functions of 
purified MycCI and MycG proteins were determined in vitro using natural substrates 
derived from semi-synthesis or isolated from wild-type or engineered strains of M. 
griseorubida that accumulate key mycinamycin intermediates. Moreover, specific roles 
have been proposed for both the desosamine and mycinose sugar residues in the oxidative 
cascade leading to M-II, the final product in the pathway. 
 
6.2 Results 
6.2.1 Protein Sequence Analysis of MycCI and MycG 
Comparison of the deduced amino acid sequences of MycCI and MycG showed 
relatively low sequence identity (33%). In the phylogenetic tree (Fig. 6-2) of selected 
bacterial macrolide biosynthetic P450 enzymes, they were clustered in distinct branches, 
suggesting these two unrelated P450 genes may have been integrated into the 
mycinamicin biosynthetic gene cluster sequentially from different ancestors, as opposed 
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to being derived from divergent evolution following duplication of a parental gene. 
Specifically, MycG, as the first biosynthetic monooxygenase characterized with an ability 
to catalyze both hydroxylation and epoxidation steps, is clustered with two other 
epoxidases — OleP (18) and ChmPI (19), whereas MycCI is closely related to ChmHI 
(19) and TylHI (16), both of which are responsible for methyl group hydroxylations of 
16-membered ring macrolides. Interestingly, we revealed that the clustering of macrolide 
biosynthetic P450s correlated with not only the functionalities (i.e., hydroxylases, 
epoxidases, or ones responsible for carboxylic acid formation) but also the substrate 
macrolactone ring size, suggesting that selection based on product structure derived from 
the upstream PKS biosynthetic system might be among the significant factors directing 




Figure 6-2. Phylogenetic tree of macrolide biosynthetic P450 monooxygenases. The 
selected cytochrome P450s include OleP (accession number AAA92553) [oleandomycin 
pathway], ChmHI and ChmPI (accession numbers AAS79447 and AAS79453) [chalcomycin 
pathway], MycCI and MycG [mycinamicin pathway] (accession numbers BAC57023 and 
BAA03672), AmphL and AmphN (accession numbers AAK73504 and AAK73509) 
[amphotericin pathway], NysL and NysN (accession numbers AAF71769 and AAF71771) 
[nystatin pathway], PimD and PimG (accession numbers CAC20932 and CAC20928) 
[pimaricin pathway], TylHI and TylI (accession numbers AAD41818 and AAA21341) 
[tylosin pathway], EryF and EryK (accession numbers AAA26496 and YP-001102980) 
[erythromycin pathway], and PikC (accession numbers AAC68886) [pikromycin pathway]. 
The numbers in parentheses indicate the macrolactone ring size of the corresponding P450 
substrate. Unless otherwise specified, all selected P450 enzymes are hydroxylases. The 
epoxidases are noted in italics. The enzymes marked with an asterisk are presumed to mediate 
carboxylic acid formation. MycCI and MycG are highlighted in bold. 
 111 
6.2.2 Heterologous Expression of MycCI, MycCII, and MycG 
The mycCI, mycCII, and mycG genes were overexpressed in E. coli BL21(DE3), 
and the resulting proteins were purified (see Supplementary Information). MycCI was 
overexpressed as either a C- or N-terminal 6× His tagged protein. After purification using 
Ni-NTA agarose chromatography, the individual polypeptides showed molecular weights 
of approximately 44 and 45 kDa, corresponding to the estimated masses of C- and N-
terminal 6× His tagged MycCI. The wild-type MycCII (MycCII-wt, m.w. ~ 8 kDa) and 
N-terminal 6× His-tagged ferredoxin MycCII (MycCII-NH, m.w. not, ~ 10 kDa) were 
purified to homogeneity (see Experimental Procedures). MycG expression was placed 
under the control of a T7 promoter including a 6× His-tag introduced at its amino 
terminus. Similarly, one-step purification was performed using a Ni-NTA agarose 
column to obtain homogeneous protein with expected molecular weight of 46 kDa. 
Subsequently, the CO-bound reduced difference spectra confirmed the identity of both 
MycCI and MycG as cytochrome P450 enzymes (see Supplementary Information). 
 
4.2.3 Synthesis of Mycinamicin VIII (M-VIII) from Protomycinolide IV (PML-IV) 
Because of the limited quantity (< 0.1 mg) of totally available M-VIII isolated 
from M. griseorubida fermentation culture, the presumed substrate of MycCI, we 
developed an effective chemical glycosylation strategy to obtain this important 
intermediate by coupling desosamine as sugar donor to the readily available PML-IV 
aglycone precursor (20). Glycosylation with desosamine has previously employed either 



































Figure 6-3. Synthetic scheme for M-VIII. 
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(21-27). After examining several combinations of protecting groups and anomeric 
leaving groups, we found that the C2 acetoxy-protected glycosyl fluoride of desosamine 
was conveniently obtained, easily purified, stable to storage, and effective in the transfer 
of desosamine to a range of aglycones. In this procedure (Fig. 6-3), erythromycin hydrate 
was hydrolyzed under acidic conditions to obtain a crude sample of desosamine 
hydrochloride that was converted to the bis(acetate) of desosamine in 88% isolated yield, 
as reported elsewhere (28). Further treatment of this material with HF·pyridine afforded 
the C2 acetoxy glycosyl fluoride of desosamine 1, which serves as a stable and 
convenient precursor for chemical glycosylations. Direct treatment of PML-IV (Fig. 6-1) 
with the glycosyl fluoride and BF3·Et2O in CH2Cl2 afforded C2 acetoxy mycinamycin 
VIII as a 2:1 mixture of β and α anomers in 39% (not optimized) isolated yield. Higher 
yielding desosamine glycosylations with other mycinamicins have been reported (22); 
however, these alternative procedures with different glycosyl donors were not explored 
for comparison. Purification by preparative HPLC (SiO2) afforded the pure β-anomer 
(Fig. 6-3), which was deprotected with K2CO3 in methanol to afford semisynthetic M-
VIII in 89% isolated yield. The 1H NMR spectrum of this synthetic material was 
coincident with previously reported data (29). 
 
6.2.4 Functional Analysis of MycCI In Vitro 
To establish the role of each mycinamicin P450, we first tested whether MycCI is 
capable of hydroxylating the predicted substrate M-VIII using a typical heterologous 
spinach ferredoxin and ferredoxin reductase system (10). As expected, M-VIII was 
converted to the corresponding C21 hydroxymethyl product M-VII (Fig. 6-4), albeit 
inefficiently. Notably, the C- and N-terminal His-tagged MycCI showed similar 
activities, indicating that the location of His-tag has no significant impact on MycCI 
activity. We selected the C-terminal His-tagged MycCI to perform biochemical studies 
and refer to this form as MycCI for convenience. The low conversion ratio of M-VIII 
(11.0 ± 0.8%) might be due to the higher activation energy required to functionalize the 
primary C-H bond. Alternatively, the fact that a specific ferredoxin gene mycCII is 
clustered with mycCI suggests that MycCI might possess higher ferredoxin specificity 
than MycG. Thus, the capability of MycCII (together with spinach ferredoxin reductase, 
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since the native ferredoxin reductase for MycCI remains unknown) to reconstitute the in 
vitro M-VIII hydroxylation activity of MycCI was assessed and compared to spinach 
ferredoxin. Thus, when partnered by MycCII-wt and MycCII-NH, MycCI converted 28.6 
± 2.0% and 37.4 ± 1.4% of M-VIII to M-VII, respectively, suggesting MycCII mediates 
the electron transfer from spinach ferredoxin reductase to MycCI more efficiently than 
does spinach ferredoxin (Fig. 6-4). However, it is currently unclear why the activity of 
the His-tagged MycCII is higher than that of MycCII-wt. Considering that spinach 
ferredoxin and ferredoxin reductase are natural partners, we reason that the higher 
activity of MycCII could derive from a more favorable interaction with the MycCI P450, 
compared with the spinach ferredoxin reductase. Therefore, the binding affinities of 
different ferredoxins toward MycCI were compared with one another. As expected, the 
most active form (MycCII-NH) exhibited the lowest dissociation constant (Kd) of 7.0 ± 
0.1 µM. In contrast, the binding affinity of spinach ferredoxin to MycCI (Kd = 148.9 ± 
 
 
Figure 6-4. In vitro M-VIII conversions catalyzed by MycCI. All LC traces were analyzed 
at 280 nm: (1) negative control, M-VIII + boiled MycCI; (2) M-VIII + MycCI + spinach 
ferredoxin; (3) M-VIII + MycCI + MycCII-NH; (4) M-VIII + MycCI + MycCII-wt; and (5) 
M-VII standard. The right diagram shows M-VIII conversion ratios calculated by using 
Equation 1-AUCunreacted M-VIII/AUCtotal M-VIII (AUC: area under curve) based on the corresponding 
LC-traces in parallel. Error bars are shown since the conversion ratios (mean ± s.d.) are 
calculated from two independent experiments. In addition, dissociation constants (Kd) with 
standard errors of the spinach and MycCII ferredoxins toward MycCI are shown. 
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10.2 µM) is much lower than that of either MycCII-wt or MycCII-NH. Interestingly, we 
found MycCII is unable to support in vitro activity of MycG (see Supplementary 
Information), the other P450 enzyme involved in mycinamicin biosynthesis. These results 
strongly suggest MycCII has evolved to selectively serve MycCI catalysis. 
In addition, similar MycCI reactions were assessed with the PML-IV, M-VI, M-
III, M-IV, and M-V (Fig. 6-1), but no products were observed, and starting materials 
were quantitatively recovered. These results establish that MycCI catalyzes the first 
oxidation step, converting the C21 methyl group to the corresponding hydroxymethyl that 
is subsequently functionalized with 6-deoxyallose, followed by two methylation steps to 
mycinose. Moreover, the substrate requires desosamine modification at the C5 hydroxyl 
group in order to be accepted by MycCI. This is analogous to PikC, shown through 
cocrystal structure analysis with natural 12- and 14-membered ring macrolides to involve 
desosamine-mediated substrate anchoring (30). 
 
6.2.5 Functional Analysis of MycG In Vitro 
Previous genetic studies on the mycinamicin biosynthetic pathway identified a 
gene fragment that complemented a M-II nonproducing mutant of M. griseorubida (17). 
DNA sequence analysis revealed an open reading frame whose translated product showed 
high-level amino acid sequence similarity to cytochrome P450 enzymes. The 
mycinamicin biosynthetic intermediate isolated from the M-II nonproducing M. 
griseorubida strain lacked both C14 hydroxyl and C12-C13 epoxide functionalities, and 
the subcloned fragment bearing the putative P450 gene was able to restore production of 
M-II (17). These data provided strong but indirect evidence that the mycG gene product 
is capable of catalyzing both oxidation steps at adjacent positions on the macrolactone 
ring (Fig. 6-1). 
To confirm the dual function of MycG, our in vitro analysis was initiated by 
testing directly the ability of MycG to convert the putative substrate M-IV. As shown in 
Fig. 6-5A, the LC trace of the reaction extract [2] at 280 nm showed two peaks a and b. 
The corresponding mass spectra indicate M-V ([M+H]+ = 712.35) and M-II ([M+H]+ = 
728.35) co-eluted as peak a, and peak b includes M-IV ([M+H]+ = 696.35) and M-I 
([M+H]+ = 712.35). This LC-MC analysis clearly demonstrates the dual function of 
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MycG as hydroxylase and epoxidase. However, despite efforts to optimize reverse-phase 
HPLC conditions, we were unable to separate M-IV and M-V from their epoxidized 
 
 
Figure 6-5. LC-MS analysis of in vitro conversions catalyzed by MycG. All LC traces were 
analyzed at 280 nm unless otherwise specified. (A) MycG reaction using M-IV as substrate: 
(1) negative control, M-IV + boiled MycG; (2) M-IV + MycG. The right panel shows the mass 
spectra of peak a and b; (3) M-II standard amplified 20× because of its poor absorbance at 280 
nm; (4) M-V standard; (5) M-I standard amplified 20×. (B) MycG reaction using M-V as 
substrate: (1) negative control, M-V + boiled MycG; (2) M-V + MycG. The inset shows the 
240 nm LC trace, under which M-II has better absorbance. The right panel shows the mass 
spectrum of peak c; (3) M-II standard amplified 20×. (C) MycG reactions using M-III and M-
VI as alternative substrates: (1) negative control, M-III + boiled MycG; (2) M-III + MycG; (3) 
negative control, M-VI + boiled MycG; (4) M-VI + MycG. LC traces (3) and (4) amplified 20 
× compared to (1) and (2) to visualize the peak e in trace amount. The right panel shows the 
mass spectra of peak d and e. 
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products. 
To determine the precursor of M-II, M-V and M-I were incubated with MycG in 
separate reactions. When M-V was used as substrate, it was almost completely converted 
into M-II. Since M-II (and M-I) lacks strong absorbance at 280 nm (11), only a minor 
peak c was observed in the LC trace, although substantial M-II was formed on the basis 
of mass spectral analysis (Fig. 6-5B; notably, the M-II product was visible at 240 nm). 
However, M-I was not converted into M-II in vitro (see Supplementary Information), 
indicating that M-II can only be generated from M-V as substrate. Epoxidation of M-IV 
prior to hydroxylation evidently results in termination of this post-PKS tailoring pathway 
(Fig. 6-1). 
To assess further enzyme selectivity and ability to catalyze alternative oxidative 
reactions against the mycinamicin aglycone and several early glycosylated intermediates 
(PML-4, M-VIII, M-VII, M-VI, and M-III), MycG-mediated reactions were performed. 
No products were observed when using PML-4, M-VIII, and M-VII (see Supplementary 
Information), but two new compounds appeared at low levels in LC-MS analysis of the 
M-VI and M-III reactions (Fig. 6-5C). When M-III was used as a substrate, a minor new 
peak d was detected with m/z = 698.40, which is 16 Da higher than the molecular weight 
of M-III. Moreover, in the MycG reaction with M-VI, a new peak e (m/z = 684.25), 
presumed to be oxidized M-VI, was detected at an even lower conversion level. Both 
peak d and e were visible under 280 nm, and their retention times were faster than 
corresponding starting materials, strongly suggesting they are hydroxylated instead of 
epoxidized products. Moreover, the MS-MS analysis of d and e indicated that both 
hydroxylations occurred on the macrolactone ring, although we could not further 
determine the site of modification because of limited amounts of each compound. 
Interestingly, the C14 hydroxylated forms of M-III and M-VI have already been reported 
as minor components of the mycinamicin pathway designated as mycinamicin IX (M-IX) 
and mycinamicin XV (M-XV), respectively (31). Accordingly, it is likely that d and e 
correspond to M-IX and M-XV, providing direct evidence for the in vivo origin of these 
two minor compounds. More importantly, we established that efficient catalysis by 
MycG requires mycinose, derived from dimethylation of the second sugar residue as C21 
OH linked 6-deoxyallose. 
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6.2.6 Measurement of Substrate Dissociation Constants 
To understand why mycinamicin P450 enzymes (especially MycG) behave 
differently toward compounds with subtle structural differences, we performed 
spectrophotometric substrate binding assays to determine dissociation constants (Kd). As 
shown in Table 6-1, M-VIII binds to MycCI with a Kd value of 28.1 ± 3.2 µM, which is 
significantly higher than 0.7 ± 0.1 µM, the Kd value of M-IV toward MycG. Evidently, 
the substrate binding to MycG is much tighter than that to MycCI, which is likely 
attributed to additional interactions of mycinose within the P450 substrate-binding 
pocket. Interestingly, the C14 hydroxylated M-V showed approximately 14 times lower 
binding affinity toward MycG than M-IV, suggesting that M-V is a less suitable substrate 
for MycG. However, this finding is inconsistent with the results from in vitro assays 
(described in Fig. 6-4C above) in which M-V was converted to oxidized product more 
effectively than M-IV (kinetic analysis [see below] provided insights into this apparent 
paradox). In contrast to M-V, the epoxidized product M-I was not able to function as a 
substrate since we did not observe a Type-I difference spectra even at high substrate 
concentrations. This result is consistent with a lack of MycG activity toward M-I in vitro. 
It was particularly surprising that the final product M-II bound to MycG with a 
dissociation constant of 71.5 ± 8.4 µM, indicating the compromising effect of the epoxide 
moiety toward substrate binding could be overridden by an adjacent C14 hydroxyl group. 
The reason for this unusual finding will await substrate cocrystallographic analysis of 
MycG, which is currently in progress. 
Table 6-1. Binding and steady-state kinetic analysis of MycCI and MycG 
 
Enzyme Substrate Kd (µM) Km (µM) kcat (min−1) kcat/Km (µM-1•min-1) 
MycCI M-VIII 28.1 ± 3.2 34.5 ± 5.5a 71.7 ± 3.2a 2.1a 
   5.8 ± 0.7b 104.1 ± 1.8b 17.9b 
MycG M-IV 0.7 ± 0.1 NDc NDc NDc 
 M-V 10.4 ± 0.2 16.2 ± 3.1a 415.7 ± 22.9a 25.7a 
 M-I NBd - - - 
 M-II 71.5 ± 8.4 - - - 
-. No reaction. 
aKinetic parameters were determined when spinach ferredoxin was used. 
bKinetic constants were determined when MycCII0NH ferredoxin was used. 
cND: The kinetic parameters were not determined because multiple reactions occur at the same time. 




6.2.7 Steady-State Kinetic Analysis of MycCI and MycG 
Assuming a 1:1 stoichiometric relationship between NADPH consumption and 
substrate oxidation, the steady-state kinetic parameters of MycCI were determined using 
purified synthetic M-VIII as substrate. When partnered with spinach ferredoxin, MycCI 
demonstrated a Km of 34.5 ± 5.5 µM and a kcat of 71.7 ± 3.2 min−1 for the C21 methyl 
group hydroxylation step. In contrast, with MycCII-NH coupled with MycCI, catalysis 
became more efficient with a decreased Km of 5.8 ± 0.7 µM and an improved kcat of 104.1 
± 1.8 min−1. This finding suggests that MycCII not only induces better substrate binding 
of MycCI but also improves electron transfer efficiency as reflected by increased 
turnover number (kcat). 
Although MycG is capable of catalyzing three different reactions (M-IV to M-V; 
M-IV to M-I; and M-V to M-II), we limited our study to kinetic constants for M-V to M-
II conversion (Km = 16.2 ± 3.1 µM; kcat = 415.7 ± 22.9 min−1). This was because of the 
complexity of the analysis when M-IV was used as substrate, since multiple reactions 
(M-IV to M-V or M-I and M-V to M-II) did not allow fitting of data to the Michaelis-
Menten equation. However, it is noteworthy that we observed the overall NADPH 
consumption rate at high M-IV concentration (e.g., 100 µM) to be considerably reduced, 
compared with low M-IV concentration (e.g., 10 µM), suggesting strong substrate 
inhibition. This could explain the above-mentioned contradiction between the conversion 
ratio and binding affinity. According to the in vitro analysis of MycG activity (Fig. 6-5A 
and 6-5B), M-V appears to be a better substrate than M-IV on the basis of the conversion 
ratios. However, this result might be misleading since M-IV has better binding affinity 
toward MycG (Table 6-1). Thus, on the basis of in vitro reactions using substrate 




Mycinamicins represent a large family of macrolide antibiotics with more than 20 
members (31, 32). The structural diversity is derived primarily from post-PKS tailoring 
modifications, including glycosylation, oxidation, and methylation steps. Therefore, this 
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biosynthetic pathway represents an important system to explore the mechanism and 
significance of secondary metabolite diversification. 
Here, we provide a detailed analysis of two cytochrome P450 enzymes, MycCI 
and MycG, and their role in late-stage chemical modifications. By gene cloning, protein 
expression, purification, and reconstitution assays with heterologous redox partners, we 
unambiguously confirmed their physiological role in vitro. To the best of our knowledge, 
the functional and kinetic analysis of MycCI represents the first enzymatic 
characterization of a biosynthetic monooxygenase responsible for methyl group 
hydroxylation. In addition, we established that MycCII is a specific ferredoxin, whose 
corresponding gene (mycCII) is immediately adjacent to mycCI and capable of effectively 
supporting MycCI activity. Compared with spinach ferredoxin, MycCII binds to MycCI 
more tightly, presumably leading to more efficient electron transfer. On the other hand, 
we established that C21 hydroxylation by MycCI depends on C5-linked desosamine, 
which is analogous to PikC (10), another cytochrome P450 involved in pikromycin 
biosynthesis. Recent cocrystallographic analysis of PikC (30) and its natural substrates 
(YC-17 and narbomycin) revealed that desosamine acts as an indispensable anchor 
responsible for productive binding and proper positioning of substrate in the active site. 
Accordingly, we surmise that desosamine plays a similar role in hydroxylation of 
precursor macrolide M-VIII. 
The current study has revealed that MycG is a more versatile enzyme than 
MycCI, providing the first example of a biosynthetic P450 involved physiologically in 
catalyzing both hydroxylation and epoxidation reactions. In addition, MycG represents 
the primary basis for structural diversification in the mycinamicin pathway since it is 
solely responsible for generating multiple products, including M-V, M-I, and M-II, as 
well as some minor components, including M-IX and M-XV. This work has also 
demonstrated that MycG function depends on the presence of both desosamine and the 
second sugar mycinose in the substrate. It is also noteworthy that both deoxysugars are 
essential for mycinamicin bioactivity (29). Although the precise role of the second sugar 
for MycG substrate recognition remains obscure because of the lack of X-ray structural 
information, on the basis of the high binding affinity of M-IV toward MycG (Kd = 0.7 ± 
0.1 µM), we predict that there might be a specific active site-binding pocket in the 
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polypeptide to accommodate mycinose, thereby significantly improving substrate 
affinity. Moreover, of particular interest, the activity of MycG against diglycosylated 
substrates (M-VI, M-III, and M-IV) is related to the extent of methylation mediated by 
sequential O-methyltransfer by MycE and MycF (15). In the absence of methylether 
groups installed on the second sugar molecule, M-VI bearing 6-deoxyallose appears to be 
a very poor substrate for MycG. This situation can be improved by the first methylation 
to form javose in M-III, although its conversion is low (Fig. 6-5C). Subsequently, the 
second methylation catalyzed by MycF imparts a pronounced effect upon MycG-
mediated binding of M-IV. It appears likely that these stepwise methylations decrease the 
polarity of 6-deoxyallose in M-VI, thus enabling it to be accepted by a putative 
hydrophobic MycG-binding pocket. 
Substrate inhibition occurs in about 20% of all known enzymes (33). In 
biosynthetic P450 enzymes, this phenomenon has been observed in previous kinetic 
analysis of PikC (34), EryK (35), and PimD (36). In this study, M-IV inhibition of MycG 
was also detected indirectly even though the kinetic parameters were not obtained 
because of the complexity of the multiple-reaction system. Thus, the mechanism of this 
substrate inhibition cannot be further elucidated without generating detailed kinetic 
curves. However, we realize that this behavior of MycG might be physiologically 
significant for maintaining the chemical diversity within the mycinamicin pathway. In the 
event that M-IV inhibition does not occur, MycG would convert all M-IV into final 
products M-I and M-II, instead of a mixture of M-I, II, IV, and V as shown in Fig. 6-5A 
and observed in the fermentation culture of M. griseorubida strain A11725 (11). This 
would ultimately limit the spectrum of its metabolic output and perhaps compromise the 
ability of the microorganism to adapt to a variable and competitive environment. 
 
6.4 Experimental Procedures 
Materials — Unless otherwise specified, all chemical reagents were ordered from 
Sigma-Aldrich. DNA oligonucleotides were purchased from Integrated DNA 
Technologies (Coralville, IA). Molecular cloning used New England Biolabs (Ipswich, 
MA) restriction enzymes, Stratagene (La Jolla, CA) Pfu Turbo DNA polymerase, 
Novagen (Madison, WI) pET vectors, Invitrogen (Carlsbad, CA) T4 DNA ligase, and Z-
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Competent Escherichia coli Transformation Buffer set from Zymo Research (Orange, 
CA). Protein purification used QIAGEN (Valencia, CA) Ni-NTA resin, Millipore 
(Billerica, MA) Amicon Ultra centrifugal filter, PD-10 desalting columns from GE 
Healthcare (Piscataway, NJ), and Thrombin restriction grade Kit from Novagen 
(Madison, WI). LB Broth was from EM Sciences (Gibbstown, NJ). All mycinamicins 
except M-VIII were obtained from the fermentation broth of M. griseorubida A11725. M-
VIII was synthesized from PML-IV using the method described above. 
 
DNA Manipulation, Cloning, and PCR — Using cosmid pMR01 (15) as template, 
mycCI, mycCII, and mycG genes were amplified by PCR under standard conditions with 
primers as follows: forward, 5′-
CAGCATATGGTGGTCTGGCCCATGGACCGCACCTG-3′ for mycCI, 5′-
GTGCCATATGCGGATAGTCCTGGACGCCGAAC-3′ for mycCII, and 5′-
CGGTCATATGACTTCAGCTGAACCTAGGGCGTATCC-3′ for mycG (the underlined 
bases represent the introduced NdeI site for further cloning); reverse, 5′-
TCGTAAGCTTCCACTCGACCAGCAGCTCGTCGATG-3′ for cloning mycCI gene 
without a stop codon, 5′-TCCAAAGCTTTCCGCATACCGCACCCCCATTCGTC-3′ for 
amplifying the mycCI gene retaining a stop codon, 5′-
TGACAAGCTTACTCCTGTTGGCCCACCTGTCCCGTG-3′ for mycCII, and 5′-
GGCAAAGCTTCTCCGACGAGATCGTCGAGATCGAC-3′ for mycG (the italic letters 
indicate a HindIII restriction site for later cloning). The gel purified cDNAs were rescued 
by double digestion of NdeI and HindIII. Then, the fragment containing the mycCI gene 
with stop codon removed was ligated into NdeI/HindIII treated pET21b to generate 
recombinant plasmid pET21b-mycCI for expression of C-terminal His-tagged MycCI. 
Genes retaining stop codons, including mycCI, mycCII, and mycG, were ligated into 
previously NdeI/HindIII-digested pET28b to generate recombinant plasmids for 
expression of N-terminal His6-tagged proteins. After confirming the identity of inserted 




Protein Overexpression and Purification — MycCI and MycG (P450s) overexpression 
and purification followed previously developed procedures with minor modifications (10, 
34). The E. coli BL21 (DE3) transformants carrying certain plasmids were grown at 37°C 
in 1 liter of LB broth containing thiamine (1 mM), 5% glycerol, 50 µg/ml selective 
antibiotics (ampicillin for pET21b and kanamycin for pET28b), and a rare salt solution 
(6750 µg/l FeCl3, 500 µg/l ZnCl2, CoCl2, Na2MoO4, 250 µg/l CaCl2, 465 µg/l CuSO4, and 
125 µg/l H3BO3) until OD600 reached 0.6–0.8. Then isopropyl β-D-thiogalactoside (IPTG, 
0.1mM) and δ-aminolevulinic acid (1mM) were added, and the cells were cultured at 
18°C overnight. After harvesting cells by centrifugation, 40 ml of lysis buffer (50 mM 
NaH2PO4 [pH 8.0], 300 mM NaCl, 10% glycerol, and 10 mM imidazole) was used to 
resuspend the cell pellet. Lysis was accomplished on a Model 500 Sonic Dismembrator 
(ThermoFisher Scientific). The insoluble material was separated by centrifugation 
(35,000 × g, 30 min at 4°C). The soluble fraction was collected and incubated for 1 h at 
4°C after addition of 1ml Ni-NTA resin. The slurry was loaded onto an empty column, 
and the column was then washed with 40 to 80 ml of wash buffer (50 mM NaH2PO4 
[pH8.0], 300 mM NaCl, 10% glycerol, and 20–30 mM imidazole). The elution buffer (50 
mM NaH2PO4 [pH8.0], 300 mM NaCl, 10% glycerol, and 250 mM imidazole) was added 
onto the column, and eluted protein fraction was concentrated with Amicon Ultra 4, 
Ultracel −30K. Subsequent desalting was attained by buffer exchange into desalting 
buffer (50 mM NaH2PO4 [pH7.3], 1 mM EDTA, 0.2 mM dithioerythritol, and 10% 
glycerol) with a PD-10 column. 
Overexpression and purification of N-terminal 6 × His-tagged ferredoxin MycCII-
NH are similar to above procedures with minor modifications as follows: 1) δ-
aminolevulinic acid, the precursor for heme biosynthesis, was omitted in the culture 
broth; and 2) the protein obtained from elution buffer was concentrated using Amicon 
Ultra 4, Ultracel −5K because of the low molecular weight of MycCII ( ~ 10 kDa). To 
obtain MycCII-wt lacking a His-tag, 2.4 mg of MycCII-NH in desalting buffer was 
digested by 2 units of thrombin at 4°C overnight. The cleaved His-tag and residual 
thrombin were removed by use of Ni-NTA resin and a 30K size exclusion filter 
sequentially. The concentration of purified ferredoxins was determined by Coomassie 
protein assay using spinach ferredoxin as standard. 
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CO-Bound Reduced Difference Spectra — The identification of MycCI and MycG as 
active P450 enzymes was performed through getting the CO-bound reduced difference 
spectra using a UV-visible spectrophotometer 300 Bio (Cary). First, the P450 enzyme in 
desalting buffer was reduced by adding several milligrams of sodium dithionite 
(Na2S2O4), and a spectrum was recorded from 350 to 600 nm. Then, after CO bubbling of 
the solution for 30–60 sec, the spectrum of CO-bound reduced P450 species was recorded 
using previous reduced spectrum as reference. This assay was also used to determine the 
functional P450 concentration using the extinction coefficient of 91,000 M−1·cm−1 (36). 
 
Functional Analysis of In Vitro Activities of MycCI and MycG — The standard 
conversion was accomplished by combining 1 µM of desalted MycCI or MycG, whose 
functional concentrations were determined using UV-visible absorption spectrum method 
(35), 0.5 mM mycinamicin biosynthetic intermediate, 3.5 µM spinach ferredoxin or 
MycCII ferredoxin, 0.1 U/ml spinach ferredoxin-NADP+ reductase, and 0.5 mM NADPH 
in 100 µl of desalting buffer. The reaction with boiled P450 enzyme was used as a 
negative control. The reaction was performed for 2 h at 30°C and was terminated by 
extraction, using 3 × 200 µl of CHCl3. The resulting organic extraction was dried and 
redissolved in 150 µl of methanol. The LC-MS analysis of reaction extract was 
performed on LCMS-2010 EV (Shimadzu) by using an XBridge™ C18 3.5 µm 150 mm 
reverse-phase HPLC column under following conditions: mobile phase, 20–100% solvent 
B over 18 min (A = deionized water + 0.1% formic acid, B = acetonitrile + 0.1% formic 
acid); flow rate: 0.2 ml/min; UV wavelength: 240 and 280 nm. 
 
Spectral Substrate Binding Assay — Spectral substrate binding assay was performed 
on UV-visible spectrophotometer 300 Bio (Cary) at room temperature by titrating 
substrate DMSO solution (blank DMSO for reference group) into 1 ml of 0.5–1 µM P450 
solution in 1 µl aliquots (34). The series of Type I difference spectra were used to deduce 
ΔA (Apeak − Atrough). Then, the data from duplicated experiments were fit to Michaelis-
Menten equation to obtain the dissociation constant Kd. 
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Spectral Ferredoxin Binding Assay — Spectral ferredoxin titrations were performed as 
described elsewhere (37) using 0.7 µM MycCI and 10 µM M-VIII in desalting buffer at 
room temperature. Ferredoxin solutions in appropriate concentrations were used to titrate 
the P450 solution. Binding of ferredoxins to MycCI induced increased M-VIII binding, 
thus leading to a larger absorbance difference ΔA (Apeak − Atrough). The data from 
duplicated experiments were linearized by using a Hanes-Wolf plot to deduce 
dissociation constant Kd. 
 
Steady-State Kinetics of MycCI and MycG — The standard reactions contain 0.6 µM 
of MycCI (when partnered with spinach ferredoxin), 0.1 µM of MycCI (when partnered 
with MycCII-NH), or 0.1 µM of MycG, 1.9 µM spinach or MycCII ferredoxins, 0.02 
U/ml spinach ferredoxin-NADP+ reductase, 5–200 µM M-VIII for MycCI and 2–160 µM 
M-V for MycG in 90 µl of desalting buffer. After preincubation in 96-well plate at room 
temperature for 5 min, the reactions with different substrate concentrations were initiated 
spontaneously by adding 10 µl of 2 mM NADPH with a multichannel pipette. The rate of 
NADPH consumption was monitored continuously over 2 min under 340 nm by 
SpectraMax M5 spectrophotometer (Molecular Devices). The initial velocities of 
NADPH consumption were deduced from the absorbance curves within the linear range 
(0–20 s). Then, assuming a 1:1 stoichiometric relationship between NADPH consumption 
and substrate oxidation, the initial velocities of hydroxylation reactions were calculated 
by using the millimolar absorption coefficient 6.22 mM−1·cm−1 of NADPH at 340 nm 
(38). Finally, the results from duplicated experiments were fit to Michaelis-Menten 



















Figure 6-S1. SDS-PAGE analsis and CO-bound reduced difference spectra of MycCI and 
MycG. (A) Coomassie blue stained SDS-PAGE gel results of purified MycCI, MycG and 
MycCII. Lanes: M, protein marker; 1, N-terminal 6 × His tagged MycG; 2, N-terminal 6 × His 
tagged MycCI; 3, C-terminal 6 × His tagged MycCI; 4, N-terminal 6 × His tagged MycCII; 5, 




























Figure 6-S2. The activities of MycCI and MycG toward various mycinamicin intermediates 
(all LC traces were recorded under 280 nm except for M-I group at 240 nm). (A) PML-IV 






























                         
 
                          
 
Figure 6-S4. Binding analysis of MycG and MycCI. The substrate dissociation constants (Kd) 
measurement of (A) M-VIII toward MycCI and (B) M-IV, (C) M-V, and (D) M-II toward MycG. 







         
 
 
Figure 6-S5. Kinetic analysis of MycG and MycCI. Michaelis-Menten curves of (A) MycCI 
using M-VIII as substrate (partnered by spinach ferredoxin and ferredoxin reductase), (B) MycCI 
using M-VIII as substrate (partnered by MycCII-NH and spinach ferredoxin reductase) and (C) 
MycG using M-V as substrate (partnered by spinach ferredoxin and ferredoxin reductase). All 
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Functional Analysis of MycE and MycF, Two  
O-Methyltransferases Involved in the Biosynthesis of 
Mycinamicin Macrolide Antibiotics 
 
7.1 Introduction 
Deoxysugars are prevalent structural components of many antibiotics and often 
contribute substantially to their biological properties (1-3). Methylation of hydroxy 
group(s) on the deoxysugar ring is relatively common (Fig. 7-1), as O-methylation not 
only protects the reactive hydroxy group from undesired modifications, such as oxidation 
or dehydration, but also alters the solubility and pharmacokinetic properties of the 
resulting molecule (4). Biosynthetically, these O-methylation reactions are mainly 
catalyzed by a variety of S-adenosyl-L-methionine (SAM or AdoMet)-dependent 
methyltransferases in a site-specific manner. For example, the two SAM-dependent O-
methyltransferases TylE and TylF in the tylosin biosynthetic pathway of Streptomyces 
fradiae sequentially methylate individual hydroxy groups (C2-OH and C3-OH) in the 6-
deoxyallose moiety of demethylmacrocin to generate the macrolide antibiotic tylosin (5-
8). ElmMI, ElmMII, and ElmMIII are responsible for the consecutive methylation of 
three hydroxy groups of L-rhamnose in the antitumor polyketide antibiotic elloramycin 
(9). Moreover, a growing number of O-methyltransferases involved in various 
deoxysugar methylation reactions such as EryG (10), OleY (11), SpinH, SpinI, and 
SpinK(12) have been reported in diverse antibiotic biosynthetic systems. 
Mycinamicins represent a family of macrolide antibiotics with more than 20 
members produced by the rare actinomycete Micromonospora griseorubida (13-15). The 
antibacterial activities of some mycinamicin products against Staphylococcus aureus are 
higher than those of the clinical macrolide antibiotics erythromycin and leucomycin. 
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More importantly, mycinamicins have shown strong activity against a number of 
antibiotic-resistant human pathogens (13). Structurally, the major mycinamicin products 
of wild-type strain M. griseorubida A11725, including mycinamicins I, II, IV, and V, are 
composed of a 16-membered ring macrolactone core, an N,N-dimethylated deoxysugar 
desosamine, and a di-O-methylated deoxyhexose mycinose (Fig. 7-1). During the past 
two decades, the biosynthesis of mycinamicin has been elucidated through strain 
mutagenesis, bioconversion studies (16, 17), and sequence analysis of the complete 
mycinamicin gene cluster (18), wherein two putative O-methyltransferase genes mycE 
and mycF were tentatively assigned. 
Initial bioinformatics analysis of the corresponding genes revealed that MycE and 
MycF show high amino acid sequence similarities to TylE (demethylmacrocin O-
 
 
Figure 7-1. Antibiotics containing various O-methylated deoxysugars. The methyl groups 
installed by O-methyltransferases are numbered. 
 
 
Figure 7-2. Physiological reactions catalyzed by MycE and MycF. 
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methyltransferase) and TylF (macrocin O-methyltransferase), respectively, in the tylosin 
biosynthetic pathway (18). Accordingly, the function of MycE was proposed to methylate 
the C2-OH group of 6-deoxyallose in mycinamicin VI, leading to mycinamicin III, 
whereas MycF was presumed to transfer a methyl group to the C3-OH group of javose 
(that is, C2-methylated 6-deoxyallose) in mycinamicin III to generate mycinamicin IV 
(Fig. 7-2). The proposed functions of MycE and MycF were supported by in vivo 
precursor feeding studies (16, 19). Herein, we report the expression of mycE and mycF in 
Escherichia coli, and purification of MycE and MycF to establish their biochemical 
function for regiospecific deoxysugar O-methylation in mycinamicin macrolide 
antibiotics. 
 
7.2 Results and Discussion 
7.2.1 Protein Sequence Analysis of MycE and MycF 
Comparative analysis revealed that MycE (399 amino acids) is significantly larger 
than MycF (222 amino acids). Alignment of these two O-methyltransferases exhibits low 
sequence identity (11.3 %), suggesting they might have evolved from distinct ancestors. 
A protein BLAST search revealed a number of O-methyltransferases with either MycE or 
MycF as the query protein. Interestingly, all candidates with high sequence similarities 
are O-methyltransferases involved in deoxysugar biosynthesis. In the phylogenetic tree 
(Fig. 7-3A) of selected O-methyltransferases with high similarities to MycE and MycF, it 
is evident that they are located in distinct branches; this indicates their potentially 
disparate evolutionary origins. In the sequence alignment of MycE with corresponding 
close relatives (Fig. 7-3B and 7-3C), three conserved motifs (motifs I-III) (9, 20) were 
identified that are predicted to contribute to SAM binding. In contrast, there are only two 
conserved SAM binding motifs (motifs I and III) found in MycF. 
 
7.2.2 In Vitro Characterization of MycE and MycF  
To confirm the proposed function of MycE and MycF, we cloned mycE and mycF 
genes into pET28b for overexpression in E. coli BL21 (DE3). The recombinant N-
terminal His6-tagged proteins were purified to homogeneity by one-step Ni-NTA agarose 
chromatography (Fig. 7-4). With the purified enzymes in hand, we initially tested the 
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activities of MycE and MycF in sodium phosphate buffer (50 mM, pH 7.4) at 30 oC using 
SAM as methyl donor and mycinamicin VI and mycinamicin III as substrates (Fig. 7-2). 
MycE was unreactive toward both substrates, whereas MycF was able to moderately 
methylate mycinamicin III (but not VI), forming mycinamicin IV (data not shown). 
Because the dependence of this class of methyltransferases on a metal cofactor is not 
uncommon, we next investigated the effect of various divalent metal ions on the activities 
of MycE and MycF. Both enzymes achieved optimal activity in the presence of 10 mM 
MgCl2 (Fig. 7-5A). A number of alternative divalent ions including Co2+, Fe2+, Mn2+, and 
Zn2+ are capable of supporting suboptimal activities. Interestingly, the Mg2+ dependence 
of MycE appears to be more pronounced than MycF, as MycF remained moderately 
 
 
Figure 7-3. Amino acid sequence analysis of MycE and MycF. A) Phylogenetic tree of 
selected O-methyltransferases generated by MegAlign (DNASTAR) with the Clustal W 
method. MycE and MycF are highlighted in bold and italic. The selected O-methyltransferases 
include MycE and MycF (mycinamicin pathway), TylE and TylF (tylosin pathway), ChmMI 
and ChmMII (chalcomycin pathway), SpnH, SpnI, and SpnK (spinosad pathway), BusH, 
BusI, and BusK (butenyl spinosyn pathway), SnogY (nogalamycin pathway), OleY 
(oleandomycin pathway), ElmMI, ElmMII, and ElmMIII (elloramycin pathway), NovP 
(novobiocin pathway), CumN (coumermycin pathway), and MtfB (mycobacterial serovar-
specific glycopeptidolipid pathway). B) SAM binding motifs of MycE and its homologues. C) 
SAM binding motifs of MycF and its homologues. 
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active in the absence of Mg2+. The metal dependence of MycF was further assessed by 
the addition of 2 mM of EDTA; however, this treatment failed to abrogate activity, 
suggesting that a metal ion might be dispensable in the O-methyltransferase reaction 
catalyzed by MycF. In contrast, EDTA significantly lowered the activity of MycE even in 
the presence of 10 mM Mg2+. The optimal pH and temperature range for MycE and 
MycF assays were determined through comparison of enzymatic activities under various 
reaction conditions. The optimal reaction conditions of the two O-methyltransferases is 
pH 9.0 (Fig. 7-5B), significantly higher than the corresponding homologues TylE 
(optimal pH 7.5-8.5) and TylF (pH 7.5-8.0) (7). At pH 9.0, the maximal activities of 
MycE and MycF were observed at 50 and 37 oC (Fig. 7-5C), respectively, higher than 
those of TylE (42 oC) and TylF (31 oC) (7). 
Under optimal conditions, the in vitro activities of MycE and MycF were 
analyzed to reveal that MycE methylated the C2-OH of 6-deoxyallose, converting a 
majority of mycinamicin VI to mycinamicin III (Fig. 7-6B). MycE was incapable of 
double methylation to generate mycinamicin IV. The second C3-OH methylation of 
javose was catalyzed by MycF, with a higher conversion than MycE toward mycinamicin 
VI (Fig. 7-6F). Co-incubation of MycE and MycF with starting substrate mycinamicin VI 
resulted in the accumulation of both mycinamicins III and IV (Fig. 7-6D). Notably, 
mycinamicin IV cannot be further methylated by these two methyltransferases, despite 
the remaining hydroxy group at the C4 position in mycinose. Collectively, it is evident 
 
 
Figure 7-4. SDS-PAGE analysis of purified MycE and MycF.  
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that both MycE and MycF possess high substrate specificity. 
 
7.2.3 Kinetic Analysis of MycE and MycF 
Finally, we determined the steady-state kinetic parameters (Table 7-1) for MycE 
and MycF based on substrate consumption monitored by HPLC. MycE converted 
mycinamicin VI to mycinamicin III with a KM value of 26.4 ± 7.0 µM and a kcat value of 
5.0 ± 0.5 min-1. In contrast, MycF methylated mycinamicin III approximately two-fold 
more efficiently (with respect to kcat/KM value) than MycE toward mycinamicin VI. 
Notably, these kinetic data for MycE and MycF are similar to those of TylE and TylF in 
the tylosin pathway, as previously reported (7). 
 
7.3 Summary 
The mycinamicin post-PKS (polyketide synthase) tailoring pathway includes two 
glycosylation steps mediated by two glycosyltransferases (MycB and MycD), four 
oxidation steps mediated by two cytochrome P450 monooxygenases (MycCI and MycG), 
and two methylation steps catalyzed by MycE and MycF (16). These post-PKS 
modifications not only lead to structural diversification, but also confer biologically 
active properties on the resulting metabolites. We recently confirmed all oxidative 
Table 7-1. Steady-state kinetic parameters of MycE and MycF. 
 
 KM (µM) kcat (min-1) kcat/KM (µM-1•min-1) 
MycE 26.4 ± 7.0 5.0 ± 0.5 0.19 




Figure 7-5. Optimization of methylation reactions catalyzed by MycE and MycF. Effects 
of A) divalent metal ion, B) pH, and C) temperature. 
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tailoring steps in vitro through functional analysis of two P450 enzymes (21). This work 
revealed the importance of both methylation steps in 6-deoxyallose for substrate 
recognition by the MycG monooxygenase. In this study, we have advanced the 
knowledge about this pathway by analyzing MycE and MycF O-methyltransferases in 
vitro. Taking advantage of the reconstituted optimal in vitro assay, the substrate 
specificity of MycE and MycF and hence the order of sugar modification (mycinamicin 
VI→III→IV) in this pathway was unambiguously determined. This new information will 
help facilitate future efforts to manipulate deoxysugar biosynthesis for generation of 
novel macrolide antibiotics. 
 
7.4 Experimental Procedures 
 
 
Figure 7-6. LC-MS analysis (UV, 280 nm) of in vitro conversions catalyzed by MycE and 
MycF. A) Mycinamicin VI (M-VI) standard; B) M-VI + MycE; C) M-VI + MycF; D) M-VI + 
MycE + MycF; E) mycinamicin III (M-III) standard; F) M-III + MycF; G) M-III + MycE; H) 
mycinamicin IV (M-IV) standard. Compound identity was confirmed by mass spectrometry 
and comparison with standard compound regarding retention time and co-injection. 
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MycE and MycF gene cloning — Using cosmid pMR01 (18) as template, mycE and 
mycF genes were amplified by PCR under standard conditions with primers as follows: 
forward, 5’-GGA GTT CCA TAT GAC CGC ACA GAC CGA A-3’ for mycE and 5’-
GGA GTT CCA TAT GAG CCC GTC GAC CGG A-3’ for mycF (bases in italics 
represent the NdeI cutting site); reverse, 5’-ACA TCA AGC TTT CAT GTC GCG CCT 
CCG GA-3’ for mycE and 5’-ACA TCA AGC TTT CAG GCC GAG CGA CGC CA-3’ 
for mycF (underlined bases indicate the HindIII restriction site). The gel-purified cDNAs 
were double digested by NdeI and HindIII (New England Biolabs), followed by the 
ligation of fragments containing mycE and mycF genes into NdeI/HindIII-treated pET28b 
(Novagen) to generate recombinant plasmids pET28b-mycE and pET28b-mycF for the 
expression of N-terminal His6-tagged MycE and MycF, respectively. The identity of the 
inserted gene was confirmed by nucleotide sequencing. 
 
Protein expression and purification — Recombinant plasmids pET28b-mycE and 
pET28b-mycF were used to transform E. coli BL21 (DE3) cells with a Z-CompetentTM 
Kit (Zymo Research). The resulting transformants were grown at 37 oC in 1 L of LB 
broth containing kanamycin (50 g/mL) for 2-3 h until OD600 reached 0.6-0.8. Isopropyl--
D-thiogalactopyranoside (IPTG) was then added to a final concentration of 0.1 mM to 
induce gene expression, and the cells were cultured at 18 oC overnight. The culture was 
centrifuged at 5000 g for 10 min to collect cells. The freeze-thaw cell pellet was 
resuspended in 30 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, 10 % glycerol, pH 8.0) and applied to sonication. Cell debris was removed by 
centrifugation at 35,000 g for 30 min, and the supernatant was mixed with 1 mL of Ni-
NTA agarose (Qiagen) for 1 h at 4 oC. The slurry was loaded onto an empty column, and 
the column was washed stepwise with 10 mL of lysis buffer and 40-60 mL of wash buffer 
(50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10 % glycerol, pH 8.0). The bound 
His6-tagged proteins were eluted with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
250 mM imidazole, 10 % glycerol, pH 8.0). The MycE (45 kDa) and MycF (30 kDa) 
proteins were further purified and concentrated with 30 kDa and 10 kDa size-exclusion 
filters (Amicon), respectively. The final desalting step was attained by buffer exchange 
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into storage buffer (50 mM NaH2PO4, 10 % glycerol, pH 7.4) with a PD-10 column (GE 
Healthcare). 
 
Enzyme assays — The optimized enzyme assay was carried out in 100 L of 50 mM Tris-
buffer (pH 9.0) containing 2 M MycE or MycF, 250 M substrate (mycinamicin VI for 
MycE or mycinamicin III for MycF), 10 mM MgCl2, and 500 M SAM at 50 oC (for 
MycE) or 37 oC (for MycE) for 1 h. The reactions were quenched by extraction with 
CHCl3 (2 × 200 µL). The resulting organic extracts were dried and redissolved in 120 µL 
methanol. LC-MS analysis of the reaction extract was performed with an LC-MS-2010 
EV instrument (Shimadzu) by using an XBridgeTM reversed-phase HPLC column (C18, 
3.5 µm, 150 mm; Waters) under the following conditions: 20-100 % solvent B over 18 
min (solvent A=deionized H2O+0.1 % formic acid; solvent B=CH3CN+0.1 % formic 
acid), flow rate: 0.2 mL/min, UV wavelength: 280 nm. 
 
Steady-state kinetics — The standard reaction buffered with 50 mM Tris-HCl (pH 9.0) 
contained 0.3 µM MycE or MycF, 500 µM MgCl2, 2-100 M mycinamicin VI for MycE 
or 3-100 µM mycinamicin III in a total volume of 396 µL. After pre-incubation at 
optimal temperature for 5 min, the reactions with various substrate concentrations were 
initiated by adding 4 µL of SAM (50 mM), and three aliquots (100 µL) were taken at 
three time points (0, 1, 2 min and 0, 2, 4 min for reactions with substrate concentrations < 
40 µM and > 60 µM, respectively) within the linear range to thoroughly mix with 100 µL 
of methanol for reaction termination. The proteins were removed by centrifugation at 
16,000 g for 15 min. The supernatant was subject to HPLC analysis to monitor substrate 
consumption within the linear range, thereby deducing the initial velocity of the O-
methylation reaction. The HPLC conditions were: XBridgeTM reversed-phase HPLC 
column (C18, 5 µm, 250 mm; Waters) 20-100 % solvent B over 20 min (solvent 
A=deionized H2O +0.1 % trifluoroacetic acid; solvent B=CH3CN +0.1 % trifluoroacetic 
acid), flow rate: 1.0 mL/min, UV wavelength: 280 nm. All measurements were 
performed in duplicate, and velocities determined under different substrate concentrations 
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Structural Diversification of Tirandamycin by Versatile and 
Codependent Oxidative Tailoring Enzymes 
 
8.1 Introduction 
The antibiotic tirandamycin is of the tetramic acid natural product class defined 
by a 2,4-pyrrolidinedione ring system that typically originates biosynthetically from the 
condensation of an amino acid to a polyketide-derived acyl chain to yield a 3-acyl 
tetramate moiety that confers metal chelating activity (1).  Beyond this common feature, 
this class of compounds enjoys a substantial structural and bioactive diversity represented 
by the HIV-1 integrase inhibitor equisetin (2), the antimycotic dihydromaltophilin (3), 
and the first discovered tetramate antibiotic streptolydigin (4) (Str, 1), for which the 
specific biological target was found to be bacterial RNA polymerase (RNAP) (5).  
Recently, Str has generated considerable interest as a chemical tool for the inhibition of 
RNAP (6), and as a subject of biosynthetic study in isotope feeding experiments (7, 8).  
The structural feature of predominant biosynthetic interest in Str is an intriguing bicyclic 
ketal skeleton (Fig. 8-1) that is common to tirandamycin, tirandalydigin (2), BU-2313B 
(3), and nocamycin II (4), all of which also possess antimicrobial activity (1).  
Tirandamycin A (TirA, 5) and tirandamycin B (TirB, 6) were originally discovered in the 
1970’s from the fermentation broths of terrestrial Streptomyces species as anti-microbial 
agents (10, 11).  In this current study, we have discovered three new tirandamycin 
derivatives including tirandamycin C (TirC, 7), tirandamycin D (TirD, 8), and 
tirandamycin E (TirE, 9) together with known 5 and 6 from the marine-derived 
environmental isolate Streptomyces sp. 307-9.  These five tirandamycins (5-9, Fig. 8-1) 
differ in the oxidative modification state of the bicyclic ketal moiety, and this 
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modification state was found to be a key determinant of potency against vancomycin-
resistant Enterococcus faecalis (VRE).  Additionally, the co-crystal structures of 
Escherichia coli and Thermus thermophilus RNAP complexed with Str display extensive 
contacts with the bicyclic ketal (12, 13).  Taken together, these observations indicate that 
the formation and modification of the bicyclic ketal is critical for the production of a 
potent bioactive molecule, but to date there has been no genetic or biochemical insight 
into this process.  We herein report the elucidation of the tirandamycin gene cluster 
(Tam) and the in vitro reconstitution of the complete oxidative pathway for structural 
diversification of tirandamycin, leading to formation of tirandamycin A-E via a cascade 
of oxidative modifications on the bicyclic ketal. 
 
8.2 Results and Discussion 
8.2.1 Isolation and Structural Identification of TirC and TirD 
During a screen to discover new natural products from marine-derived 
actinomycetes with activity against vancomycin-resistant Enterococcus faecalis (VRE), 

































































































































































































Figure 8-1. Tetramic acid natural products bearing a bicyclic ketal moiety. 
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designated as strain Streptomyces sp. 307-9.  Analysis of extracts from shake-flask 
fermentation identified the major anti-VRE components in the culture broth as the 
previously reported TirA (5) and TirB (6).  Varying the duration of culture prior to 
extraction indicated a gradual change in the ratio of the two major products, with 6 
accumulating over time at the expense of 5.  This suggests that 5 is a transiently secreted 
or diffusible intermediate en route to the biosynthesis of the final product 6.  Isolation of 
5 was likely enabled by the capture of this intermediate from the culture broth via early 
harvest.  We imagined that an adsorbent resin might be used to capture and observe 
previously undetected biosynthetic intermediates, protecting them from bioconversion 
and facilitating their isolation. 
We and others have previously used XAD-16 resin in microbial fermentation to 
increase the yield of a desired final product (sequestration of the final product 
presumably evades feedback repression mechanisms), facilitate convenient extraction 
from culture broth (14-17), or stabilize a desired fermentation product against 
spontaneous degradation and/or enzymatic conversion (18, 19). We added sterile XAD-
16 resin bags to shake flask cultures of Streptomyces sp. 307-9 entering stationary phase 
and allowed fermentation to proceed for several days, after which the mesh bags were 
removed and the resin extracted.  Reverse-phase HPLC analysis of the resulting crude 
extracts revealed two major new peaks that share the characteristic UV spectrum of 5 and 
6 (Table 8-1). Notably, these two presumable intermediates (identified as new 
Table 8-1. Chemophysical properties of tirandamycins. 
 
HRESIMS Compound Appearance [α]D UV, λmax calc. obs. 
TirA, 5 Yellow +9 (c 0.3, EtOH) 238, 356 nm [M+H]
+ 
418.1860 ND 
TirB, 6 Yellow -14 (c 0.5, EtOH) 238, 356 nm [M+H]
+ 
433.1809 ND 










TirE, 9 Yellow ND 238, 356 nm [M+H]
+ 
404.2068 ND 
TirA* Yellow +4 (c 0.5, EtOH) 238, 356 nm - - 
TirB* Yellow -8 (c 0.55, EtOH) 238, 356 nm - - 
*Tirandamycins isolated from S. tirandis  
ND: Not determined 
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tirandamycin derivatives TirC, 7 and TirD, 8) were never observed when resin was 
omitted from the culture flask.  Using the resin-trapping method, 7 and 8 were observed 
reproducibly and were purified by semi-preparative HPLC. 
Molecular formulas for 7 and 8 were established by high-resolution ESI-MS (Table 8-1), 
which indicated that 8 (C22H27NO6) differs from 5 (C22H27NO7) by the absence of a 
single oxygen atom, and that 7 (C22H29NO5) differs further by the absence of an 
additional oxygen and the presence of two additional protons.  As shown in Table 8-2, 1H 
NMR spectra of 7 and 8 supported a close structural relationship to 5 and 6, demonstrated 
by the consistent appearance of the olefinic and methyl signals of the dienoyl acyl chain, 
and the geminal protons of the tetramic acid methylene carbon.  2D correlations observed 
in COSY, HSQC and HMBC experiments further confirmed the identical composition of 
this region in 5-8, and highlighted structural differences in the pendant oxygenation 
patterns on the bicyclic ketal system.  When compared to 5, 8 was determined to contain 
a C-11/C-12 cis double bond in place of the epoxide, indicated by the chemical shift 
values for positions 11 (δH 6.08, δC 127.4) and 12 (δC 156.7), and the adjacent carbonyl at 
C-10 (δC 195.7).  This assignment was further supported by 2D correlations including (a) 
a long-range COSY coupling between H-11 and H-18, and (b) HMBC correlations from 
H-11 to C-13 and C-18, H-18 to C-11 and C-12, and H-14 to C-12.  1 was also 
determined to contain this double bond, but presented a methylene carbon (δC 24.5) in 
place of the C-10 carbonyl of 2, demonstrated by the appearance of new multiplet signals 
for H-10a (δH 1.96) and H-10b (δH 2.33) and the reduced deshielding at positions 9 (δH 
3.90, dC 71.4) and 11 (δH 5.70, δC 123.6).  This feature was confirmed by 2D COSY 
correlations including (a) a geminal coupling between H-10a and H-10b and (b) 
couplings between the H-10 protons and the H-11 olefin signal, the H-9 methine signal 
(coupled to H-10b only) and a long range coupling to the H-18 methyl signal (See 
Supporting Information for a complete mapping of 2D correlations).  Assignment of the 
diastereotopic protons of the C-10 center of 1 was achieved through analysis of a NOESY 
spectrum which indicated (a) proximity between H-10a and H-17, and (b) proximity 
between H-10b and H-9.  With this information, H-10a was determined to be the pro-S 
proton and H-10b was assigned as pro-R.  To confirm the absolute stereochemistry of 5-
8, we obtained optical rotation measurements for tirandamycins A and B from both 
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Streptomyces sp. 307-9 and S. tirandis NRRL 3689, the original strain from which 
tirandamycin A was isolated and characterized by X-ray crystallography (6, 20). [α]D 
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values of 5 and 6 from Streptomyces sp. 307-9 are consistent with those for tirandamycin 
A and B from S. tirandis (Table 8-1), indicating the same absolute configuration.  Based 
on these data, the configuration of 7 and 8 was presumed to correspond to that of 5 and 6. 
 
8.2.2 Anti-VRE Activities of Tirandamycins 
With purified 5-8 in hand, we compared their anti-VRE activities in a microtiter 
plate format with a consecutive two-fold dilution series of each compound spanning a 
concentration range of six orders of magnitude.  5 exhibited the highest activity with the 
minimal inhibitory concentration (MIC) of 2.25 µM, whereas all others presenting 
diminished inhibitory activity: 7, MIC = 110 µM, 6 MIC = 100 µM, 8 MIC > 9 µM.  The 
MIC for 8 can only be expressed as a lower limit because of a minor presence of 3 in this 
sample that accounts for the apparent MIC.  A comparison of these activities suggests 
that the C-10 ketone and C-11/C-12 epoxide (present in 5 but not in 7) confer increased 
potency, but this affect can be attenuated by the hydroxyl group at C-18 (as in 6). 
Previous studies have shown that inhibition of bacterial RNA polymerase (RNAP) is the 
primary mechanism behind the antibacterial activity of tirandamycin and streptolydigin 
(9, 21-23). The crystal structures of E. coli and Thermus thermophilus RNAP complexed 
with streptolydigin have been solved and revealed an abundance of key contacts in the 
streptolol ring system (structurally analogous to the bicyclic ketal system of 
tirandamycin) (12, 13). This is consistent with the bioassay results presented here which 
demonstrate that the substituents of this moiety are key determinants of potency, 
assuming that in vivo anti-VRE activity reflects inhibition of RNAP. 
 
8.2.3 Elucidation of Tirandamycin Biosynthetic Gene Cluster 
To understand the details of tirandamycin biosynthesis and especially the 
mechanism for varying oxidative modifications of the bicyclic ketal ring system, the 
tirandamycin biosynthetic gene cluster in Streptomyces sp. 307-9 has been elucidated 
(24). The contiguous 56 kb sequence assigned as the tirandamycin biosynthetic cluster 
(Tam) contains 15 open reading frames (ORFs) including three PKS (polyketide 
synthases) genes and one NRPS (nonribosomal polypeptide synthetase) gene, and several 
genes proposed to be involved in post-assembly line tailoring steps, self-resistance, and 
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regulation of cluster expression (Fig. 8-2). The predictions of the building block 
specificity of the PKS/NRPS assembly and the stereochemistry of modifications during 
linear chain elongation based on the analysis of the conserved sequence motifs in 
PKS/NRPS are well consistent with the resultant tirandamycin structure (24). More 
importantly, two oxidative enzyme genes including the cytochrome P450 
monooxygenase gene tamI and the flavin-dependent oxidase gene tamL, whose encoding 
proteins are likely responsible for the oxidative modifications of tirandamycin, were 
identified within the Tam cluster. However, mechanisms for the bicyclic ketal formation 
and the tetramic acid ring formation upon linear chain release remain obscure due to lack 
of apparent enzyme candidates. 
 
8.2.4 Characterization of the oxidative cascade catalyzed by TamI and TamL 
TirC (7), represents the least modified intermediate that has been identified from 
culture broth of Streptomyces sp. 307-9.  Transformation into TirB (6), the most modified 
and final product, requires several oxidative modifications.  We had originally anticipated 
that a cytochrome P450 enzyme would be capable of the epoxidation and hydroxylation 
steps, and indeed the presence of the P450 homolog TamI in the Tam cluster encouraged 
 
Figure 8-2. Organization of the tirandamycin biosynthetic gene cluster.  Genes are 
classified by color for encoding assembly line enzymes (blue), tailoring enzymes (red), 
proteins involved in regulation and resistance (yellow), and proteins with accessory or 
unknown functions (green). 
 
 149 
this hypothesis.  Sequence analysis of TamI revealed that it contains all of the highly 
conserved motifs of this enzyme class, including the Helix I, ExxR, and heme binding 
motifs (Fig. 8-3A) (25).  We overexpressed and purified His8-tagged recombinant TamI 
(Fig. 8-S1) in E. coli to yield an orange-red enzyme solution that was characterized by 
UV-visible spectroscopy using standard techniques (26). The sodium dithionite reduced 
enzyme solution displayed an absorbance peak at 420 nm with a 450 nm peak arising 
after bubbling of the solution with CO (Fig. 8-3C), though even after this CO treatment 
the enzyme preparation existed mainly as a presumably inactive P420 species, as was 
observed for the EpoK enzyme of epothilone biosynthesis (27).  However, unlike EpoK, 
incubation with substrates failed to rescue the inactive P420 species of TamI, implying 
that only a small subpopulation of this enzyme is catalytically competent. 
To test the hypothesis that TamI installs the C-11/C-12 epoxy and the C-18 
hydroxy groups, the recombinant enzyme was incubated with the substrate tirandamycin 
A in reaction buffer containing NADPH, spinach ferredoxin, and spinach ferredoxin-
NADP+ reductase.  LC-MS analysis of reaction supernatants revealed a small but 
reproducible conversion of TirA to TirB by hydroxylation at C-18.  Under the same 
reaction conditions but with the substrate TirD, we observed a complete conversion of the 
 
Figure 8-3. Sequence and spectral analysis of TamI and TamL. (A) TamI sequence motifs 
typical of cytochrome P450 enzymes. (B) TamL sequence motifs include Rossmann fold 
motifs (top) and a berberine bridge enzyme motif proposed to be the site of covalent 
attachment of the FAD cofactor. (C) UV-vis absorption spectrum for purified His8-tagged 
TamI P450 (left) and His6-tagged TamI-RhFRED fusion (right) in oxidized form (solid line), 
sodium dithionite reduced form (dotted line), and CO reduced form (dashed line); insets show 
CO-bound reduced difference spectra.  (D) Fluorescence excitation and emission spectra (left) 
and UV-vis absorption spectrum (right) for purified His8-tagged TamL flavoprotein; inset 
shows UV-vis absorption spectrum of pure FAD and FMN cofactors. 
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substrate predominantly to TirA and a small amount of TirB (Fig. 8-4A).  In addition, 
TirB cannot be further modified by TamI. Taken together, these experiments demonstrate 
that the penultimate and final steps of tirandamycin biosynthesis are a C-11/C-12 
epoxidation and a C-18 hydroxylation, respectively. 
Next, we tested the possible role of TamI in formation of the C-10 ketone by 
incubating TirC with recombinant P450 as above, and observed the formation of a very 
small amount of TirA (Fig. 8-4A), in addition to a new species that had not been 
identified previously.  The new species, which we named tirandamycin E (TirE, 9), 
possessed a molecular mass 16 amu greater than TirC and was of an increased polarity 
consistent with a tentative hydroxylation.  To characterize TirE by NMR and identify the 
site of hydroxylation, we acquired several milligrams of product prepared by enzyme 
 
 
Figure 8-4. Oxidative cascade modifications of the tirandamycin bicyclic ketal.  (A) In vitro 
reconstitution of TamI and TamL mediated oxidation steps.  Peaks were identified by 
comparison to authenticated standards and MS detection of anticipated species. (B) The 
complete oxidative pathway as elucidated by biochemistry and mutagenesis studies; the 
predominant TamI P450 reactions are highlighted in red with the intervening TamL oxidation 
reaction highlighted in yellow; the dashed arrows represent a trace activity proposed to afford 
a minor TamL-independent route. (C) Metabolite profiles of wild type and mutant strains.  
Scales of each chromatogram have been zoomed as follows: Wild Type 4.1×, ∆tamI 1×, 
∆tamL 17.5×. 
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reaction, which was cost prohibitive using the existing reaction setup with expensive 
spinach ferredoxin and ferredoxin-NADP+ redox partners that are required to activate 
molecular oxygen.  To overcome this limitation, we employed a recently developed 
strategy (28) to make a self-sufficient biosynthetic P450 reaction system by fusing TamI 
to the RhFRED (Fig. 8-S1), an FMN/Fe2S2 containing reductase domain, thus obviating 
the need for costly exogenous redox partners.  Using this system we conducted a 
preparative scale conversion of TirC to TirE, purified the product by preparative HPLC 
and assigned the structure using extensive 1D and 2D NMR analysis (Table 8-2), which 
clearly indicated a C-10 hydroxylation.  The stereochemistry was assigned based on the 
observation of a through-space deshielding effect between the C-10 hydroxyl and the H-7 
and H-17 protons, and also by comparison of NOESY data between TirC and TirE which 
confirmed the disappearance of the pro-S proton at C-10. 
These results demonstrate that the major activity of TamI on the C-10 center is a 
hydroxylation, but the minor conversion to TirA by TamI alone indicates that this 
enzyme also has a trace activity capable of installing the ketone.  It is likely that this 
reaction proceeds through sequential hydroxylations at C-10 to form a gem-diol that 
exists in equilibrium predominantly in the ketone form of TirD.  This route to carbonyl 
formation resembles that used by P450s to install a carboxylate at a terminal carbon, as in 
the biosyntheses of artemisinic acid (29).  However, because this activity for TamI is so 
weak we speculated that another oxidative enzyme in the cluster might be responsible for 
the predominant route to TirD, and we therefore examined the ability of TamL, a 
predicted flavin-dependent oxidoreductase, to catalyze this reaction.  Detailed sequence 
alignments revealed potential Rossmann fold nucleotide binding motifs (30) and a 
berberine sequence motif that bears the site of covalent attachment of FAD in some FAD-
dependent enzymes (Fig. 8-3B) (31).  We overexpressed and purified recombinant His8-
tagged TamL (Fig. 8-S1) in E. coli to yield a deep yellow protein solution with 
fluorescence excitation/emission and UV-visible absorption spectra consistent with a 
flavoprotein (Fig. 8-3D) (31, 32).  We verified that the cofactor was covalently bound by 
boiling the protein solution and observing that the yellow color was retained with the 
denatured protein, and that the supernatant did not contain any released cofactor as 
determined by LC-MS.  Acid hydrolysis treatment of the protein released AMP, 
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confirming FAD instead of FMN as the cofactor (Fig. 8-S2) (33), and MS analysis of the 
intact protein also supported a single FAD per enzyme molecule (Fig. 8-S3). 
Incubation of recombinant TamL with purified TirE resulted in complete 
conversion to TirD, thus confirming the role of this enzyme in oxidizing the C-10 
hydroxyl of TirE to a ketone (Fig. 8-4A).  Furthermore, when reactions containing TamI 
P450 and TirC were amended with TamL, we observed nearly complete conversion to 
tirandamycin A with no residual TirE detected, indicating that oxidation of TirE by TamL 
affords the C-10 ketone with far greater efficiency than does TamI alone. 
We were also able to confirm the roles of TamI and TamL in vivo by genetic 
disruption of the relevant ORFs which resulted in the accumulation of the anticipated 
intermediates in the fermentation broth.  We developed a protocol for the intergenic 
conjugation between Streptomyces sp. 307-9 (acceptor) and E. coli S-17 (donor) (34), and 
used this system to transfer in suicide knockout vectors created using the REDIRECT 
system (35).  Double-crossover allelic exchange mutants, which contained an in-frame 
replacement of the ORF by an apramycin resistance gene, were selected/screened on 
appropriate antibiotics, and verified by PCR screening of gDNA.  Verified mutants were 
grown in fermentation media containing apramycin, and the broths were extracted and 
analyzed for tirandamycin metabolite profiles.  As expected, wild-type cultures 
accumulated TirA and TirB whereas the P450 TamI knockout accumulated exclusively 
TirC (Fig. 8-4C), indicating that TamI is the sole P450 in this organism responsible for 
initiating the oxidative cascade.  The flavoprotein TamL knockout accumulated TirE, 
which is consistent with in vitro results in which TamI alone was unable to efficiently 
catalyze the conversion beyond TirE. 
The characterization of this oxidative cascade has revealed a remarkably versatile 
cytochrome P450 enzyme TamI that catalyzes at least two hydroxylations and one 
epoxidation at three distinct centers, which to our knowledge is the first reported example 
of a biosynthetic P450 with such versatile activity.  These oxygenations occur in a 
precisely defined order with no detected promiscuity at a given step, but more notably 
these three reactions are not consecutive (Fig. 8-4B).  Following the initial hydroxylation 
of TirC by TamI, TamL must oxidize this group to the ketone of TirD, which is the 
exclusively observed substrate for sequential epoxidation to TirA and hydroxylation to 
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TirB. The repeated exchange of substrates between these two enzymes represents a 
unique synergistic biosynthetic pathway, in which a P450 catalyzes multiple oxidations 
co-dependently with a second biosynthetic enzyme, in contrast to numerous examples of 
multi-step P450 reactions in which no intervening enzymatic steps are required. 
 
8.3 Experimental Procedures 
General Experimental Procedures — All NMR spectra were acquired on a Varian 
INOVA 400 MHz and a Varian INOVA 600 MHz spectrometer at the Center for 
Chemical Genomics, University of Michigan.  High-resolution ESI-MS spectra were 
measured at the University of Michigan core facility in the Department of Chemistry 
using a Waters Micromass AutoSpec Ultima. Optical rotation measurements were 
obtained on an AUTOPOL III polarimeter.  UV spectra were extracted from HPLC 
photo-diode array chromatograms.  RP-HPLC purification was performed using Waters 
XBridge 5 µm ODS columns and a solvent system of MeCN and H2O supplemented with 
0.1% TFA.  LC-MS analysis of HPLC fractions was performed on a Shimadzu 2010 EV 
ESI spectrometer.  NMR spectra were processed using MestReNova software. 
 
Biological materials — Streptomyces sp. 307-9 was isolated from marine sediments 
collected at a depth of 15 meters during a SCUBA expedition in Salt Cay, U. S. Virgin 
Islands.  The procedure for the isolation of Actinomycetes from these samples has been 
described previously (16). Maintenance and propagation of cultures was performed using 
standard media and protocols (34). On 2xYT agar, this strain grew as substrate-adherent 
mycelia that secreted a dark pigment into the media, and produced a top layer of white 
and purple spores.  Light microscopy images of stained cells from agar plate cultures 
revealed Gram-positive, filamentous cells as well as spore chains.  These characteristics 
are consistent with morphology of Streptomyces species.  A phylogenetic analysis was 
performed using a fragment of the 16S rRNA gene amplified from genomic DNA of 
Streptomyces sp. 307-9 using a previously described protocol (36). BLAST analysis 
revealed the highest sequence identity (97-99%) with previously characterized 
Streptomyces species.  This strain is preserved and available from an in-house collection 
(database index DHS1549).  See Supporting Information for microscopy images and 16S 
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rRNA gene sequence analysis.  Streptomyces tirandis NRRL3689 was obtained from the 
USDA Agricultural Research Service. 
 
Culture maintenance and fermentation — Seed cultures of 10 mL 2xYT media were 
inoculated with a loopful of vegetative cells from an ISP2 agar plate culture of 
Streptomyces sp. 307-9 and incubated with shaking (150 rpm) at 30 °C for 2 days.  Six 2 
L baffled flasks each containing 1 L of autoclaved production media Md2 (10 g dextrose, 
2 g NZ-Amine A, 1 g yeast extract, 0.77 g meat extract, 30 g NaCl per 1 L H2O) were 
each inoculated with 1 mL of seed culture and grown for 2 days under identical 
conditions.  To each flask was then added two autoclaved resin bags containing 10 g 
XAD-16 resin (Supelco,  Bellefonte, PA) enclosed in Unitherm 100 fabric (Midwest 
Filtration, Cincinnati, OH) by heat sealing.  Production cultures were grown for an 
additional four days, after which the resin bags were collected for extraction. 
 
Isolation and purification of tirandamycins — Resin bags were cut open and the free 
resin was rinsed with water, filtered, and batch extracted with 90% CH2Cl2/10% MeOH 
(3 x 1.5 L).  The combined extract was washed twice with an equal volume of 1 M NaCl 
(adjusted to pH 4.0 with TFA).  The dichloromethane layer was collected and dried by 
rotary evaporation to give a dark yellow oil that was dissolved into 2 mL DMSO.  This 
extract was purified by RP-HPLC on a gradient of 30-100% MeCN and followed by 
UV/Vis photo-diode array detection.  Compounds exhibiting the characteristic absorption 
spectrum of the tirandamycin tetramic acid moiety (λmax 356 nm) were collected.  The 
purest fractions (as determined by LC-MS analysis) were combined and dried to afford 
(in order of elution) 6 (3.0 mg), 5 (9.0 mg), 8 (1.4 mg), and 7 (7.0 mg).   
 
Anti-VRE bioassay —  2 µL of 20 mM DMSO solutions of 5-8 were added to 100 µL 
LB broth (to give 400 µM final concentrations), and two-fold serial dilutions of this stock 
were prepared in LB.  All cultures of Vancomycin-Resistant Enterococcus faecalis 
(VRE) were grown in LB supplemented with 10 µg/µL of vancomycin at 37 °C with 
shaking (150 rpm).  An overnight seed culture of VRE was diluted to an OD600 of 0.05, 
grown to an OD600 of 0.4, back diluted to an OD600 of 0.005, and 50 µL of this dilution 
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was added to each well of a microtiter plate that contained 50 µL of a given dilution of 
compound in LB.  Plate cultures were grown for 16 hours and OD600 measurements were 
taken.  MIC values were taken as the lowest concentration of compound for which no 
growth was observed. 
 
Cloning and preparation of recombinant enzymes — tamI and tamL were PCR 
amplified from Streptomyces sp. 307-9 genomic DNA using primers that append EcoRI 
and HindIII sites at the N and C termini, respectively.  These PCR products were digested 
with EcoRI/HindIII and ligated into a pSJ2 overexpression vector that was similarly 
digested and dephosphorylated.  pSJ2 is an in-house derivative of pET-21a containing a 
coding region for an N-terminal His8-tag, and insertion of our gene cassettes creates an 
in-frame fusion to this tag.  To create the TamI-RhFRED fusion protein, the tamI gene 
with stop codon removed was PCR amplified using primers that append NdeI and EcoRI 
sites and the N and C termini, respectively.  The NdeI/EcoRI digested product was ligated 
into similarly digested pET28b-pikC-RhFRED as previously reported (28).  The accuracy 
of all constructs was verified by DNA sequencing.  These constructs were transformed 
into E. coli BL21(DE3) overexpression host and the resulting proteins were purified 
using nickel affinity chromatography by following a previously developed procedure 
(28). 
 
CO-bound reduced difference spectrum of TamI —  TamI was identified as an active 
P450 by obtaining the CO-bound reduced difference spectra using a UV-visible 
spectrophotometer 300 Bio (Cary). TamI in conversion buffer was reduced by adding 
several milligrams of sodium dithionite (Na2S2O4) and a spectrum was recorded from 350 
to 650 nm.  After CO bubbling of the solution for 30-60 s, the spectrum of CO-bound 
reduced P450 species was recorded using the previous reduced spectrum as reference. 
This assay was also employed to determine the functional P450 concentration using the 
extinction coefficient of 91,000 M-1⋅cm-1 (26). 
 
Preparation of TirE (9) — TirE was obtained by preparative scale enzymatic 
conversion in 40 × 500 µl parallel reactions (overnight, 30°C), each containing 
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approximately 10 µM purified TamI-RhFRED, 0.15 mg TirC, 1 mM NADPH, and 5 µM 
glucose-6-phosphate and 2 Unit/ml glucose-6-phosphate dehydrogenase for NADPH 
regeneration. The reaction mixtures were combined and extracted by 3 × 40 mL of 
CH2Cl2, after which the extract was dried, redissolved in 2 mL of methanol, and purified 
by RP-HPLC to yield TirE.  The structural assignment of TirE was based on analysis of 
1H, 13C, COSY, HSQC, HMBC, and NOESY data sets. 
 
Enzymatic Assays — The in vitro enzymatic conversions of tirandamycins were 
performed in a total volume of 100 µl of conversion buffer (50mM NaH2PO4, pH 7.3, 1 
mM EDTA, 0.2 mM dithioerythritol, 10% glycerol) containing 2 µM TamL (or 1 µM 
TamI partnered by 3.5 µM spinach ferredoxin and 0.1 Unit/ml spinach ferredoxin-
NADP+ reductase), 200 µM substrate, and 500 µM NADPH. As negative controls, 
corresponding enzymes were omitted. After incubation at 30°C for 2 h, the reactions 
were quenched by extraction, using 2 × 200 µl of CHCl3.  The resulting organic 
extraction was dried, redissolved in 120 µl of methanol, and analyzed by LC-MS using 
354 nm UV detection and positive/negative ion MS detection. 
 
Identification of flavin cofactor of TamL — The UV-vis absorption spectrum of TamL 
was obtained by scanning a 400 µl sample of the purified enzyme (8.6 µM) in a cuvette.  
A FluoroMax-3 (HORIBA Jobin Yvon) fluorescence spectrophotometer was used to 
obtain the fluorescence excitation and emmision spectra. To determine the identity of 
flavin cofactor, following previously developed protocol with minor modifications (33), 
200 µl of TirL (9.4 mg/ml) was boiled in presence and absence of 0.1 M HCl for 10 min. 
The denatured proteins were removed by centrifugation and 3 kDa size exclusion column 
(YM-3, Microcon), sequentially. The filtrates were analyzed by C18 reverse phase HPLC 
with established conditions (33).  
 
TamI and tamL in vivo genetic disruption — Knockout vectors were constructed by 
PCR targeted mutagenesis of appropriate cosmids as described previously (34).  This 
REDIRECT system was used to completely replace tamI of cosmid 6G9 (24) and tamL of 
cosmid 2H2 (24) with a cassette bearing an apramycin resistance gene and an origin of 
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transfer for conjugation. The AprR mutagenized cosmid was introduced into E. coli S17-1 
by transformation and then transferred to Streptomyces sp. 307-9 by conjugation.  
Intergeneric conjugation between E. coli S17-1 and Streptomyces sp. 307-9 was 
performed as described previously, with minor modifications (35).  An overnight culture 
of the E. coli donor strain was diluted into fresh medium and incubated for 3 hours.  The 
cells were harvested, washed twice and concentrated 10-fold in TS broth.  Cells of 
Streptomyces sp. 307-9 were grown in 2xYT broth for several days, harvested by 
centrifugation, washed and re-suspended in a half volume of TS broth.  These recipient 
cells were mixed with a half volume of E. coli donor cells, and 150 µL of the mixture was 
plated on MS agar.  The plates were incubated at 30°C for 20 hours, and then covered 
with 1 mL water containing 500 µg of nalidixic acid to inhibit further growth of E. coli 
and 1 mg apramycin to select Streptomyces sp. 307-9 exconjugants.  Incubation at 30°C 
was continued for 1–2 weeks to allow outgrowth of the exconjugants.  AprR exconjugants 
were screened for chloramphenicol sensitivity to detect double-crossover allelic 
exchange. Exconjugants with the correct antibiotic resistance phenotype were confirmed 
for gene replacement by PCR and corresponding restriction digest of the PCR products.  
Metabolite profiles for mutants were determined by culturing and extraction as described 






















Figure 8-S1. SDS-PAGE analysis of purified recombinant enzymes. M, Protein marker; 1, 































Figure 8-S2. Cofactor analysis of TamL. A. FMN standard; B, FAD standard; C, supernatant of 
the boiled TamL; D, supernatant of the boiled TamL in presence of 0.1 M HCl; E, boiled FAD in 
presence of 0.1 M HCl; F, boiled FMN in presence of 0.1 M HCl; G, 5’-AMP standard; H, boiled 
5’-AMP in presence of 0.1 M HCl. Peak identities: 1, 5’-AMP; 2, decomposited AMP; 3, 
















































Figure 8-S3. LC-MS analysis of intact TamL showing all multiply charged species 
(top) and the zoomed in region (bottom) used to deconvolute the neutral mass (peaks 
in red box).  From this data the calculated molecular mass of TamL is 58801.1 +/- 6 Da, 
which is 32 daltons off from an expected molecular mass of 58769.1 (TamL - Met + FAD 
- 2H) for a single covalently bound FAD molecule, suggesting the presence of 2 oxidized 
methionines in the observed species.  The observed mass is 359.3 Da away from the 
expected mass for an FMN cofactor (expected mass 58441.8 Da), thus ruling out the 
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During preparation of this chapter, the first part of this work about identification of 
tirandamycin C and D has been submitted to J. Nat. Prod. as “Isolation and 
characterization of tirandamycins from a marine-derived Streptomyces sp..” Jacob, C. 
Carlson, Li, S. (Co-first author), Douglas, A. B., and Sherman, D. H. The second part of 
this work about characterization of the oxidative cascade will be submitted soon.  
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Molecular Analysis of the Role of Tyrosine 224  
in the Active Site of Streptomyces coelicolor RppA,  
A Bacterial Type III Polyketide Synthase 
 
9.1 Introduction 
Type III polyketide synthases (PKSs) represent the structurally simplest member 
of the PKS superfamily (1, 2), which also consists of the giant modular multifunctional 
type I PKS (3, 4) and the discrete multienzyme type II PKS (5, 6). Since the discovery of 
the first type III PKS, chalcone synthase (CHS), in the 1970s (7), a growing number of 
type III PKSs have been identified in plants (8–10), bacteria (11–13), and fungi (14). All 
members of the family characterized to date share some common structural and 
mechanistic features (2) including a homodimeric architecture, similar subunit molecular 
mass (40–47 kDa), analogous active site structure, a conserved Cys-His-Asn catalytic 
triad (thus a common reaction mechanism), and the utilization of acyl-coenzyme A (acyl-
CoA) thioesters as substrates instead of the acyl-carrier protein-linked substrates 
employed by type I and II PKSs. To diversify polyketide product output, type III PKSs 
have evolved to use a wide range of natural acyl-CoA substrates. For example, the plant 
type III PKSs, which share 60–95% amino acid identity (2), utilize a variety of different 
substrates ranging from aliphatic-CoA to aromatic-CoA, from small acetyl-CoA (2-
pyrone synthase in Gerbera hybrida) (15) to bulky p-coumaroyl-CoA (Medicago sativa 
CHS) (16) or from the polar malonyl-CoA (Aloe arborescens pentaketide chromone 
synthase) (17) to the relatively nonpolar isovaleroyl-CoA (Humulus lupulus 
phlorisovalerophenone synthase) (18). 
Interestingly, the more divergent bacterial type III PKSs (with as low as 20% 
amino acid identity) utilize a much narrower pool of natural acyl-CoA substrates than 
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their relatives in plants (1, 2). Specifically, RppA from either Streptomyces coelicolor or 
Streptomyces griseus (19, 20), Pseudomonas fluorescens PhlD (21), and Amycolatopsis 
mediterranei DpgA (22, 23) coincidentally employ malonyl-CoA as their physiological 
starter unit, although alternative starter substrates are known to be accepted by these 
enzymes (24, 25). Such limited physiological substrate specificity may be misleading 
because of a paucity of information on functionally identified bacterial type III PKSs (12, 
26, 27), a reflection of the short period of time since their discovery. Alternatively, the 
more limited substrate variability of bacterial type III PKSs might reflect convergent 
evolution within this family resulting from the more limited availability of acyl-CoA 
building blocks in prokaryotes compared with eukaryotes. With respect to the limited 
"building block" diversity in bacteria, it is intriguing that such seemingly divergent 
bacterial type III PKSs utilize a common starter unit. Understanding the convergence of 
bacterial type III PKS structure and function could provide important insights into 
substrate preferences and specificity, potentially enabling expansion of the repertoire of 
unnatural substrates and thus the creation of functionally diverse and novel natural 
products. 
S. griseus RppA (Sg-RppA) has provided substantial fundamental information 
about the catalytic properties of the type III PKS subfamily as the first functionally 
characterized bacterial enzyme of its class (19, 28). The physiological reaction (Fig. 9-
1A) is initiated by loading a malonyl-CoA molecule covalently onto the catalytic Cys138 
of the RppA polypeptide. Four acetyl-CoA extender units, generated from 
decarboxylation of malonyl-CoA, are then added sequentially to the elongating linear 
intermediate via Claisen condensation. Finally, the linear pentaketide intermediate is 
cyclized and aromatized to form 1,3,6,8-tetrahydroxynaphthalene (THN), although the 
mechanism of this termination step remains unclear. During growth of the linear 
polyketide intermediate, the terminal carboxyl group is presumably derived from the 
starter malonyl-CoA and is prevented from premature decarboxylation, which would 
result in derailment to acetyl-CoA or triacetic acid lactone (TAL; 4-hydroxy-6-methyl-2-
pyrone) via intramolecular cyclization (Fig. 9-1A). 
The importance of the active site Tyr224 residue in the first step of this reaction 
relating to starter unit specificity of Sg-RppA was previously identified through 
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analyzing the ability of a series of mutants to produce THN (28). It was revealed that 
although the aromatic amino acid Trp or Phe replacement of Tyr224 is tolerated by Sg-
RppA, other Tyr224 mutants including Y224L, Y224G, and Y224C are inactive. In 
contrast, these mutants are functional when hexanoyl-CoA or phenylacetyl-CoA is 
presented as a nonphysiological starter unit. On the basis of these observations, Funa et 
al. (28) proposed that Tyr224 in Sg-RppA is critical for starter unit (malonyl-CoA) 
selection. Interestingly, this Tyr residue is also conserved in DpgA and PhlD (see 
Supplementary Information, Fig. 9-S1), the other two functionally identified bacterial 
type III PKSs that utilize malonyl-CoA as the physiological starter unit. The function of 
Tyr224 in RppA was further discussed by Austin et al. (29) upon analyzing the crystal 
structure of S. coelicolor RppA (Sc-RppA), which is the closest relative to S. griseus 
RppA (67% amino acid identity) and catalyzes an identical series of reactions. In the 2.22 
Å crystal structure, Tyr224 was found at the surface of the active site pocket of Sc-RppA 
(8.5 Å away from the catalytic Cys138) and was believed to exert a horizontal steric 
constraint to the first entering malonyl-CoA through its bulky side chain, thereby 
 
 
Figure 9-1. Reactions catalyzed by Sc-RppA. A, malonyl-CoA-initiated reaction. The 
dashed arrows indicate reactions leading to derailed products, and the boxed moieties derive 
from the starter malonyl-CoA. B, acetyl-CoA and acetoacetyl-CoA-primed reactions. C, 
hexanoyl-CoA 1- and benzoyl-CoA 2-initiated reactions. 
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positioning the starter unit at a favorable location (near the catalytic Cys138) by limiting 
conformational freedom. Accordingly, the small amino acid Gly cannot play a similar 
role. Thus, when the position corresponding to Tyr224 is occupied by a Gly in CHS (Fig. 
9-S1), this plant type III PKS cannot use malonyl-CoA as a starter unit. It is evident that 
the Gly residue provides additional space for accommodating the bulky substrate p-
coumaroyl-CoA (30, 31). This volume-modulating model for substrate specificity is 
currently well accepted (2, 31). However, it has remained unclear how inactive Tyr224 
mutants (Y224L, Y224G, and Y224C) enable selection of unnatural acyl-CoAs as the 
starter unit substrate in Sg-RppA. 
Although Sc-RppA and Sg-RppA are highly homologous and possess nearly 
identical active site compositions, Sc-RppA was reported to have higher tolerance toward 
unnatural acyl-CoA starter units than Sg-RppA (25). For example, both acetyl-CoA and 
benzoyl-CoA were substrates for the Sc-RppA yet were not accepted by Sg-RppA (24). 
Thus, considering the broader flexibility, together with the corresponding x-ray crystal 
structure, Sc-RppA represents a compelling target for the study of substrate specificity 
because of its ability to accept various unnatural substrates, especially acyl-CoAs, which 
cannot be utilized by Sg-RppA. 
In the current study we generated a series of point mutations at the Tyr224 residue 
in Sc-RppA and compared the resulting product profile to the wild type (WT) enzyme. 
To elucidate further how this residue determines substrate selectivity, acetoacetyl-CoA, 
acetyl-CoA, hexanoyl-CoA, and benzoyl-CoA, which, respectively, represent the 
spectrum of similar, smaller, and larger (aliphatic hexanoyl-CoA and aromatic benzoyl-
CoA) substrates compared with malonyl-CoA, were examined as unnatural acyl-CoA 
starter units by both WT and Tyr224 mutant forms of Sc-RppAs. Moreover, the 
correlation between substrate loading and product formation of these enzymes was 
examined by radioactive substrate binding analysis. This investigation confirmed that the 
inability of Tyr224 mutants to synthesize THN results from failure to load malonyl-CoA 
onto the catalytic Cys residue as opposed to failure of subsequent chain elongation, 
cyclization, or product release steps. 
 
9.2 Results  
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9.2.1 WT and Mutant RppA Overexpression and Purification 
The substitution of Leu, Gly, Ala, Ser, Met, His, Cys, and Phe for Tyr224 was 
conducted to explore the effect of locally modifying steric and electronic/polarity 
properties on starter unit loading. The WT enzyme and Tyr224 series of RppA mutants 
were overexpressed in E. coli BL21 (DE3) and purified to homogeneity. As shown by 
SDS-PAGE (Fig. 9-2A), the monomer of each purified protein migrated with a molecular 
mass of ~ 43 kDa. Interestingly, previously reported purification efforts of the 
corresponding Sg-RppA Y224S and Y224H mutants were unsuccessful due to 
insolubility (28). This discrepancy might result from an intrinsic difference between these 
two RppAs, the type of cloning system or purification procedure used, or other variables. 
Nevertheless, each of the Sc-RppA mutant enzymes was expressed as a soluble 
polypeptide to enable more detailed analysis. 
 
9.2.2 Mutant Activity Analysis 
Using WT Sc-RppA as a positive control and the catalytic Cys mutants C138A 
and C138S as negative controls, we first examined the activities of the Tyr224 mutants of 
Sc-RppA to utilize malonyl-CoA. The reactivity of each mutant was assayed by 
measuring the amount of accumulated THN by HPLC analysis. Because authentic THN 
is not isolable due to its rapid conversion to flaviolin (Fig. 9-1A) (19), we elected to 
deduce the relative yield of THN by integration of the HPLC peak area using WT RppA 
enzyme as a reference. As shown in Fig. 3A, among the eight Tyr224 mutants, Y224G, 
 
 
Figure 9-2. Radioactive substrate binding analysis of WT and mutant Sc-RppAs with [2-
14C]malonyl-CoA as radioactive label. A, Coomassie bluestained 15% SDS-polyacrylamide 
gel. B, autoradiograph of the dried SDS-polyacrylamide gel. Lanes: 1, WT Sc-RppA; 2, 
C138A; 3, C138S; 4, Y224L; 5, Y224G; 6, Y224A; 7, Y224S; 8, Y224M; 9, Y224H; 10, 
Y224C; 11, Y224F. 
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Y224S, and Y224H were unable to catalyze assembly of THN (as negative controls). The 
inactivity of Y224G is not surprising because Y224G of Sg-RppA was also an inactive 
mutant (28). For Y224S (whose counterpart in Sg-RppA was insoluble), this inactivation 
could be attributed to horizontal expansion of the active site through replacement of a 
smaller side chain. However, it is currently unclear why the RppA Y224H mutant cannot 
 
 
Figure 9-3. The product profile of malonyl-CoA-initiated reactions catalyzed by WT or 
mutant Sc-RppA. The product profile of Sc-RppA catalyzed reactions was analyzed by 
HPLC at 280 nm. All reactions were duplicated and the relative yields calculated from the 
integrated peak area of the HPLC trace using WT enzyme as reference (100%). A, the upper 
portion shows the THN production profile. The lower portion displays the amino acid 
hydrophobicity tendency and bulkiness (van der Waals volume). B, profile of the derailment 
products acetyl-CoA and TAL. The percentage of incorporated malonyl-CoA is shown above 
each bar. 
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synthesize THN from malonyl-CoA considering the size of the His side chain. In 
contrast, Y224F, Y224L, Y224C, Y224M, and Y224A retained 71, 67, 48, 16, and 3% of 
its activity, respectively, relative to WT Sc-RppA. A previous study reported Y224L, 
Y224C, and Y224A (but not Y224F) from Sg-RppA to be inactive toward malonyl-CoA 
(28). To further probe the basis for this discrepancy, we prepared WT Sg-RppA (from S. 
griseus NRRL B-2682) and its corresponding Y224L mutant to compare their ability to 
generate THN. Surprisingly, this Y224L mutant produced an ~50% level of THN 
compared with WT Sg-RppA (Fig. 9-S2). Therefore, this (re)examination of Y224L 
mutants indicates that the Leu replacement retains significant catalytic activity in both 
Sc-RppA and Sg-RppA. 
As described, in addition to the major product THN, a low level of malonyl-CoA 
would be incorporated into two other derailment products (acetyl-CoA and TAL) because 
of premature decarboxylation of the oligoketide chain (Fig. 9-1A). Because the synthesis 
of these by-products might provide new mechanistic insights into this type III PKS, we 
extended our analysis to the production of acetyl-CoA and TAL (Fig. 9-3B). Specifically, 
the five partially active mutants (Y224F, Y224L, Y224M, Y224C, and Y224A) 
accumulated corresponding increased levels of TAL relative to WT Sc-RppA, suggesting 
the dual function of Tyr224. In addition to the contribution to substrate specificity 
determination, Tyr224 potentially is able to influence the extent of polyketide chain 
elongation, thus affecting the partitioning of TAL formation. On the contrary, the mutants 
that lack an ability to synthesize THN were not able to accumulate TAL. This clearly 
indicates that the biochemical effect from the Tyr mutation occurs prior to formation of 
the triketide intermediate. Moreover, no CoASH was released (data not shown) strongly 
suggesting that these inactive mutants cannot load malonyl-CoA. Significantly, all 
Tyr224 mutants (together with the negative controls) were capable of producing acetyl-
CoA, which indicates that this residue has no significant influence on the decarboxylative 
activity of Sc-RppA. It was also noteworthy that the decarboxylative activities of both the 
C138A and C138S mutants were significantly higher than WT enzyme. Approximately, 
24 and 75% of the malonyl-CoA substrate was converted to the terminal metabolite 
acetyl-CoA in the C138A and C138S mutant forms of Sc-RppA, respectively. A similar 
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observation was reported previously in the C138A and C138S mutant forms of DpgA 
(23). 
Next, using acetoacetyl-CoA or acetyl-CoA as the starter substrate and malonyl-
CoA as the extender unit, we observed that all Tyr224 mutants (except for the negative 
controls C138A and C138S) were able to produce TAL from either acetoacetyl-CoA or 
acetyl-CoA (Fig. 9-4A) via intramolecular lactonization of the triketide linear chain 
elongation intermediate (Fig. 9-1B). The mutants with partial ability to generate THN 
produced significantly higher levels of TAL from either acetoacetyl-CoA or acetyl-CoA 
compared with WT Sc-RppA. We surmise that this was a result of the decreased loading 
efficiency of malonyl-CoA as a starter unit, resulting in a greater propensity for loading 
of alternative acyl-CoAs due to increased availability of the active site toward unnatural 
substrates. Moreover, these partially active Tyr224 mutants still accumulated THN, 
leading to a production profile similar to that shown in Fig. 9-3A (data not shown), 
although the corresponding yields were lower because of competition of unnatural acyl-
CoA against malonyl-CoA as starter unit. More importantly, the inactive Tyr224 mutants 
including Y224H, Y224S, and Y224G were capable of accepting acetoacetyl-CoA and 
acetyl-CoA, resulting in a substantial accumulation of TAL with an incorporation rate 
ranging from 41 to 71% and 2 to 5% for acetoacetyl-CoA and acetyl-CoA, respectively. 
 
 
Figure 9-4. The product profile of diverse acyl-CoA-initiated reactions catalyzed by WT 
or mutant Sc-RppA. A, acetoacetyl-CoA- and acetyl-CoA-initiated reactions. Production of 
TAL from either acetoacetyl-CoA or acetyl-CoA was monitored at UV280 in duplicate. The 
numbers above each bar indicate the percentage of incorporated starter unit substrates that 
were calculated based on absolute yields of TAL. B, hexanoyl-CoA- and benzoyl-CoA-primed 
reactions. The relative yields of hexanoyl triketide pyrone 3 and benzoyl triketide pyrone 4 
were measured at 280 and 320 nm, respectively, by using WT enzyme as reference (100%). 
All reactions were duplicated. 
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It was evident that the incorporation rate of acetoacetyl-CoA (41–85%) was significantly 
higher than acetyl-CoA (2–25%). For instance, by calculating the absolute yield of TAL 
using authentic material as a standard, we determined that 52% of acetoacetyl-CoA was 
converted to TAL by WT Sc-RppA, whereas only 5% of acetyl-CoA was found to be 
incorporated as TAL product (similar results were also observed in Sg-RppA (24) and 
PhlD (32)). 
Finally, when we utilized hexanoyl-CoA or benzoyl-CoA as alternate starter units, 
the corresponding product profiles were comparable with those of acetoacetyl-CoA and 
acetyl-CoA generated by different Sc-RppAs (Fig. 9-4). Specifically, the products 
hexanoyl triketide pyrone 3 and benzoyl triketide pyrone 4 of Y224F, Y224L, Y224M, 
Y224C, and Y224A were observed in significantly higher amounts. With respect to the 
inactive Tyr224 mutants (Y224H, Y224S, Y224G), we demonstrated that they are also 
capable of synthesizing the corresponding triketide pyrones from hexanoyl-CoA and 
benzoyl-CoA, albeit at relatively low levels. In this analysis, however, we were not able 
to determine the incorporation rates due to lack of standard compounds. 
 
9.2.3 Steady-state Kinetics of RppAs 
The HPLC-based product profile analysis only provided qualitative information 
on the activities of Tyr224 mutants. To better understand the effect of each mutation, 
steady-state kinetic parameters based on overall THN formation of WT Sc-RppA and the 
Tyr224 mutants were determined (Table 9-1). The kinetics of WT Sc-RppA (kcat = 1.33 ± 
0.05 min-1, Km = 3.9 ± 0.5 µM, kcat/Km = 5739 M-1 · s-1 were comparable with previous 
reports (20, 29). The mutants Y224F, Y224C, Y224L, and Y224M exhibited an ~2-, 13-, 
32-, and 42-fold decrease in the kcat/Km value, respectively. These results provide direct 
support for the significance of Tyr224 on the substrate specificity of Sc-RppA. 
Concomitant with the increasing Km value, the mutation of this Tyr residue also 
decreased the turnover number (kcat), implicating its potential influence on the catalytic 
steps that follow substrate loading. Furthermore, we also determined the kinetic constants 
of WT Sg-RppA to be kcat = 2.84 ± 0.07 min-1, Km = 1.1 ± 0.2 µM, kcat/Km = 44476 M-1 · 
s-1, showing that Sg-RppA is more reactive toward malonyl-CoA than is Sc-RppA. 
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Likewise, the Leu replacement of Tyr224 in Sg-RppA decreased the substrate specificity 
constant by 148-fold (Table 9-1). 
 
9.2.4 Radioactive Substrate Binding to WT and Mutant Sc-RppAs  
All previous data support the hypothesis that Tyr224 in the active site of RppA is 
involved in substrate specificity determination (28, 29, 31). However, direct evidence that 
Tyr224 facilitates covalent linkage of the first malonyl-CoA to Cys138 has been lacking. 
Previous work that revealed the inability of mutant Sg-RppAs to synthesize THN from 
malonyl-CoA could also result from successful loading but with an inability to catalyze 
polyketide chain extension, cyclization, or release of final product. To exclude these 
possibilities, radioactive malonyl-CoA was employed to detect the covalent radiolabel on 
WT or mutant RppA. Again, the Sc-RppA mutants C138A and C138S were included as 
negative controls. As expected, WT Sc-RppA and all Tyr224 mutants capable of 
synthesizing THN (Y224F, Y224L, Y224A, Y224M, and Y224C) were successfully 
radiolabeled through the covalent acylation of Cys138 with [2-14C]-malonyl-CoA (Fig. 9-
2B). Together with negative controls, Y224H, Y224G, and Y224S were not labeled by 
radioactive malonyl-CoA. This substrate binding profile is consistent with the THN 
production profile (Fig. 9-3A), demonstrating the correlation between the starter substrate 
loading and product formation of Tyr224 mutants. Notably, compared with radiolabeled 
mutants, the radioactive intensity of acylated WT Sc-RppA was significantly lower. This 
might result from fast turnover of WT enzyme, thus leading to more released 
intermediates and products, both of which carry radioactivity. Moreover, WT and Y224L 
mutant Sg-RppA were also labeled by radioactive malonyl-CoA in a similar assay (data 
not shown). 
 
Table 9-1. Steady-state kinetic constants for THN production in WT and Tyr224 
mutants of Sc-RppA and Sg-RppA. 
 
 Sc-RppA Sg-RppA 
 WT Y224F Y224C Y224L Y224M WT Y224L 
kcat × 10-2 (min-1) 133.4 ± 4.8 110.0 ± 2.4 28.5 ± 0.8 26.4 ± 0.9 13.6 ± 0.7 284.2 ± 6.8 19.9 ± 0.6 
Km (µM) 3.9 ± 0.5 9.5 ± 0.3 12.0 ± 1.2 23.4 ± 2.0 17.1 ± 2.5 1.1 ± 0.2 11.1 ± 1.1 




Recently, the first ligand-free crystal structure of the bacterial type III PKS Sc-
RppA was reported (29). However, until co-crystal structures bearing substrate, product, 
and chain elongation intermediates become available, the answers to three key 
mechanistic questions will remain outstanding. These include substrate specificity 
determination, polyketide chain length control, and mode of acyl chain cyclization. 
Dissection of these parameters currently depends primarily on biochemical analyses and 
modeling from CHS plant type III PKS. In the current study, we decided to revisit the 
role of Tyr224 in the active site of Sc-RppA and used site-directed mutagenesis to replace 
it with a series of alternative amino acid residues to probe its effect on starter unit 
specificity. 
Jez et al. (30) observed, via comparison of x-ray crystal structures, that a point 
mutation at Gly256 (homologous to Tyr224 in RppA) of CHS does not cause significant 
alteration in the conformation of the polypeptide backbone. Based on the similarity 
between CHS and RppA, we reasoned that our series of Tyr224 substitutions would 
change only the local active site properties without inducing conformational changes. 
Surprisingly, our mutagenesis analysis results were significantly different from previous 
studies on the highly related type III PKS Sg-RppA (28). A series of Tyr224 mutants of 
Sc-RppA including Y224F, Y224C, Y224L, Y224M, and Y224A retained the ability to 
load malonyl-CoA and produce THN, although the catalytic activities were reduced. The 
current study demonstrates a higher tolerance toward certain amino acid changes at 
Tyr224 (28). Furthermore, we have demonstrated that the Leu replacement of Tyr224 in 
Sg-RppA does not eliminate malonyl-CoA starter unit selectivity (and hence THN 
formation). Interestingly, this positional tolerance was also observed recently in two plant 
type III PKSs, including A. arborescens pentaketide chromone synthase (17) and 
octaketide synthase (33), both of which harbor a Leu residue at the site corresponding to 
Tyr224 in RppA (Fig. 9-S1) and utilize malonyl-CoA exclusively to initiate their 
physiological reactions. This demonstrates that plant type III PKSs employ a different 
strategy than bacterial enzymes to favor malonyl-CoA as the physiological starter unit. 
Quantitatively, the reported catalytic efficiencies (kcat/Km) of pentaketide chromone 
synthase and octaketide synthase with malonyl-CoA (kcat/Km = 104 and 16 M-1 · s-1 for 
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pentaketide chromone synthase and octaketide synthase, respectively) (17, 33) are 
dramatically lower than those of the RppAs (kcat/Km = 5739 and 44476 M-1 · s-1 for Sc-
RppA and Sc-RppA, respectively). The magnitude of the discrepancy suggests that Tyr 
might be the more highly optimized residue to favor malonyl-CoA with high efficiency. 
Correspondingly, we hypothesized that the Leu residue in these two plant type III PKSs 
might represent a compromise between malonyl-CoA incorporative efficiency and 
product complexity (or diversity), because the presence of a bulky residue at position 224 
(such as Tyr) would presumably limit the number of chain extensions, thus impairing 
chemical diversity (30). In addition, Rheum palmatum aloesone synthase (34) and G. 
hybrida 2-pyrone synthase (15, 31) possessing Leu at the homologous position (Fig. 9-
S1) can also generate products solely from malonyl-CoA, although their physiological 
starter unit is acetyl-CoA. This alternate conversion was previously thought to begin by 
decarboxylation of malonyl-CoA to generate acetyl-CoA (15). The studies reported here 
suggest that these two enzymes can directly incorporate malonyl-CoA, which competes 
directly with acetyl-CoA. Furthermore, studies showing that G256L and G256F mutants 
of CHS are able to produce TAL solely from malonyl-CoA could be interpreted similarly 
(30). 
Prior to the work reported here, the conservation and presumed role of Tyr224 in 
bacterial type III PKSs indicated its importance in substrate specificity determination (28, 
29). However, the hypothesis for its function has been focused on steric factors. The 
bulky aromatic side chain is believed to be essential for recruiting malonyl-CoA to the 
thiol group of catalytic Cys through a horizontal steric constriction for the malonyl-CoA 
starter unit. In this study, we obtained experimental data that could not be explained 
clearly by this model. First, together with the active Tyr224 mutants of Sc-RppA (Y224F, 
Y224C, Y224L, Y224M, and Y224A), all mutants (Y224G, Y224S, and Y224H) that 
were not able to use the physiological starter unit (malonyl-CoA) retained function 
toward diverse unnatural substrates including acetyl-CoA, acetoacetyl-CoA, hexanoyl-
CoA, and benzoyl-CoA. Based on incorporation rates, all of these mutants displayed 
good activities toward acetoacetyl-CoA. This is not surprising considering that 
acetoacetyl-CoA is similar in size to malonyl-CoA. However, it remains unclear how 
Y224G, Y224S, and Y224H mutants are able to differentiate acetoacetyl-CoA from the 
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isosteric malonyl-CoA. Second, we did not observe a correlation between the THN 
producing activity and the size of the replaced amino acid (Fig. 9-3A). Unexpectedly, the 
substitution of a series of nonconservative amino acids with significantly smaller side 
chains for Tyr224 (Y224C, Y224L, Y224M, and Y224A) was tolerated by Sc-RppA, 
which contradicts the described volume-modulating model (2, 31) for substrate 
specificity determination. For instance, in Y224C (one of the active mutants that 
continues to accommodate malonyl-CoA to produce THN), the small substituent Cys is 
isosteric to Ser; however the Ser mutation abrogated loading of the physiological starter 
unit (malonyl-CoA) based on radioactive substrate binding analysis. In contrast, modest 
modification of the active cavity volume by replacing Tyr224 with His completely 
disabled the malonyl-CoA loading ability of the mutant type III PKS. These results 
suggest that there might be an additional type of mechanism other than steric constraints 
that influences linkage of the first malonyl-CoA to the catalytic Cys. We initially 
considered that the most significant difference between acetoacetyl-CoA and malonyl-
CoA was the terminal electronic property of the latter substrate. Based on observations 
reported here, it appears that the terminal negative charge of malonyl-CoA could be 
recognized by RppA. However, the polarity discrepancy is unable to be distinguished by 
the steric property of Tyr224 or other substituted residues at this position. Therefore, we 
propose that the hydrophobicity of Tyr224 could contribute to the preference for 
malonyl-CoA. Compared with other unnatural acyl-CoA substrates, malonyl-CoA carries 
a terminal negative charge at physiological pH (~7.5). Taking this electronic feature into 
account, when Tyr224 is replaced by a hydrophobic amino acid such as Leu, Cys, Met, or 
Ala (although missing the bulky side chain of Tyr), the hydrophobic interaction between 
the nonpolar side chain and the charged malonyl-CoA could limit the conformational 
freedom of this starter unit, thus decreasing the entropy penalty of covalent bond 
formation to active site Cys. However, hydrophobicity does not correlate perfectly with 
the THN productivity (Fig. 9-3A), indicating that steric factors remain important. Thus, 
the robustness of WT RppA likely derives from a combination of steric and 
electronic/polarity factors that favor malonyl-CoA. Additionally, the hydrophobic Y224A 
replacement generates only a slightly active mutant, possibly because of lack of steric 
effect to select the substrate. With respect to Y224H, the hydrophilic amino acid 
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substitution might counteract the steric effect of its bulky side chain. Specifically, it is 
possible that the protonated His side chain could form an ionic interaction with the 
terminal negative charge of malonyl-CoA to prevent it from being linked to Cys138. 
Considering the current data, we propose that the ability of the malonyl-CoA-
inactive mutants to accept unnatural acyl-CoAs that lack a terminal charge is governed by 
the hydrophobic interior of enzyme and the thermodynamically unfavorable conditions 
for delivering a formal charge there. Accordingly, an entropy compensation for substrate 
binding through limiting the conformational freedom of the substrate might be more 




In summary, we have demonstrated a surprising level of substrate tolerance 
involving a series of RppA Tyr224 mutations including both aromatic and hydrophobic 
amino acids with medium or large side chains. Both steric and electronic constraints 
exerted by Tyr224 in the active site are involved in facilitating the loading of the 
physiological substrate malonyl-CoA. In practical terms, re-engineering of plant and 
bacterial type III PKS to increase the preference for malonyl-CoA could be utilized to 
enable further product diversification. The identification of a number of active Tyr224 
mutants with lower turnover numbers could provide potential candidates for subtle 
presteady-state kinetic studies, enzyme-linked intermediate trapping, or co-crystallization 
efforts. Moreover, the Tyr224 mutants that preferentially accept unnatural acyl-CoAs 
instead of malonyl-CoA could be applied for the production of novel pyrone products 
with higher yields. 
 
9.5 Experimental Procedures 
S. coelicolor RppA Gene Cloning — Genomic DNA was prepared from S. coelicolor 
A3 (2) using a Wizard genomic DNA purification kit (Promega). The Sc-RppA gene was 
amplified by PCR under standard conditions with a pair of primers as follows: forward, 
5'-AATCATATGGCGACTTTGTGC-3' (the underlined bases represent the introduced 
NdeI site for further cloning); reverse, 5'-
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AATAAGCTTTCATGCCTGCCTGCCTCACCC-3' (the underlined letters indicate a 
HindIII restriction site for later cloning). The full-length cDNA encoding Sc-RppA was 
rescued by double digestion of NdeI and HindIII. The fragment containing Sc-RppA gene 
was ligated into previously NdeI/HindIII-digested pET-28b(+) (Novagen) to generate the 
recombinant plasmid pET-28b(+)-Sc-RppA. This construct was then transformed into 
Escherichia coli BL21 (DE3) for protein overexpression. The accuracy of the inserted 
Sc-RppA gene was confirmed by nucleotide sequencing.  
 
Site-directed Mutagenesis, Protein Overexpression, and Purification — Site-directed 
mutagenesis was performed according to the QuikChange (Stratagene) protocol with 
pET-28b(+)-Sc-RppA as template. The PCR-amplified plasmids containing mutations 
were verified by DNA sequencing and then directly used for transforming the protein 
overexpression strain E. coli BL21 (DE3). The resulting transformants were grown at 37 
°C overnight in Luria broth containing 50 µg/ml kanamycin, and 10 ml of culture was 
used to inoculate 1 liter of Terrific Broth containing 50 µg/ml of kanamycin. The Terrific 
Broth culture was incubated at 37 °C for 3~4 h until A600 reached 0.6–1.0. Then, gene 
overexpression was induced by adding isopropyl-β-D-thiogalactopyranoside to a final 
concentration of 0.1 mM and cultured at 18 °C overnight. The culture was centrifuged at 
4,000 g for 10 min to collect cells. The freeze-thaw cell pellet was resuspended in 40 ml 
of lysis buffer (250 mM NaCl, 50 mM NaH2PO4, 10 mM imidazole, 20% glycerol, pH 
7.9), and the cell lysate was prepared by lysozyme digestion at 1 mg/ml for 30 min with 
subsequent sonication. Cell debris was removed by centrifugation at 15,000 g for 30 min, 
and the soluble fraction was mixed with 2 ml nickel-nitrilotriacetic acid-agarose (Qiagen) 
for 1 h at 4°C. The slurry was loaded onto an empty column. The column was then 
washed stepwise with 20 ml of lysis buffer and 40–60 ml of wash buffer (250 mM NaCl, 
50 mM NaH2PO4, 40 mM imidazole, 20% glycerol, pH 7.9). The His6 tag bound proteins 
were eluted with elution buffer (250 mM NaCl, 50 mM NaH2PO4, 200 mM imidazole, 
20% glycerol, pH 7.9). The target protein was further purified and concentrated with 
YM-10 centrifuge filters (Amicon). Finally, the elution buffer was exchanged for storage 
buffer (250 mM NaCl, 50 mM NaH2PO4, 20% glycerol, pH 7.4) with a PD-10 column 
(GE Healthcare), and the resulting product concentrations were measured by Bio-Rad 
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protein assay kit using bovine serum albumin as standard. Purity and molecular mass 
were examined by standard SDS-PAGE analysis. 
 
RppA Enzymatic Assay — The standard assay containing 50 mM sodium phosphate 
(pH 7.4), 0.2 mM acyl-CoA starter, and 3 µM WT or mutant RppA in a total volume of 
100 µl was initiated by adding malonyl-CoA to a final concentration of 0.5 mM and was 
quenched with the addition of 10 µl of 6 M HCl after incubation at 30 °C for 1 h. Small 
amounts of enzyme were removed by centrifugation at 16,100 g for 10 min. The 
supernatant was used directly as the sample for HPLC analysis. Reverse-phase HPLC 
conditions were as follows, using an XBridge C18 5-µm column (4.6 x 250 mm): the 
mobile phase for the malonyl-CoA-, acetyl-CoA-, and acetoacetyl-CoA-primed reaction 
was linear from 5 to 35% B (A = deionized water + 0.1% trifluoroacetic acid; B = 
acetonitrile + 0.1% trifluoroacetic acid) over 20 min, and the mobile phase for the 
hexanoyl-CoA- and benzoyl-CoA-primed reaction was linear from 20 to 70% B over 20 
min; the UV detection wavelength was 280 nm for the malonyl-CoA-, acetyl-CoA-, 
acetoacetyl-CoA-, and hexanoyl-CoA-primed reactions and 320 nm for the benzoyl-CoA 
primed reaction, at a flow rate of 0.8 ml/min. The peak identity in HPLC trace was 
determined by mass spectrometry and comparison with authentic compounds regarding 
HPLC retention time and UV spectrum. 
 
Enzyme Kinetics — We exploited the reported coefficient constant for THN at 340 nm 
(ε = 18,000) (20) to obtain the steadystate kinetic parameters using a spectrophotometric 
method. The standard reaction buffered with 100 mM Tris-HCl (pH 7.5) containing the 
appropriate concentration of WT or mutant RppA in a total volume of 400 µl was 
initiated by adding a series of concentrations of malonyl-CoA ranging from 1 to 100 µM 
and was immediately monitored with a UV-visible spectrophotometer 300 Bio (Cary) at 
30 °C. The initial velocity of THN accumulation was deduced from the absorbance curve 
within the linear range. All measurements were determined in triplicate, and velocities 
determined under different malonyl-CoA concentrations were fit to the Michaelis-Menten 
equation to calculate the kinetic constants kcat and Km. 
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Radioactive Substrate Binding Assay — The optimized reaction contained 50 mM 
HEPES buffer (pH 7.4), 50 µM [2-14C]malonyl-CoA (55 mCi/mmol) and 15.0 µM WT or 
mutant enzymes in a total volume of 25 µl. Reactions were quenched by the addition of 
25 µl of 2x SDS gel loading dye after a 5-min incubation at 30 °C. 10 µl of each reaction 
mixture was analyzed by SDS-PAGE (15%). After staining, destaining, and drying the 
protein gel on filter papers, the radioactivity bound to the protein was determined by 












































Figure 9-S1. Multiple alignment of amino acid sequences of heterologous type III PKSs. (Sc-
RppA: Streptomyces coelicolor RppA; Sg-RppA: Streptomyces griseus RppA; Pf-PhlD: 
Pseudomonas fluorescens PhlD; Am-DpgA: Amycolatopsis mediterranei DpgA; Ms-CHS: 
Medicago sativa CHS; Aa-PCS: Aloe arborescens PCS; Aa-OKS: Aloe arborescens OKS; Gh-
2PS: Gerbera hybrida 2-PS; Rp-ALS: Rheum palmatum ALS). The Tyr224 and catalytic triad 
Cys138, His270, and Asn303 are marked with # (numbering in Sc-RppA). The amino acids 





















Figure 9-S2. HPLC analysis (UV280) of THN production catalyzed by wt and Y224L 
mutant Sg-RppA. The reactions containing 200 µM malonyl-CoA and 1 µM enzyme in 100 
µL of 100 mM Tris-HCl (pH 7.5) were incubated for 1 hr and quenched by adding 10µL of 
6M HCl. HPLC gradient conditions: linear from 10% to 100% solvent B (acetonitrile + 0.1% 
trifluoroacetic acid) in solvent A (deionized water + 0.1% trifluoroacetic acid ) over 30 min, 
then 100% solvent B for 10 min. The flow rate was 0.8 mL/min. The HPLC traces of wt Sg-
RppA and Y224L mutant catalyzed reactions are colored in red and green, respectively. The 
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In this Ph.D. dissertational study, I have been focused on the biochemical, 
structural, and bioengineering investigations of PikC, the cytochrome P450 enzymes with 
innate substrate flexibility and hydroxylation versatility from the macrolide antibiotic 
pikromycin biosynthetic pathway in Streptomyce venezuelae. In collaboration with the 
crystallographic group led by Dr. Larissa M. Podust and the synthetic group led by John 
Montgomery, the structural basis for the substrate flexibility of PikC has been elucidated; 
a more catalytically active mutant PikCD50N was identified and the mechanism for the 
improved activity has been understood via analysis of its crystal structure; a self-
sufficient version of PikC enzyme was created by fusing this P450 enzyme to a 
heterologous reductase domain RhFRED; and the unique desosamine anchoring 
functionality observed in the substrate-enzyme co-crystal structures has been harnessed to 
achieve regioselective oxidation of a series of carbocyclic rings linked to the desosamine 
glycoside by using the engineered PikCD50N-RhFRED. All these results indicate that PikC 
is a good model to help answer some fundamental questions of P450 catalysis and 
PikCD50N-RhFRED possesses great potential to be developed into an applicable catalyst 
in synthetic chemistry. However, this study also leaves a number of unsolved questions 
awaiting for future investigations. 
First, the observation of two different substrate binding modes clearly provides 
the structural basis for the substrate flexibility of PikC. However, the observed position 
and orientation of substrates in the active site does not well explain the C10 
hydroxylation of YC-17 and the C12 hydroxylation of narbomycin since these two sites 
are substantially distant from the heme iron reactive center, leaving the possibilities 
including: 1) the substrate could be repositioned upon the dioxygen binding to the heme 
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iron during the catalytic cycle; 2) the genuine oxidative species in the C10 hydroxylation 
of YC-17 and the C12 hydroxylation of narbomycin might be the more extended ferric 
hydroperoxy species (Fe3+−OOH, Compound 0) other than the ferryl-oxo species 
(Fe4+=O, Compound I) proposed to be responsible for the C-12 hydroxylation of YC-17. 
There will be several options to test these hypotheses. First, we could investigate the 
hydroxylation pattern of YC-17 and narbomycin by using synthetic metalloporphyrins at 
different oxidative stages to mimic the chemistry of P450 “Compound 0” and 
“Compound I”. Second, we could attempt to solve the crystal structure of the ferrous 
dioxygen adduct of PikC with substrate bound to see if the substrate repositioning occurs. 
Third, we may select a mutant PikC that displays a different hydroxylation pattern toward 
either YC-17 or narbomycin through random mutagenesis, and then compare its structure 
to that of wild type PikC. 
Second, taking advantage of the unique desosamine anchoring functionality in the 
substrate binding process of PikC, considerable regioselectivity in oxidation of a group of 
desosaminyl derivatives has been achieved by using the engineered PikCD50N-RhFRED, 
which is approximately 13-fold more active than wild type PikC. However, the 
stereoselective control was not successful. This will require more future work focusing 
on protein engineering such as directed evolution of PikCD50N-RhFRED regarding its 
stereoselectivity against certain substrates, and/or substrate structural refinement. 
Third, the presence of desosamine (or desosamine analogs) in diverse secondary 
metabolite substrates of different biosynthetic P450 enzymes suggest that the desosamine 
anchoring functionality might have been utilized extensively in nature. For example, in 
addition to PikC, MycCI, TylHI, and EryK, which are cytochrome P450s involved in 
tailoring of mycinamicin, tylosin, and erythromycin, are capable of hydroxylating 
different desosamine (or mycaminose, a desosamine analog, in the case of tylosin) 
containing substrates (mycinamicin VIII, 23-deoxy-O-mycaminosyltylonolide, and 
erythromycin D) at sites remote from the sugar linkage. These findings suggest that more 
natural product P450s could be further harnessed for a similar substrate engineering 
approach as we have done for PikC to selectively oxidize C-H bonds, and to facilitate 
further chemical diversification of both synthetic and natural product molecules of 
biological interest. 
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Finally, the knowledge and experience accumulated in the PikC project could be 
applied to more functional analysis of biosynthetic P450 enzymes in future, which is 
likely to result in new biochemistry, more insights into biosynthesis of natural products 
and biodegradation, more candidates for application in biotechnology, and more facile 
models for understanding CYP structures and catalytic mechanisms. 
 
 
